



10.04.2019

**11:45 - 13:15 ESMO Colloquium supported by Lilly Oncology in collaboration with MSD Room  
- How to best use immune checkpoint inhibitors in NSCLC: Single agents A  
or combined with chemotherapy?**

Moderation: D. Planchard, Villejuif, FR

11:45 - 11:45 **Session DOI**

11:45 - 11:50 **Introduction**

D. Planchard, Villejuif, FR

11:50 - 12:10 **First-line immunotherapy options for patients without an oncogene driver**

R. Califano, Manchester, GB

12:10 - 12:30 **What is the biological rationale for combining chemotherapy with immune checkpoint inhibitors?**

M. Garassino, Milan, IT

12:30 - 12:50 **Are immune checkpoints (ICPs) better as single agent, doublet ICPs or combined with chemo +/- anti-angiogenics?**

S. Peters, Lausanne, CH

12:50 - 13:10 **Recommendation on second-line treatment according to first-line choice**

D. Planchard, Villejuif, FR

13:10 - 13:15 **Conclusion**

D. Planchard, Villejuif, FR

**13:00 - 13:30 Welcome reception**

**Hall 1**



<b>13:30 - 13:45</b>	<b>Opening and welcome</b>	<b>Room B</b>
	Moderation: P. Garrido Lopez <sup>1</sup> , J. Wolf <sup>2</sup> ; <sup>1</sup> Madrid, ES, <sup>2</sup> Cologne, DE	
13:30 - 13:30	<b>Session DOI</b>	
13:30 - 13:35	<b>Welcome to the Congress</b> <u>P. Garrido Lopez</u> <sup>1</sup> , <u>J. Wolf</u> <sup>2</sup> ; <sup>1</sup> Madrid, ES, <sup>2</sup> Cologne, DE	
13:35 - 13:40	<b>Introduction to IASLC</b> <u>G. Scagliotti</u> , Orbassano, TO/IT	
13:40 - 13:45	<b>Introduction to ESMO</b> <u>S. Peters</u> , Lausanne, CH	
<b>13:45 - 14:15</b>	<b>HHH Award lecture</b>	<b>Room B</b>
	Moderation: S. Peters <sup>1</sup> , G. Scagliotti <sup>2</sup> ; <sup>1</sup> Lausanne, CH, <sup>2</sup> Orbassano, TO/IT	
13:45 - 13:45	<b>Session DOI</b>	
13:45 - 14:15	<b>The HHH model applied to radiotherapy: Honour the past, evaluate the present and stimulate the future</b> <u>F. Mornex</u> , Pierre Bénite, FR	



**14:30 - 16:00 My patient has stage IIIA (N2) disease: Surgery or radiotherapy? Room B**  
Moderation: M. Guckenberger<sup>1</sup>, S. Zimmermann<sup>2</sup>; <sup>1</sup>Zürich, CH, <sup>2</sup>Lausanne, CH

14:30 - 14:30 **Session DOI**

14:30 - 14:40 **Case presentation**  
M. Pless, Winterthur, CH

14:40 - 15:07 **My patient needs neoadjuvant treatment followed by surgery**  
W. Eberhardt, Essen, DE

15:07 - 15:34 **My patient needs surgery upfront followed by adjuvant treatment**  
M. Pless, Winterthur, CH

15:34 - 16:01 **My patient needs chemoradiotherapy and durvalumab**  
D. De Ruyscher, Maastricht, NL

**14:30 - 16:00 Current management of early stage NSCLC Room A**  
Moderation: A.C. Dingemans<sup>1</sup>, R. Rami-Porta<sup>2</sup>; <sup>1</sup>Maastricht, NL, <sup>2</sup>Terrassa, Barcelona/ES

14:30 - 14:30 **Session DOI**

14:30 - 14:50 **Early stage lung cancer: Progress in TNM**  
R. Rami-Porta, Terrassa, Barcelona/ES

14:50 - 15:10 **Is invasive staging necessary in early stage NSCLC?**  
W. Weder, Zurich, CH

15:10 - 15:30 **Current treatment approaches in early disease**  
R. Califano, Manchester, GB

15:30 - 15:50 **Early stage lung cancer: The importance of co-morbidity**  
A.C. Toffart, La Tronche, FR

15:50 - 16:00 **Q&A**



<b>14:30 - 16:00</b>	<b>Early detection, screening, prevention</b> Moderation: S. Novello <sup>1</sup> , N. Peled <sup>2</sup> ; <sup>1</sup> Orbassano, IT, <sup>2</sup> Beer Sheva, IL	<b>Room C</b>
14:30 - 14:30	<b>Session DOI</b>	
14:30 - 14:45	<b>Primary prevention European campaigns</b> <u>S. Novello</u> , Orbassano, IT	
14:45 - 14:48	<b>Q&amp;A</b>	
14:48 - 15:03	<b>e-CIG: Already time to talk about “prevention”?</b> <u>C. Dresler</u> , Washington, US	
15:03 - 15:06	<b>Q&amp;A</b>	
15:06 - 15:21	<b>Low dose CT and secondary prevention: Where we are in Europe</b> <u>J. Field</u> , Liverpool, GB	
15:21 - 15:24	<b>Q&amp;A</b>	
15:24 - 15:39	<b>Early detection of mesothelioma and lung cancer in ultra-high risk populations using a biomarker approach</b> <u>T. Behrens</u> , Bochum, DE	
15:39 - 15:42	<b>Q&amp;A</b>	
15:42 - 15:57	<b>Biomarkers for early detection</b> <u>N. Peled</u> , Beer Sheva, IL	
15:57 - 16:00	<b>Q&amp;A</b>	
<b>16:00 - 16:30</b>	<b>Coffee break</b>	<b>Hall 1</b>



**16:30 - 18:00 NSCLC stage IV oncogenic addicted disease Room B**  
Moderation: E. Felip<sup>1</sup>, D. Planchard<sup>2</sup>; <sup>1</sup>Barcelona, ES, <sup>2</sup>Villejuif, FR

16:30 - 16:30 **Session DOI**

16:30 - 16:50 **Current treatment algorithms for EGFR-mutated patients**  
F. Cappuzzo, Ravenna, IT

16:50 - 17:10 **Current treatment algorithms for ALK+ and ROS1+ patients**  
T. Newsom-Davis, London, GB

17:10 - 17:30 **Targeted therapy beyond EGFR, ALK and ROS1**  
D. Planchard, Villejuif, FR

17:30 - 17:50 **Immunotherapy in oncogenic addicted NSCLC**  
J. Mazieres, Toulouse, FR

17:50 - 18:00 **Q&A**

**16:30 - 18:00 Optimising treatment in stage III Room A**  
Moderation: W. Eberhardt<sup>1</sup>, H. Choy<sup>2</sup>; <sup>1</sup>Essen, DE, <sup>2</sup>Dallas, TX/US

16:30 - 16:30 **Session DOI**

16:30 - 16:50 **Is there only one standard of care in stage III NSCLC?**  
P. Garrido Lopez, Madrid, ES

16:50 - 17:10 **Integration of I-O in the management of stage III**  
K. Park, Seoul, KR

17:10 - 17:30 **What is the role of surgery for stage III patients in the I-O era?**  
P. van Schil, Edegem, BE

17:30 - 17:50 **Innovative radiotherapy approaches for stage III NSCLC patients**  
H. Choy, Dallas, TX/US

17:50 - 18:00 **Q&A**



<b>16:30 - 18:15</b>	<b>Proffered Paper session I</b>	<b>Room C</b>
	Moderation: A.C. Dingemans <sup>1</sup> , T. Mitsudomi <sup>2</sup> ; <sup>1</sup> Maastricht, NL, <sup>2</sup> Osaka, JP	
16:30 - 16:30	<b>Session DOI</b>	
16:30 - 16:45	<b>680 - Electromagnetic navigation bronchoscopy in the European cohort of the prospective, multicenter NAVIGATE study</b>	
	<u>K. Lau</u> <sup>1</sup> , J. Flandes <sup>2</sup> , M. Christensen <sup>3</sup> , M. Bezzi <sup>4</sup> , B. Lamprecht <sup>5</sup> , M. Salio <sup>6</sup> , J.M. Vergnon <sup>7</sup> , M. Studnicka <sup>8</sup> , M. Trigiani <sup>4</sup> , I. Fernandez <sup>2</sup> , R. Kropfmüller <sup>5</sup> , E. Barisione <sup>6</sup> , N. Viby <sup>3</sup> , S. Khandhar <sup>9</sup> , E. Folch <sup>10</sup> ; <sup>1</sup> London, GB, <sup>2</sup> Madrid, ES, <sup>3</sup> Copenhagen, DK, <sup>4</sup> Firenze, IT, <sup>5</sup> Linz, AT, <sup>6</sup> Genova, IT, <sup>7</sup> St. Etienne, cédex 2/FR, <sup>8</sup> Salzburg, AT, <sup>9</sup> Falls Church, VA/US, <sup>10</sup> Boston, MA/US	
16:45 - 17:00	<b>690 - Comprehensive profiling of genomic and TCR repertoire in localized stage lung adenocarcinomas from a prospective cohort study</b>	
	<u>K. Chen</u> , J. Bai, H. Zhao, F. Yang, C. Zhang, Y. Wang, L. Chang, Y. Guan, X. Yi, L. Feng, K. Zhang, S. Cheng, J. Wang; Beijing, CN	
17:00 - 17:15	<b>Invited Discussant 680 and 690</b>	
	<u>A. Dingemans</u> , Maastricht, NL	
17:15 - 17:30	<b>830 - Impact of subsequent post-discontinuation immunotherapy on overall survival in patients with unresectable, stage III NSCLC from PACIFIC</b>	
	M. Ouwens <sup>1</sup> , A. Darilay <sup>2</sup> , Y. Zhang <sup>2</sup> , P. Mukhopadhyay <sup>3</sup> , H. Mann <sup>4</sup> , J. Ryan <sup>4</sup> , <u>P. Dennis</u> <sup>2</sup> ; <sup>1</sup> London, GB, <sup>2</sup> Gaithersburg, MD/US, <sup>3</sup> Gaithersburg, US, <sup>4</sup> Cambridge, GB	
17:30 - 17:45	<b>LBA2 - Patient-reported outcomes (PROs) with durvalumab by PD-L1 expression in unresectable, stage III NSCLC (PACIFIC)</b>	
	<u>M. Garassino</u> <sup>1</sup> , L. Paz-Ares <sup>2</sup> , R. Hui <sup>3</sup> , C. Faivre-Finn <sup>4</sup> , A. Spira <sup>5</sup> , D. Planchard <sup>6</sup> , M. Ozguroglu <sup>7</sup> , D. Daniel <sup>8</sup> , D. Vicente <sup>9</sup> , S. Murakami <sup>10</sup> , A. Rydén <sup>11</sup> , Y. Zhang <sup>12</sup> , C. O'Brien <sup>13</sup> , P. Dennis <sup>12</sup> , S. Antonia <sup>14</sup> ; <sup>1</sup> Milan, IT, <sup>2</sup> Madrid, ES, <sup>3</sup> Westmead, NSW/AU, <sup>4</sup> Manchester, GB, <sup>5</sup> Fairfax, US, <sup>6</sup> Villejuif, FR, <sup>7</sup> Istanbul, TR, <sup>8</sup> Chattanooga, US, <sup>9</sup> Seville, ES, <sup>10</sup> Chou-Ku, Tokyo, JP, <sup>11</sup> Mölnådal, SE, <sup>12</sup> Gaithersburg, MD/US, <sup>13</sup> Macclesfield, GB, <sup>14</sup> Tampa, FL/US	
17:45 - 18:00	<b>LBA4 - Effect of post-study immunotherapy (IO) on overall survival (OS) outcome in patients with metastatic (m) NSCLC treated with first-line durvalumab (D) vs chemotherapy (CT) in the phase III MYSTIC study</b>	
	<u>N. Reinmuth</u> <sup>1</sup> , B.C. Cho <sup>2</sup> , K.H. Lee <sup>3</sup> , A. Luft <sup>4</sup> , M. Ahn <sup>2</sup> , J. Schneider <sup>5</sup> , F. Shepherd <sup>6</sup> , S. Geater <sup>7</sup> , Z. Pápai-Székely <sup>8</sup> , T. Van Ngoc <sup>9</sup> , M. Garassino <sup>10</sup> , F. Liu <sup>11</sup> , D. Clemett <sup>12</sup> , P. Thiyagarajah <sup>12</sup> , M. Ouwens <sup>13</sup> , U. Scheuring <sup>14</sup> , S. Peters <sup>15</sup> , N. Rizvi <sup>16</sup> ; <sup>1</sup> Gauting, DE, <sup>2</sup> Seoul, KR, <sup>3</sup> Cheongju, KR, <sup>4</sup> Saint-Petersburg, RU, <sup>5</sup> Mineola, US, <sup>6</sup> Toronto, CA, <sup>7</sup> Hat Yai, TH, <sup>8</sup> Székesfehérvár, HU, <sup>9</sup> Ho Chi Minh, VN, <sup>10</sup> Milan, IT, <sup>11</sup> Gaithersburg, US, <sup>12</sup> Cambridge, GB, <sup>13</sup> London, GB, <sup>14</sup> Melbourn, GB, <sup>15</sup> Lausanne, CH, <sup>16</sup> New York, NY/US	



18:00 - 18:15 **Invited Discussant 830, LBA2 and LBA4**

F. Barlesi, Marseille, CEDEX 20/FR

**18:15 - 19:15 Bristol-Myers Squibb - Industry Satellite Symposium**

**Room A**

Moderation: S. Peters, Lausanne, CH

18:15 - 18:20 **Welcome and introductions**

S. Peters, Lausanne, CH

18:20 - 18:45 **Clinical practice today and future considerations**

S. Peters<sup>1</sup>, M. Reck<sup>2</sup>; <sup>1</sup>Lausanne, CH, <sup>2</sup>Grosshansdorf, DE

18:45 - 18:45 **Moderator**

H. Borghaei, Philadelphia, US

18:45 - 19:00 **Treating the I-O-experienced patient: Where are we now and where are we headed?**

H. Borghaei, Philadelphia, US

19:00 - 19:00 **Moderator**

S. Peters<sup>1</sup>, M. Reck<sup>2</sup>; <sup>1</sup>Lausanne, CH, <sup>2</sup>Grosshansdorf, DE

19:00 - 19:15 **Closing remarks and audience Q&A**

S. Peters, Lausanne, CH





11.04.2019

**08:00 - 08:50 Treatment related pneumonitis in lung cancer patients** **Room W**  
Moderation: K.N. Franks<sup>1</sup>, J.G. Aerts<sup>2</sup>; <sup>1</sup>Leeds, Yorkshire/GB, <sup>2</sup>Rotterdam, Noord Brabant/NL

08:00 - 08:00 **Session DOI**

08:00 - 08:15 **The radiation oncology perspective**  
K. Franks, Leeds, Yorkshire/GB

08:15 - 08:30 **The respiratory and medical oncology perspective**  
J. Aerts, Rotterdam, Noord Brabant/NL

08:30 - 08:50 **Discussion**

**08:00 - 08:50 Mini Oral session I** **Room A**  
Moderation: P. Garrido Lopez<sup>1</sup>, E.F. Smit<sup>2</sup>, S. Novello<sup>3</sup>; <sup>1</sup>Madrid, ES, <sup>2</sup>Amsterdam, NL, <sup>3</sup>Orbassano, IT

08:00 - 08:00 **Session DOI**

08:00 - 08:05 **1110 - Activity of larotrectinib in TRK fusion lung cancer**  
A. Drilon<sup>1</sup>, S. Kummar<sup>2</sup>, V. Moreno<sup>3</sup>, J. Patel<sup>4</sup>, U. Lassen<sup>5</sup>, L. Rosen<sup>6</sup>, B. Childs<sup>7</sup>, S. Nanda<sup>7</sup>, M. Cox<sup>8</sup>, N. Ku<sup>8</sup>, A. Farago<sup>9</sup>; <sup>1</sup>New York, NY/US, <sup>2</sup>Stanford, CA/US, <sup>3</sup>Madrid, ES, <sup>4</sup>Chicago, IL/US, <sup>5</sup>Copenhagen, DK, <sup>6</sup>Los Angeles, CA/US, <sup>7</sup>Whippany, NJ/US, <sup>8</sup>San Francisco, CA/US, <sup>9</sup>Boston, MA/US

08:05 - 08:10 **1120 - Circulating tumor (ct) DNA analysis to monitor response and resistance to ensartinib in patients (pts) with ALK+ non-small cell lung cancer (NSCLC)**  
L. Horn<sup>1</sup>, J. Whisenant<sup>1</sup>, H. Wakelee<sup>2</sup>, K. Reckamp<sup>3</sup>, H. Qiao<sup>1</sup>, L. Du<sup>1</sup>, J. Hernandez<sup>4</sup>, V. Huang<sup>1</sup>, S. Waqar<sup>5</sup>, S. Patel<sup>6</sup>, R. Sanborn<sup>7</sup>, T. Shaffer<sup>4</sup>, K. Garg<sup>4</sup>, A. Holzhausen<sup>8</sup>, K. Harrow<sup>8</sup>, C. Liang<sup>8</sup>, L. Lim<sup>4</sup>, M. Li<sup>4</sup>, C. Lovly<sup>1</sup>; <sup>1</sup>Nashville, TN/US, <sup>2</sup>Stanford, CA/US, <sup>3</sup>Duarte, US, <sup>4</sup>Kirkland, WA/US, <sup>5</sup>St. Louis, MO/US, <sup>6</sup>La Jolla, CA/US, <sup>7</sup>Portland, OR/US, <sup>8</sup>Palm Beach Gardens, FL/US

08:10 - 08:15 **1130 - Entrectinib in NTRK fusion-positive non-small cell lung cancer (NSCLC): Integrated analysis of patients (pts) enrolled in STARTRK-2, STARTRK-1 and ALKA-372-001**





L. Paz-Ares<sup>1</sup>, R. Doebele<sup>2</sup>, A. Farago<sup>3</sup>, S. Liu<sup>4</sup>, S. Chawla<sup>5</sup>, D. Tosi<sup>3</sup>, C. Blakely<sup>6</sup>, J. Krauss<sup>7</sup>, D. Sigal<sup>8</sup>, L. Bazhenova<sup>9</sup>, T. John<sup>10</sup>, B. Besse<sup>11</sup>, J. Wolf<sup>12</sup>, T. Seto<sup>13</sup>, E. Chow-Maneval<sup>9</sup>, C. Ye<sup>6</sup>, B. Simmons<sup>6</sup>, G. Demetri<sup>3</sup>, L. Paz-Ares<sup>14</sup>; <sup>1</sup>Sevilla, ES, <sup>2</sup>Aurora, CO/US, <sup>3</sup>Boston, MA/US, <sup>4</sup>Washington, DC/US, <sup>5</sup>Los Angeles, CA/US, <sup>6</sup>South San Francisco, CA/US, <sup>7</sup>Ann Arbor, MI/US, <sup>8</sup>La Jolla, CA/US, <sup>9</sup>San Diego, CA/US, <sup>10</sup>Heidelberg, VIC/AU, <sup>11</sup>Villejuif, CEDEX/FR, <sup>12</sup>Cologne, DE, <sup>13</sup>Fukuoka, Fukuoka/JP, <sup>14</sup>Madrid, ES

- 08:15 - 08:20 **1140 - Potential resistance mechanisms using next generation sequencing from Chinese EGFR T790M+ non-small cell lung cancer patients with primary resistance to osimertinib: A multicenter study**  
C. Xu<sup>1</sup>, W. Wang<sup>2</sup>, Y. Zhu<sup>2</sup>, Z. Yu<sup>1</sup>, H. Zhang<sup>3</sup>, H. Wang<sup>4</sup>, J. Zhang<sup>4</sup>, W. Zhuang<sup>1</sup>, T. Lv<sup>5</sup>, Y. Song<sup>5</sup>; <sup>1</sup>Fuzhou, CN, <sup>2</sup>Zhenjiang, CN, <sup>3</sup>Xi'an, CN, <sup>4</sup>Beijing, CN, <sup>5</sup>Nanjing, CN
- 08:20 - 08:25 **1150 - Afatinib in EGFR TKI-naïve patients (pts) with locally advanced/metastatic NSCLC harbouring EGFR mutations: An interim analysis of a phase IIIB trial**  
A. Passaro<sup>1</sup>, K. Laktionov<sup>2</sup>, A. Poltoratskiy<sup>3</sup>, I. Egorova<sup>3</sup>, M. Hochmair<sup>4</sup>, M.R. Migliorino<sup>5</sup>, G. Metro<sup>6</sup>, M. Gottfried<sup>7</sup>, D. Tsoi<sup>8</sup>, G. Ostoros<sup>9</sup>, S. Rizzato<sup>10</sup>, G. Mukhametshina<sup>11</sup>, M. Schumacher<sup>12</sup>, S. Novello<sup>13</sup>, R. Dziadziuszko<sup>14</sup>, W. Tang<sup>15</sup>, L. Clementi<sup>1</sup>, A. Cseh<sup>4</sup>, D. Kowalski<sup>16</sup>, F. De Marinis<sup>1</sup>; <sup>1</sup>Milan, IT, <sup>2</sup>Moscow, RU, <sup>3</sup>St-Petersburg, RU, <sup>4</sup>Vienna, AT, <sup>5</sup>Rome, IT, <sup>6</sup>Perugia, IT, <sup>7</sup>Tel Aviv, IL, <sup>8</sup>Murdoch, WA/AU, <sup>9</sup>Budapest, HU, <sup>10</sup>Udine, IT, <sup>11</sup>Kazan, RU, <sup>12</sup>Linz, AT, <sup>13</sup>Orbassano, IT, <sup>14</sup>Gdansk, PL, <sup>15</sup>Ridgefield, CT/US, <sup>16</sup>Warsaw, PL
- 08:25 - 08:30 **1960 - STELLAR: Final updated results of a phase II trial of TTFIELDS with chemotherapy for unresectable malignant pleural mesothelioma**  
G.L. Ceresoli<sup>1</sup>, J. Aerts<sup>2</sup>, R. Dziadziuszko<sup>3</sup>, S. Cedres<sup>4</sup>, B. Hiddinga<sup>5</sup>, J. Van Meerbeeck<sup>6</sup>, M. Mencoboni<sup>7</sup>, D. Planchard<sup>8</sup>, A. Chella<sup>9</sup>, L. Crinò<sup>10</sup>, M. Krzakowski<sup>11</sup>, J. Madrzak<sup>3</sup>, R. Ramlau<sup>12</sup>, F. Grosso<sup>13</sup>; <sup>1</sup>Bergamo, IT, <sup>2</sup>Rotterdam, Noord Brabant/NL, <sup>3</sup>Gdańsk, PL, <sup>4</sup>Barcelona, ES, <sup>5</sup>Groningen, NL, <sup>6</sup>Edegem, BE, <sup>7</sup>Genova, IT, <sup>8</sup>Villejuif, FR, <sup>9</sup>Pisa, IT, <sup>10</sup>Meldola, (PG)/IT, <sup>11</sup>Warsaw, PL, <sup>12</sup>Poznan, PL, <sup>13</sup>Alessandria, IT
- 08:30 - 08:50 **Discussion led by moderators**



**09:00 - 10:30 Immunotherapy in stage IV** **Room B**  
Moderation: E. Felip<sup>1</sup>, S. Peters<sup>2</sup>; <sup>1</sup>Barcelona, ES, <sup>2</sup>Lausanne, CH

09:00 - 09:00 **Session DOI**

09:00 - 09:20 **I-O monotherapy**  
M. Reck, Grosshansdorf, DE

09:20 - 09:40 **Combo I-O/Chemo**  
L. Paz-Ares, Madrid, ES

09:40 - 10:00 **Combo I-O/I-O**  
S. Peters, Lausanne, CH

10:00 - 10:20 **Predictive diagnostics and treatment algorithms**  
E. Felip, Barcelona, ES

10:20 - 10:30 **Q&A**



**09:00 - 10:30 Challenges in clinical oncology: YO case discussions** **Room C**  
Moderation: R.A. Vidra<sup>1</sup>, J. Corral<sup>2</sup>; <sup>1</sup>Floresti, RO, <sup>2</sup>Sevilla, ES

09:00 - 09:00 **Session DOI**

09:00 - 09:05 **Introduction**

R. Vidra<sup>1</sup>, J. Corral<sup>2</sup>; <sup>1</sup>Floresti, RO, <sup>2</sup>Sevilla, ES

09:05 - 09:15 **Sequence of ALK patients treatment: A case report**

P. Tarantino, Milan, IT

09:15 - 09:30 **Mentor guided discussion**

B. Besse, Villejuif, CEDEX/FR

09:30 - 09:40 **Role of radiotherapy in oligometastatic I-O progression: A case report**

F. Napolitano, Napoli, IT

09:40 - 09:55 **Mentor guided discussion**

S. Senan, Amsterdam, NL

09:55 - 10:05 **Biomarkers in 1L metastatic NSCLC beyond the PD-L1: A case report**

A. Quilez Cutillas, Cadiz, ES

10:05 - 10:20 **Mentor guided discussion**

E. Arriola Aperribay, Barcelona, ES

10:20 - 10:30 **Q&A**

**09:00 - 10:30 Proffered Paper session II** **Room A**  
Moderation: J. Mazieres<sup>1</sup>, U. Malapelle<sup>2</sup>; <sup>1</sup>Toulouse, FR, <sup>2</sup>Napoli, IT

09:00 - 09:00 **Session DOI**

09:00 - 09:12 **210 - EPAC-Lung: Pooled analysis of circulating tumor cells in advanced non-small cell lung cancer**

C. Lindsay<sup>1</sup>, F. Blackhall<sup>1</sup>, A. Carmel<sup>2</sup>, P. Gazzaniga<sup>3</sup>, H. Groen<sup>4</sup>, M. Krebs<sup>1</sup>, L. Muinelo-Romay<sup>5</sup>, K. Pantel<sup>6</sup>, E. Rossi<sup>7</sup>, L. Terstappen<sup>8</sup>, H. Wikman<sup>6</sup>, J. Soria<sup>9</sup>, F. Farace<sup>2</sup>, A. Renehan<sup>1</sup>, C. Dive<sup>1</sup>, B. Besse<sup>10</sup>, S. Michiels<sup>2</sup>; <sup>1</sup>Manchester, GB, <sup>2</sup>Villejuif, FR, <sup>3</sup>Rome, IT, <sup>4</sup>Groningen, NL, <sup>5</sup>Santiago De Compostela, ES, <sup>6</sup>Hamburg, DE, <sup>7</sup>Padova, IT, <sup>8</sup>Enschede, NL, <sup>9</sup>Gaithersburg, CEDEX/US, <sup>10</sup>Villejuif, CEDEX/FR



- 09:12 - 09:24 **1080 - Treatment duration of brigatinib in patients enrolled in the international expanded access program (EAP)**  
M. Lin<sup>1</sup>, X. Pan<sup>2</sup>, P. Hou<sup>2</sup>, S. Allen<sup>2</sup>, P. Baumann<sup>2</sup>, M. Hochmair<sup>3</sup>; <sup>1</sup>Cambridge, US, <sup>2</sup>Cambridge, MA/US, <sup>3</sup>Vienna, AT
- 09:24 - 09:39 **Invited Discussant 210 and 1080**  
J. Wolf, Cologne, DE
- 09:39 - 09:51 **1090 - Entrectinib in locally advanced or metastatic ROS1 fusion-positive non-small cell lung cancer (NSCLC): Integrated analysis of ALKA-372-001, STARTRK-1 and STARTRK-2**  
F. Barlesi<sup>1</sup>, A. Drilon<sup>2</sup>, F. De Braud<sup>3</sup>, B.C. Cho<sup>4</sup>, M.J. Ahn<sup>4</sup>, S. Siena<sup>3</sup>, M. Krebs<sup>5</sup>, C.C. Lin<sup>6</sup>, T. John<sup>7</sup>, D.S.W. Tan<sup>8</sup>, T. Seto<sup>9</sup>, R. Dziadziuszko<sup>10</sup>, H. Arkenau<sup>11</sup>, C. Rolfo<sup>12</sup>, J. Wolf<sup>13</sup>, C. Ye<sup>14</sup>, T. Riehl<sup>14</sup>, S. Eng<sup>14</sup>, R. Doebele<sup>15</sup>; <sup>1</sup>Marseille, CEDEX 20/FR, <sup>2</sup>New York, NY/US, <sup>3</sup>Milano, IT, <sup>4</sup>Seoul, KR, <sup>5</sup>Manchester, GB, <sup>6</sup>Taipei, TW, <sup>7</sup>Heidelberg, VIC/AU, <sup>8</sup>Singapore, SG, <sup>9</sup>Fukuoka, Fukuoka/JP, <sup>10</sup>Gdansk, PL, <sup>11</sup>London, GB, <sup>12</sup>Baltimore, MD/US, <sup>13</sup>Cologne, DE, <sup>14</sup>South San Francisco, US, <sup>15</sup>Aurora, US
- 09:51 - 10:03 **550 - Radiogenomic signatures of NSCLC brain metastases: A potential non-invasive imaging marker for ALK mutation**  
S. Wadhwa, G. Krishna.b, M. Malhotra, K. Prabhash, V. Noronha, A. Joshi, V. Patil, A. Mahajan; Mumbai, IN
- 10:03 - 10:15 **1100 - Plasma circulating tumor DNA analysis (ctDNA) for molecular alteration detection in advanced non-small cell lung cancer (NSCLC) patients (pts) with isolated central nervous system (CNS) metastases (mts)**  
M. Aldea<sup>1</sup>, L. Hendriks<sup>2</sup>, L. Mezquita<sup>1</sup>, J. Remon-Masip<sup>3</sup>, D. Planchard<sup>1</sup>, C. Jovelet<sup>1</sup>, J.C. Benitez<sup>3</sup>, A. Gazzah<sup>1</sup>, C. Naltet<sup>1</sup>, P. Lavaud<sup>1</sup>, L. Lacroix<sup>1</sup>, K. Howarth<sup>4</sup>, C. Morris<sup>4</sup>, E. Green<sup>4</sup>, C. Nicotra<sup>1</sup>, B. Besse<sup>5</sup>; <sup>1</sup>Villejuif, FR, <sup>2</sup>Maastricht, NL, <sup>3</sup>Barcelona, ES, <sup>4</sup>Cambridge, GB, <sup>5</sup>Villejuif, CEDEX/FR
- 10:15 - 10:30 **Invited Discussant 1090, 550 and 1100**  
U. Malapelle, Napoli, IT
- 10:30 - 11:00 Coffee break** **Hall 1**



**11:00 - 12:30 The future of I-O in advanced NSCLC Room A**  
Moderation: M.C. Garassino<sup>1</sup>, S. Zimmermann<sup>2</sup>; <sup>1</sup>Milan, IT, <sup>2</sup>Lausanne, CH

11:00 - 11:00 **Session DOI**

11:00 - 11:20 **Sequencing of I-O therapies**

S. Popat, London, GB

11:20 - 11:40 **Progression on PD1/PD-L1 inhibitors: What is in the pipeline?**

S. Zimmermann, Lausanne, CH

11:40 - 12:00 **Cell-based I-O in NSCLC (TIL, TCRs, CARs, NK): Is there a role?**

J. Aerts, Rotterdam, Noord Brabant/NL

12:00 - 12:20 **Intratumoural I-O: A niche therapy?**

A. Marabelle, Villejuif, FR

12:20 - 12:30 **Q&A / Panel Discussion**

**11:00 - 12:30 Current role and future of thoracic radiotherapy Room C**  
Moderation: S. Senan<sup>1</sup>, M. Guckenberger<sup>2</sup>; <sup>1</sup>Amsterdam, NL, <sup>2</sup>Zürich, CH

11:00 - 11:00 **Session DOI**

11:00 - 11:20 **Early stage NSCLC**

M. Guckenberger, Zürich, CH

11:20 - 11:40 **Locally advanced stage NSCLC**

J. Belderbos, Amsterdam, NL

11:40 - 12:00 **Oligometastatic NSCLC**

F. Mornex, Pierre Bénite, FR

12:00 - 12:20 **Synchronous and metachronous primary tumours**

S. Senan, Amsterdam, NL

12:20 - 12:30 **Q&A / Panel Discussion**



**11:00 - 12:30 State of art of TMB testing** **Room W**  
Moderation: M. Pérol<sup>1</sup>, M.S. Tsao<sup>2</sup>; <sup>1</sup>Lyon, CEDEX/FR, <sup>2</sup>Toronto, Ontario/CA

11:00 - 11:00 **Session DOI**

11:00 - 11:20 **TMB as predictor of immuno-oncology therapy: The science**  
D. Spigel, Nashville, TN/US

11:20 - 11:40 **TMB testing in clinic**  
J. Fassunke, Cologne, DE

11:40 - 12:00 **TMB trumps PD-L1 as predictive biomarker for immuno-oncology therapy**  
M. Pérol, Lyon, CEDEX/FR

12:00 - 12:20 **PD-L1 is superior to TMB as predictive biomarker for immuno-oncology therapy**  
F. Hirsch, New York, CO/US

12:20 - 12:30 **Q&A / Panel Discussion**

**11:00 - 12:30 Advances in the surgical management of NSCLC** **Room K**  
Moderation: A. Brunelli<sup>1</sup>, G. Veronesi<sup>2</sup>; <sup>1</sup>Leeds, GB, <sup>2</sup>Rozzano, IT

11:00 - 11:00 **Session DOI**

11:00 - 11:20 **Lobar vs. sublobar resections for stage I NSCLC**  
A. Brunelli, Leeds, GB

11:20 - 11:40 **Robotic assisted lung resection for locally advanced lung cancer**  
G. Veronesi, Rozzano, IT

11:40 - 12:00 **Quality of life after radical treatment for lung cancer**  
C. Pompili, Leeds, GB

12:00 - 12:20 **Intraoperative lymph node dissection in early stage lung cancer: Update on prognostic implications**  
D. Lardinois, Basel, CH

12:20 - 12:30 **Q&A / Panel Discussion**





- 12:30 - 13:00 Lunch & Poster Display session** **Hall 1**
- Moderation: B. Besse<sup>1</sup>, A.C. Dingemans<sup>2</sup>, D. De Ruyscher<sup>2</sup>, D. Planchard<sup>3</sup>, N. Peled<sup>4</sup>, R. Buettner<sup>5</sup>, T. Behrens<sup>6</sup>; <sup>1</sup>Villejuif, CEDEX/FR, <sup>2</sup>Maastricht, NL, <sup>3</sup>Villejuif, FR, <sup>4</sup>Beer Sheva, IL, <sup>5</sup>Cologne, DE, <sup>6</sup>Bochum, DE
- 12:30 - 12:30 **3P - Notable variation of molecular testing in metastatic lung cancer in the Netherlands**  
C. Epskamp-Kuijpers<sup>1</sup>, M. Van den Heuvel<sup>2</sup>, L. Overbeek<sup>3</sup>, A. Van Lindert<sup>1</sup>, R. Damhuis<sup>1</sup>, S. Willems<sup>1</sup>; <sup>1</sup>Utrecht, NL, <sup>2</sup>Nijmegen, NL, <sup>3</sup>Houten, NL
- 12:30 - 12:30 **4P - Correlation between folate receptor alpha (FR $\alpha$ ) expression and clinicopathological features in lung adenocarcinoma**  
N. Tamura<sup>1</sup>, Y. Fujiwara<sup>1</sup>, T. Hashimoto<sup>1</sup>, H. Shiraishi<sup>1</sup>, S. Kitano<sup>2</sup>, T. Shimizu<sup>1</sup>, N. Yamamoto<sup>1</sup>, N. Motoi<sup>1</sup>; <sup>1</sup>Tokyo, JP, <sup>2</sup>Tokyo, NY/JP
- 12:30 - 12:30 **5P - The circular RNA circXPO1 promotes tumor growth in lung adenocarcinoma**  
Q. Huang, M. Qiu; Beijing, CN
- 12:30 - 12:30 **6P - Correlation of epidermal growth factor receptor mutation status in plasma and tissue samples of patients with lung cancer**  
C. Son, Busan, KR
- 12:30 - 12:30 **7P - Immunomodulatory effects of Tumor Treating Fields (TTFields) on lung cancer models**  
U. Weinberg<sup>1</sup>, N. Kaynan<sup>2</sup>, T. Voloshin Sela<sup>2</sup>, S. Davidi<sup>2</sup>, Y. Porat<sup>2</sup>, A. Shteingauz<sup>2</sup>, M. Munster<sup>2</sup>, R. Schneiderman<sup>2</sup>, C. Tempel Brami<sup>2</sup>, E. Zeevi<sup>2</sup>, K. Gotlib<sup>2</sup>, S. Cahal<sup>2</sup>, M. Giladi<sup>2</sup>, E. Kirson<sup>2</sup>, A. Kinzel<sup>3</sup>, Y. Palti<sup>2</sup>; <sup>1</sup>Luzern, CH, <sup>2</sup>Haifa, IL, <sup>3</sup>München, DE
- 12:30 - 12:30 **8P - Role of chemokines in resectable non-small cell lung cancer (NSCLC)**  
M. Drosslerová, M. Šterclová, M. Vašáková, A. Tašková, V. Hytych, P. Horažďovský, E. Richterová, M. Směťáková, L. Havel; Prague, CZ
- 12:30 - 12:30 **9P - Clinical validation of an NGS-based assay for detecting multiple genomic alterations in Chinese patients with non-small cell lung cancer**  
H. Ge<sup>1</sup>, X. Chen<sup>2</sup>, L. Ruan<sup>1</sup>, Q. Gao<sup>1</sup>, X. Yang<sup>1</sup>, W. Shi<sup>1</sup>, X. Li<sup>1</sup>, G. Zhu<sup>1</sup>; <sup>1</sup>Xiamen, CN, <sup>2</sup>Fuzhou, CN
- 12:30 - 12:30 **10P - The prevalence and prognostic significance of JAK2 mutation subtypes in non-small cell lung cancer from Chinese populations**  
W. Wang<sup>1</sup>, C. Xu<sup>2</sup>, Q. Zhang<sup>2</sup>, W. Zhuang<sup>2</sup>, Y. Zhu<sup>1</sup>, Z. Huang<sup>2</sup>, G. Chen<sup>2</sup>, M. Fang<sup>1</sup>, T. Lv<sup>3</sup>, Y. Song<sup>3</sup>; <sup>1</sup>Zhenjiang, CN, <sup>2</sup>Fuzhou, CN, <sup>3</sup>Nanjing, CN
- 12:30 - 12:30 **11P - Autophagy inhibition potentiates the anti-angiogenic property of multikinase inhibitor anlotinib through JAK2/STAT3/VEGFA signaling in non-small cell lung cancer cells**  
L. Liang, K. Hui, C. Hu, Y. Wen, X. Jiang; Lianyungang, CN





- 12:30 - 12:30 **12P - Clinicopathologic characteristics of patients with TP63 mutations in Chinese non-small cell lung cancer**  
Q. Zhang<sup>1</sup>, C. Xu<sup>1</sup>, W. Wang<sup>2</sup>, W. Zhuang<sup>1</sup>, Z. Huang<sup>1</sup>, G. Chen<sup>1</sup>, M. Fang<sup>2</sup>, T. Lv<sup>3</sup>, Y. Song<sup>3</sup>; <sup>1</sup>Fuzhou, CN, <sup>2</sup>Zhenjiang, CN, <sup>3</sup>Nanjing, CN
- 12:30 - 12:30 **13P - The micro-environmental cross talk between mast cells and lung cancer cells through cell-to-cell contact**  
R. Shemesh<sup>1</sup>, Y. Gorzalczany<sup>1</sup>, R. Sagi-Eisenberg<sup>1</sup>, S. Geva<sup>1</sup>, L.R. Roisman<sup>2</sup>, N. Peled<sup>2</sup>; <sup>1</sup>Tel Aviv, IL, <sup>2</sup>Beer Sheva, IL
- 12:30 - 12:30 **14P - The characteristics of MET exon 14 skipping mutations in Chinese non-small cell lung cancer: A retrospective analysis**  
Y. Zhu<sup>1</sup>, C. Xu<sup>2</sup>, W. Wang<sup>1</sup>, Q. Zhang<sup>2</sup>, W. Zhuang<sup>2</sup>, G. Chen<sup>2</sup>, M. Fang<sup>1</sup>, T. Lv<sup>3</sup>, Y. Song<sup>3</sup>; <sup>1</sup>Zhenjiang, CN, <sup>2</sup>Fuzhou, CN, <sup>3</sup>Nanjing, CN
- 12:30 - 12:30 **15P - TTF1 status in non-small cell lung cancer adenocarcinoma: A prognostic factor**  
J.F. Cordoba Ortega<sup>1</sup>, A. Salud<sup>2</sup>, S. Morales<sup>2</sup>, J. Veas<sup>2</sup>, A. Rodriguez<sup>2</sup>; <sup>1</sup>Lleida, ES, <sup>2</sup>Lerida, ES
- 12:30 - 12:30 **17P - REDOXI-miRNA of Keap1/Nrf2 axis in lung tumors**  
F. Fabrizio, A. Sparaneo, S. Castellana, T. Mazza, D. Trombetta, P. Graziano, A. Rossi, V. Fazio, L.A. Muscarella; San Giovanni Rotondo, IT
- 12:30 - 12:30 **18P - Immunohistochemical expression of PD-L1 in early and late stage non-small cell lung cancer: Correlation with clinicopathological and molecular features**  
E. Kokkotou, V. Rapti, D. Grapsa, P. Bakakos, S. Papadopoulos, M. Bobos, K. Iliadis, K. Syrigos; Athens, GR
- 12:30 - 12:30 **19P - FOXP3<sup>3</sup>, the major isoform of FOXP3, promotes proliferation, migration, and invasion in non-small cell lung cancer**  
H. JIA<sup>1</sup>, H. Qi<sup>2</sup>, J. Peng<sup>2</sup>, M. Li<sup>2</sup>, G. Chen<sup>1</sup>; <sup>1</sup>Shatin, HK, <sup>2</sup>Hong Kong, HK
- 12:30 - 12:30 **20P - Atypical hyperplasia of bronchial epithelial cells induced by chronic exposure to PM 2.5 in mice**  
T.F. Hou, Q.H. Chen; Beijing, CN
- 12:30 - 12:30 **22P - Paclitaxel/ carboplatin/ bevacizumab in non-small cell lung cancer patients induces peripheral effector CD8 T cell proliferation that could be prone for treatment with checkpoint inhibitors**  
D. Dumoulin<sup>1</sup>, P. de Goeje<sup>2</sup>, M. Poncin<sup>2</sup>, K. Bezemer<sup>2</sup>, H. Groen<sup>3</sup>, E. Smit<sup>4</sup>, A. Dingemans<sup>5</sup>, A. Kunert<sup>2</sup>, R. Hendriks<sup>2</sup>, J. Aerts<sup>6</sup>; <sup>1</sup>Barendrecht, NL, <sup>2</sup>Rotterdam, NL, <sup>3</sup>Groningen, NL, <sup>4</sup>Amsterdam, NL, <sup>5</sup>Maastricht, NL, <sup>6</sup>Rotterdam, Noord Brabant/NL



- 12:30 - 12:30 **23P - Immunosenescence (iSenescence) correlates with progression (PD) to PD-(L)1 inhibitors (IO) and not to platinum-chemotherapy (PCT) in advanced non-small cell lung cancer (aNSCLC) patients (pts)**  
R. Ferrara<sup>1</sup>, M. Naigeon<sup>2</sup>, E. Auclin<sup>2</sup>, B. Duchemann<sup>3</sup>, L. Cassard<sup>1</sup>, J.J. Medhi<sup>2</sup>, L. Boselli<sup>2</sup>, J. Grivel<sup>2</sup>, A. Desnoyer<sup>2</sup>, L. Mezquita<sup>1</sup>, L. Hendriks<sup>4</sup>, D. Planchard<sup>1</sup>, C. Caramella<sup>1</sup>, J. Remon-Masip<sup>5</sup>, S. Sangaletti<sup>6</sup>, M. Garassino<sup>7</sup>, B. Besse<sup>8</sup>, N. Chaput<sup>8</sup>;  
1Villejuif, FR, 2Paris, FR, 3Bobigny, CEDEX/FR, 4Maastricht, NL, 5Barcelona, ES, 6Milano, IT, 7Milan, IT, 8Villejuif, CEDEX/FR
- 12:30 - 12:30 **24P - A new bioinformatic pipeline allows the design of small, targeted gene panels for efficient TMB estimation**  
P. Manca<sup>1</sup>, I. Mallona<sup>2</sup>, D. Santini<sup>3</sup>, G. Tonini<sup>3</sup>, C. Rolfo<sup>4</sup>, M. Robinson<sup>2</sup>, F. Pantano<sup>3</sup>;  
1Rome, IT, 2Zürich, CH, 3Roma, IT, 4Baltimore, US
- 12:30 - 12:30 **25P - Lung tumorspheres as a drug screening platform against cancer stem cells**  
A. Herreros Pomares<sup>1</sup>, H. Amado<sup>1</sup>, S. Calabuig Fariñas<sup>1</sup>, E. Escorihuela<sup>1</sup>, J. Murga<sup>2</sup>, S. Torres<sup>1</sup>, E. Durendez-Saez<sup>1</sup>, F. Zhang<sup>1</sup>, A. Blasco<sup>1</sup>, A. Navarro<sup>1</sup>, C. Sampedro<sup>1</sup>, E. Jantus-Lewintre<sup>1</sup>, C. Camps<sup>1</sup>; 1Valencia, ES, 2Castellón, ES
- 12:30 - 12:30 **26P - Potentialities of liquid biopsy in advanced non-small cell lung cancer (aNSCLC): Early evaluation of sentinel mutations in plasma and outcome of patients treated with immunotherapy**  
L. Bonanno, E. Zulato, I. Attili, A. Pavan, P. Del Bianco, G. Nardo, A. Boscolo Bragadin, L. Pasqualini, F. Calabrese, M. Fassan, G. Pasello, V. Guarneri, A. Amadori, P. Conte, S. Indraccolo; Padova, IT
- 12:30 - 12:30 **27P - Comparison of three different gene panels for determination of tumor mutational burden by next generation sequencing**  
R. Pappesch, C. Heydt, J. Rehker, S. Merkelbach-Bruse; Köln, DE
- 12:30 - 12:30 **28P - Applicability of ctDNA at diagnosis and during the monitoring of EGFR-mutated patients**  
S. Calabuig Fariñas, A. Blasco, E. Durendez-Saez, A. Fernández, M. Mosqueda, E. Escorihuela, A. Herreros Pomares, F. Aparisi, J. Garde, M. Shahin, E. Jantus-Lewintre, C. Camps; Valencia, ES
- 12:30 - 12:30 **29P - Pretreatment T790M mutation detection by ultrasensitive PCR assay as predictor of efficacy in non-small lung cancer (NSCLC) patients treated with 1st or 2nd generation EGFR tyrosine kinase inhibitors (TKIs)**  
O.J. Juan Vidal, J. Simarro, D. Lorente Estelles, G. Pérez-Simó, N. Mancheno, R. Murria, J. Gomez Codina, B. Laiz, S. Palanca; Valencia, ES
- 12:30 - 12:30 **30P - Prognostic significance of IGF-1 signaling pathway in patients with advanced non-small cell lung cancer**  
I. Kotsantis, P. Economopoulou, A. Psyrri, E. Maratou, D. Pectasides, H. Gogas, N. Kentepozidis, G. Mountzios, G. Dimitriadis, S. Giannouli; Athens, GR



- 12:30 - 12:30 **31P - Do two lungs form an integrated immune system? Learning from BALF examination in lung cancer**  
J. Domagala-Kulawik, T. Skirecki, D. Dziedzic, M. Polubiec-Kownacka, T. Kryczka, I. Kwiecien; Warsaw, PL
- 12:30 - 12:30 **32P - Exosomes in NSCLC: Analysis of its cargo as a source of biomarkers**  
E. Durendez-Saez<sup>1</sup>, S. Calabuig Fariñas<sup>1</sup>, C. Suarez<sup>2</sup>, M. Mosqueda<sup>1</sup>, S. Gallach<sup>1</sup>, E. Escorihuela<sup>1</sup>, A. Moreno<sup>1</sup>, N. Dong<sup>1</sup>, A. Herreros Pomares<sup>1</sup>, E. de la Cueva<sup>1</sup>, A. Martinez-Romero<sup>1</sup>, E. Serna<sup>1</sup>, J.M. Paramio<sup>2</sup>, E. Jantus-Lewintre<sup>1</sup>, C. Camps<sup>1</sup>; <sup>1</sup>Valencia, ES, <sup>2</sup>Madrid, ES
- 12:30 - 12:30 **33P - Prognostic value of CD8-positive tumor stroma-infiltrating lymphocytes and PD-L1 positive tumor cells at initial biopsy in patients with locally advanced NSCLC treated with chemoradiotherapy**  
K. Gennen<sup>1</sup>, L. Käsmann<sup>1</sup>, C. Eze<sup>1</sup>, M. Dantes<sup>1</sup>, O. Roengvoraphoj<sup>1</sup>, J. Taugner<sup>2</sup>, J. Neumann<sup>2</sup>, A. Tufman<sup>1</sup>, M. Orth<sup>2</sup>, S. Reu<sup>3</sup>, C. Belka<sup>1</sup>, F. Manapov<sup>1</sup>; <sup>1</sup>Munich, DE, <sup>2</sup>München, DE, <sup>3</sup>Würzburg, DE
- 12:30 - 12:30 **34P - Impacts of HDAC2 inhibition on lung cancer treatment**  
Y. Yeh<sup>1</sup>, C. Wu<sup>2</sup>, J. Lai<sup>2</sup>, C. Huang<sup>2</sup>, Y. Wei<sup>2</sup>, M. Huang<sup>2</sup>; <sup>1</sup>Kaohsiung City, TW, <sup>2</sup>Kaohsiung, TW
- 12:30 - 12:30 **35P - Clinicopathological characteristics with genetic profiling and prognostic analysis of primary lymphoepithelioma-like carcinoma in Chinese south-eastern population**  
Y. Shen, F. Hu, B. Zhang, B. Han; Shanghai, CN
- 12:30 - 12:30 **36P - Can a BALF profile distinguish hot vs cold lung tumors?**  
J. Domagala-Kulawik, D. Dziedzic, M. Polubiec-Kownacka, T. Kryczka, I. Kwiecien; Warsaw, PL
- 12:30 - 12:30 **37P - Genetic variation of lymphotoxin beta receptor (LT $\beta$ ;R) rs10849448 (A/G) is associated with risk for lung cancer and metastatic spread to adrenals**  
F. Dimitrakopoulos<sup>1</sup>, A. Antonacopoulou<sup>2</sup>, A. Kottorou<sup>1</sup>, V. Tzelepi<sup>2</sup>, N. Panagopoulos<sup>2</sup>, M. Kalofonou<sup>3</sup>, D. Dougenis<sup>2</sup>, A. Koutras<sup>2</sup>, T. Makatsoris<sup>1</sup>, H. Kalofonos<sup>2</sup>; <sup>1</sup>Patras, Rion/GR, <sup>2</sup>Patras, GR, <sup>3</sup>London, GB
- 12:30 - 12:30 **38P - Hedgehog pathway activation might mediate pemetrexed resistance in NSCLC cells**  
Y. Liu, R. Kiefl, R. Huber, A. Tufman, D. Kauffmann-Guerrero; Munich, DE
- 12:30 - 12:30 **39P - High dose apatinib in the reversal of immunosuppressive tumor microenvironment for irradiation therapy in lung carcinoma**  
L. Liang, C. Hu, Y. Wen, W. Zhuang, L. Wang, Y. Xia, K. Hui, X. Jiang; Lianyungang, CN



- 12:30 - 12:30 **40P - The metabolic phenotypes of non-small cell lung cancer cells in association with clinical treatment strategies**  
T. Kuo<sup>1</sup>, T. Hsiao<sup>2</sup>, P. Yang<sup>1</sup>; <sup>1</sup>Taipei, TW, <sup>2</sup>Taichung, TW
- 12:30 - 12:30 **41P - Diagnostic accuracy of droplet digital PCR (ddPCR) and amplification refractory mutation system PCR (ARMS-PCR) for detecting EGFR mutation in cell-free DNA of advanced lung cancer: A meta-analysis**  
C. Li, Q. He, H. Liang, J. He, W. Liang; Guangzhou, CN
- 12:30 - 12:30 **44P - Temporal trends in treatment (Tx) and overall survival (OS) among patients (pts) with incident NSCLC in the UK: A real-oncology database analysis from the I-O Optimise initiative**  
M. Snee<sup>1</sup>, S. Cheeseman<sup>1</sup>, M. Thompson<sup>2</sup>, M. Riaz<sup>1</sup>, L. Lacoïn<sup>3</sup>, W. Sopwith<sup>1</sup>, C. Chaib<sup>4</sup>, M. Daumont<sup>5</sup>, J. Penrod<sup>6</sup>, J. O'Donnell<sup>6</sup>, G. Hall<sup>1</sup>; <sup>1</sup>Leeds, GB, <sup>2</sup>London, GB, <sup>3</sup>Ladeuze, BE, <sup>4</sup>Madrid, ES, <sup>5</sup>Braine-L'alleud, BE, <sup>6</sup>Princeton, NJ/US
- 12:30 - 12:30 **45P - Treatment (Tx) patterns and overall survival (OS) in patients (pts) with stage IIIB&#x02013;IV NSCLC in Portugal: An IPO-PORTO database analysis from the I-O Optimise initiative**  
M. Soares<sup>1</sup>, L. Antunes<sup>1</sup>, P. Redondo<sup>1</sup>, M. Borges<sup>1</sup>, R. Hermans<sup>2</sup>, D. Patel<sup>2</sup>, F. Grimson<sup>2</sup>, R. Munro<sup>2</sup>, C. Chaib<sup>3</sup>, L. Lacoïn<sup>4</sup>, M. Daumont<sup>5</sup>, J. Penrod<sup>6</sup>, J. O'Donnell<sup>6</sup>, M. Bento<sup>1</sup>, F.R. Goncalves<sup>1</sup>; <sup>1</sup>Porto, PT, <sup>2</sup>London, GB, <sup>3</sup>Madrid, ES, <sup>4</sup>Ladeuze, BE, <sup>5</sup>Braine-L'alleud, BE, <sup>6</sup>Princeton, NJ/US
- 12:30 - 12:30 **46P - Evolution of overall survival (OS) in patients (pts) with incident NSCLC in Denmark and Sweden: A SCAN-LEAF study analysis from the I-O Optimise initiative**  
J. Sørensen<sup>1</sup>, S. Ekman<sup>2</sup>, O.T. Brustugun<sup>3</sup>, P. Horvat<sup>4</sup>, D. Patel<sup>4</sup>, M. Rosenlund<sup>2</sup>, A. Mette Kejs<sup>1</sup>, A. Juarez-Garcia<sup>5</sup>, M. Daumont<sup>6</sup>, L. Lacoïn<sup>7</sup>, J. Penrod<sup>8</sup>, J. O'Donnell<sup>8</sup>, M. Planck<sup>9</sup>; <sup>1</sup>Copenhagen, DK, <sup>2</sup>Stockholm, SE, <sup>3</sup>Oslo, NO, <sup>4</sup>London, GB, <sup>5</sup>Uxbridge, GB, <sup>6</sup>Braine-L'alleud, BE, <sup>7</sup>Ladeuze, BE, <sup>8</sup>Princeton, NJ/US, <sup>9</sup>Lund, SE
- 12:30 - 12:30 **47P - Treatment (Tx) patterns and overall survival (OS) in patients (pts) with NSCLC in Sweden: A SCAN-LEAF study analysis from the I-O Optimise initiative**  
S. Ekman<sup>1</sup>, J. Sørensen<sup>2</sup>, O.T. Brustugun<sup>3</sup>, P. Horvat<sup>4</sup>, D. Patel<sup>4</sup>, M. Rosenlund<sup>1</sup>, A. Mette Kejs<sup>2</sup>, A. Juarez-Garcia<sup>5</sup>, M. Daumont<sup>6</sup>, L. Lacoïn<sup>7</sup>, J. Penrod<sup>8</sup>, J. O'Donnell<sup>8</sup>, M. Planck<sup>9</sup>; <sup>1</sup>Stockholm, SE, <sup>2</sup>Copenhagen, DK, <sup>3</sup>Oslo, NO, <sup>4</sup>London, GB, <sup>5</sup>Uxbridge, GB, <sup>6</sup>Braine-L'alleud, BE, <sup>7</sup>Ladeuze, BE, <sup>8</sup>Princeton, NJ/US, <sup>9</sup>Lund, SE
- 12:30 - 12:30 **48P - Education and lung cancer: A Mendelian randomisation study**  
H. Zhou, Y. Zhang, J. Liu, Y. Yang, W. Fang, S. Hong, G. Chen, S. Zhao, Z. Zhang, J. Shen, W. Xian, Y. Huang, H. Zhao, L. Zhang; Guangzhou, CN
- 12:30 - 12:30 **49P - A Mendelian randomization study of the effects of Crohn&#x02019;s disease on lung cancer**  
J. Liu, H. Zhou, Y. Zhang, W. Fang, Y. Yang, S. Hong, G. Chen, S. Zhao, J. Shen, W. Xian, Y. Huang, H. Zhao, L. Zhang; Guangzhou, CN





- 12:30 - 12:30 **50P - Reduced-, and no-dose thin-section radiologic examinations: Comparison of capability for nodule detection in patients having pulmonary nodules**  
W. Tang, Q. Peng, Y. Huang, N. Wu, H. Ouyang; Beijing, CN
- 12:30 - 12:30 **51P - Invasive diagnostic investigation-related complications and its impact on treatment initiation in lung cancer patients in a rapid access lung lesion clinic in regional Australia**  
K. Mccann<sup>1</sup>, W. Faisal<sup>2</sup>; <sup>1</sup>Ballarat, VIC/AU, <sup>2</sup>Ballarat, AU
- 12:30 - 12:30 **52P - Concordance, decision impact, and satisfaction for a computerized clinical decision support system in treatment of lung cancer patients**  
K.A. Lee<sup>1</sup>, W. Felix<sup>2</sup>, G. Jackson<sup>3</sup>; <sup>1</sup>Jupiter, US, <sup>2</sup>Boston, MA/US, <sup>3</sup>Nashville, TN/US
- 12:30 - 12:30 **53P - Pulmonary tuberculosis: A hurdle to overcome for early lung cancer diagnosis in TB burden countries**  
M.S. Akter, S. Ahmed; Dhaka, BD
- 12:30 - 12:30 **56P - CT image standardization is superior to larger but heterogeneous data for robust radiomic models**  
D. Vuong<sup>1</sup>, M. Bogowicz<sup>1</sup>, J. Unkelbach<sup>1</sup>, R. Foerster<sup>1</sup>, S. Denzler<sup>1</sup>, A. Xyrafas<sup>2</sup>, M. Pless<sup>3</sup>, S. Thierstein<sup>2</sup>, S. Peters<sup>4</sup>, M. Guckenberger<sup>1</sup>, S. Tanadini-Lang<sup>1</sup>; <sup>1</sup>Zürich, CH, <sup>2</sup>Bern, CH, <sup>3</sup>Winterthur, CH, <sup>4</sup>Lausanne, CH
- 12:30 - 12:30 **57P - Non-small cell lung carcinoma (NSCLC) patients with baseline brain imaging: A prospective observational study**  
G. NARESH, P.S. Malik, S. Khurana, S. Pathy, M. Yadav, D. Jain, H. Kancharla; New Delhi, IN
- 12:30 - 12:30 **58P - Evaluation of a care path for patients with lung tumors and co-existing interstitial lung disease**  
M. Ronden-Kianoush, E. Nossent, C. Dickhoff, S. Nijman, I. Bahce, S. Senan, F. Spoelstra; Amsterdam, NL
- 12:30 - 12:30 **59P - Comparison of internal target volume delineation using CT datasets of four-dimensional computed tomography in lung cancer radiotherapy**  
S. Bushra, A. Tibdewal, N. Mummudi, R. Kinhikar, Y. Ghadi, J.P. Agarwal; Mumbai, IN
- 12:30 - 12:30 **60P - Nomogram for patients with stage I small cell lung cancer: A competing risk analysis**  
J. Liu, H. Zhou, Y. Zhang, W. Fang, Y. Yang, S. Hong, G. Chen, S. Zhao, X. Chen, Z. Zhang, W. Xian, J. Shen, Y. Huang, H. Zhao, L. Zhang; Guangzhou, CN
- 12:30 - 12:30 **61P - Value of post-radiotherapy for limited stage small cell lung cancer on basis of a prognostic scoring model**  
J. Yu, W. Ouyang, J. Hu, J. Zhang, C. Xie; Wuhan, CN



- 12:30 - 12:30 **62P - External validation of a survival score for limited stage small cell lung cancer treated with chemoradiotherapy**  
L. Käsmann<sup>1</sup>, R. Abdo<sup>2</sup>, J. Taugner<sup>2</sup>, C. Eze<sup>1</sup>, M. Dantes<sup>1</sup>, O. Roengvoraphoj<sup>1</sup>, C. Belka<sup>1</sup>, F. Manapov<sup>1</sup>; <sup>1</sup>Munich, DE, <sup>2</sup>München, DE
- 12:30 - 12:30 **63P - Real-life experience with the implementation of DLL3 staining and the subsequent treatment with rovalpituzumab tesirine in heavily pretreated SCLC patients**  
M. Hochmair, C. Weinlinger, H. Fabikan, R. Koger, D. Krenbeck, F. Huemer, O. Illini, M. Kulaksiz, A. Valipour, O. Burghuber; Vienna, AT
- 12:30 - 12:30 **64P - Timing of treatment with concurrent chemoradiotherapy (CRT) and impact on progression free survival (PFS) in limited stage small cell lung cancer (LSSCLC)**  
L. McSorley<sup>1</sup>, C. Goggin<sup>2</sup>, N. Elhadi<sup>2</sup>, P. O'Dea<sup>2</sup>, J. Sui<sup>3</sup>, D. Kelly<sup>3</sup>, C. Brady<sup>4</sup>, D. O'Mahony<sup>4</sup>; <sup>1</sup>Galway, IE, <sup>2</sup>Cork, IE, <sup>3</sup>Dublin, IE, <sup>4</sup>Cork, Cork/IE
- 12:30 - 12:30 **65P - Experience of prophylactic cranial irradiation in extensive stage small cell lung cancer at a regional cancer center in India**  
R. Jat, R. Rai, S. Jakhar, S. Beniwal, N. Sharma, H. Kumar; Bikaner, IN
- 12:30 - 12:30 **66P - Treatment (tx) characteristics and clinical outcomes in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) treated with carboplatin (carbo) or cisplatin (cis) in combination with etoposide (etop) in US clinical practice**  
M. Sebastian<sup>1</sup>, F. Barlesi<sup>2</sup>, R. Califano<sup>3</sup>, A. Mansfield<sup>4</sup>, F. Blackhall<sup>3</sup>, E. Flahavan<sup>5</sup>, J. Davies<sup>5</sup>, P. Arnold<sup>6</sup>, S. Morris<sup>6</sup>, M. Reck<sup>7</sup>; <sup>1</sup>Frankfurt Am Main, DE, <sup>2</sup>Marseille, CEDEX 20/FR, <sup>3</sup>Manchester, GB, <sup>4</sup>Rochester, MN/US, <sup>5</sup>Welwyn Garden City, GB, <sup>6</sup>Basel, CH, <sup>7</sup>Grosshansdorf, DE
- 12:30 - 12:30 **67TiP - ADRIATIC: A phase III trial of durvalumab &#x000B1; tremelimumab after concurrent chemoradiation for patients with limited stage small cell lung cancer**  
S. Senan<sup>1</sup>, N. Shire<sup>2</sup>, G. Mak<sup>3</sup>, W. Yao<sup>3</sup>, H. Jiang<sup>4</sup>; <sup>1</sup>Amsterdam, NL, <sup>2</sup>Gaithersburg, US, <sup>3</sup>Gaithersburg, MD/US, <sup>4</sup>Shanghai, CN
- 12:30 - 12:30 **73P - Utilization rates of stereotactic body radiation therapy for the treatment of stage I NSCLC in three European countries**  
R. Damhuis<sup>1</sup>, S. Senan<sup>2</sup>, A. Khakwani<sup>3</sup>, S. Harden<sup>4</sup>, A. Helland<sup>5</sup>, T. Strand<sup>5</sup>; <sup>1</sup>Utrecht, NL, <sup>2</sup>Amsterdam, NL, <sup>3</sup>Nottingham, GB, <sup>4</sup>Cambridge, GB, <sup>5</sup>Oslo, NO
- 12:30 - 12:30 **74P - Is there any prognostic significance of the level of change in SUVmax after SBRT in patients with early stage NSCLC?**  
G. Yaprak<sup>1</sup>, A. Ozen<sup>2</sup>, F. Tugrul<sup>2</sup>, S. Ozugur<sup>1</sup>, N. Isik<sup>1</sup>; <sup>1</sup>Istanbul, TR, <sup>2</sup>Eskisehir, TR
- 12:30 - 12:30 **75P - Thoracic ultrasound can be a trustable tool in untouchable lung nodule surgery**



H. Zhang, Berlin, CN

- 12:30 - 12:30 **76P - Endobronchial surgery and photodynamic therapy for early central lung cancer treatment**  
S. Pirogov, L. Telegina, V. Sokolov, T. Karmakova, E. Filonenko, O. Pikin, A. Kaprin; Moscow, RU
- 12:30 - 12:30 **77P - The prognostic impact of the international association for the study of lung cancer (IASLC) definitions on completeness of surgical resection for non-small cell lung cancer (NSCLC)**  
M. Gagliasso<sup>1</sup>, C. Cartia<sup>2</sup>, A. Maraschi<sup>2</sup>, R. Rapanà<sup>2</sup>, S. Sobrero<sup>2</sup>, A. Sandri<sup>2</sup>, G. Migliaretti<sup>2</sup>, F. Ardissoni<sup>2</sup>; <sup>1</sup>Cuneo, IT, <sup>2</sup>Orbassano, IT
- 12:30 - 12:30 **78P - Lung resection for cancer in patients with heart disease: Management and postoperative outcome**  
F. Caushi, I. Skenduli, A. Hatibi, A. Mezini, S. Telo, S. Bala, E. Shima, A. Cani; Tirana, AL
- 12:30 - 12:30 **79P - Tissue microarray analysis on prognostic value of coexpression of RUNX3 and trimethylated histone H3 lysine 27 in surgically resected patients with stage I non-small cell lung cancer**  
X. Chen, Y. Deng, Y. Shi; Fuzhou, CN
- 12:30 - 12:30 **80P - High blood platelets levels (BPL): A prognostic factor in patients with early or locally advanced non-small cell lung cancer (NSCLC)**  
J.F. Cordoba Ortega<sup>1</sup>, A. Salud<sup>2</sup>, S. Morales<sup>2</sup>, J. Veas<sup>2</sup>, A. Rodriguez<sup>2</sup>; <sup>1</sup>Lleida, ES, <sup>2</sup>Lerida, ES
- 12:30 - 12:30 **81P - Higher PD-L1 expression correlates with lymphocyte infiltration in early non-small cell lung cancer**  
P. Rocha, M. Rodrigo, L. Moliner, M. Hardy-Werbin, D. Casadevall Aguilar, X. Durán, O. Arpí, S. Clavé, M. Salido, X. Riera, S. Menendez, Á. Taus, L. Pijuan, L. Comerma, E. Arriola Aperribay; Barcelona, ES
- 12:30 - 12:30 **82TiP - IMpower030: Phase III study evaluating neoadjuvant treatment of resectable stage II-IIIB non-small cell lung cancer (NSCLC) with atezolizumab (atezo) &#x0002B; chemotherapy**  
S. Peters<sup>1</sup>, A. Kim<sup>2</sup>, B. Solomon<sup>3</sup>, D. Gandara<sup>4</sup>, R. Dziadziuszko<sup>5</sup>, A. Brunelli<sup>6</sup>, M. Garassino<sup>7</sup>, M. Reck<sup>8</sup>, L. Wang<sup>9</sup>, I. To<sup>9</sup>, S. Sun<sup>9</sup>, B. Gitlitz<sup>9</sup>, A. Sandler<sup>10</sup>, N. Rizvi<sup>11</sup>; <sup>1</sup>Lausanne, CH, <sup>2</sup>Los Angeles, CA/US, <sup>3</sup>Melbourne, VIC/AU, <sup>4</sup>Sacramento, CA/US, <sup>5</sup>Gdańsk, PL, <sup>6</sup>Leeds, GB, <sup>7</sup>Milan, IT, <sup>8</sup>Grosshansdorf, DE, <sup>9</sup>South San Francisco, CA/US, <sup>10</sup>South San Francisco, OR/US, <sup>11</sup>New York, NY/US
- 12:30 - 12:30 **87P - Time-series of peripheral blood biomarkers as biomarkers for immunotherapy in advanced non-small cell lung cancer (aNSCLC) patients**





A. Prelaj<sup>1</sup>, S.E. Rebuzzi<sup>2</sup>, P. Pizzutilo<sup>3</sup>, M. Bilancia<sup>3</sup>, M. Montrone<sup>3</sup>, F. Pesola<sup>3</sup>, V. Longo<sup>3</sup>, G. Del Bene<sup>3</sup>, V. Lapadula<sup>3</sup>, F. Cassano<sup>3</sup>, P. Petrillo<sup>3</sup>, D. Bafunno<sup>3</sup>, N. Varesano<sup>3</sup>, V. Lamorgese<sup>3</sup>, A. Mastranrdea<sup>3</sup>, D. Ricci<sup>3</sup>, A. Catino<sup>3</sup>, D. Galetta<sup>3</sup>; <sup>1</sup>Milan, IT, <sup>2</sup>Genova, IT, <sup>3</sup>Bari, IT

- 12:30 - 12:30 **89P - Treatment patterns and long-term survival for unresected stage III non-small cell lung cancer patients: A nationwide register study in Denmark**  
A. Green<sup>1</sup>, K. Olsen<sup>2</sup>, M. Bliddal<sup>2</sup>, H. Christensen<sup>1</sup>, E. Jakobsen<sup>2</sup>; <sup>1</sup>Copenhagen, DK, <sup>2</sup>Odense C, DK
- 12:30 - 12:30 **90P - Real-world treatment patterns, clinical practice and outcomes for locally advanced, non resectable, non-small cell lung cancer from the French ESME Lung database**  
N. Girard<sup>1</sup>, M. Pérol<sup>2</sup>, G. Simon<sup>1</sup>, C. Audigier Valette<sup>3</sup>, R. Gervais<sup>4</sup>, D. Debieuvre<sup>5</sup>, R. Schott<sup>6</sup>, X. Quantin<sup>7</sup>, B. Coudert<sup>8</sup>, H. Lena<sup>9</sup>, M. Carton<sup>1</sup>, M. Robain<sup>1</sup>, T. Filleron<sup>10</sup>, C. Chouaid<sup>11</sup>; <sup>1</sup>Paris, FR, <sup>2</sup>Lyon, CEDEX/FR, <sup>3</sup>Toulon, CEDEX/FR, <sup>4</sup>Caen, CEDEX 5/FR, <sup>5</sup>Mulhouse, FR, <sup>6</sup>Strasbourg, CEDEX/FR, <sup>7</sup>Montpellier, CEDEX 5/FR, <sup>8</sup>Dijon, Cedex/FR, <sup>9</sup>Rennes, CEDEX/FR, <sup>10</sup>Toulouse, CEDEX 3/FR, <sup>11</sup>Créteil, CEDEX 12/FR
- 12:30 - 12:30 **91P - Prognosis of EGFR-mutant advanced lung adenocarcinoma patients with different intrathoracic metastatic patterns**  
F. Hu<sup>1</sup>, B. Zhang<sup>1</sup>, C. Li<sup>1</sup>, J. Xu<sup>1</sup>, H. Wang<sup>1</sup>, P. Gu<sup>1</sup>, X. Zheng<sup>1</sup>, W. Nie<sup>1</sup>, Y. Shen<sup>1</sup>, H. Zhang<sup>1</sup>, P. Hu<sup>2</sup>, X. Zhang<sup>1</sup>; <sup>1</sup>Shanghai, CN, <sup>2</sup>Zhenjiang, CN
- 12:30 - 12:30 **92P - A prospective study on the association of dose-volume histogram parameters with oesophagitis, radiation pneumonitis, radiation induced pulmonary fibrosis after receiving chemoradiation for NSCLC**  
S. Bhowal, K. Chatterjee, J. Dey; Kolkata, IN
- 12:30 - 12:30 **93P - Heterogeneity score in inoperable stage III non-small cell lung cancer patients treated with definitive chemoradiotherapy: A single centre analysis**  
J. Taugner<sup>1</sup>, L. Käsmann<sup>2</sup>, C. Eze<sup>2</sup>, M. Dantes<sup>2</sup>, O. Roengvoraphoj<sup>2</sup>, K. Gennen<sup>2</sup>, M. Karin<sup>2</sup>, A. Tufman<sup>2</sup>, C. Belka<sup>2</sup>, F. Manapov<sup>2</sup>; <sup>1</sup>München, DE, <sup>2</sup>Munich, DE
- 12:30 - 12:30 **94P - Challenges in the management of stage III non-small cell lung cancer (NSCLC) within multidisciplinary team (MDT): A lung cancer center experience**  
K. Harbague, N. Mejri, H. El Benna, S. Labidi, N. Daoud, H. Boussen; Ariana, TN
- 12:30 - 12:30 **95P - The role of patient performance status and its changes before and after completion of multimodal treatment for inoperable stage III NSCLC**  
L. Käsmann<sup>1</sup>, J. Taugner<sup>2</sup>, C. Eze<sup>1</sup>, O. Roengvoraphoj<sup>1</sup>, M. Dantes<sup>1</sup>, K. Gennen<sup>1</sup>, M. Karin<sup>1</sup>, A. Tufman<sup>1</sup>, C. Belka<sup>1</sup>, F. Manapov<sup>1</sup>; <sup>1</sup>Munich, DE, <sup>2</sup>München, DE
- 12:30 - 12:30 **96P - Impact of thrombocytosis and neutrophil-to-lymphocyte ratio before start of chemoradiotherapy on patient survival in inoperable stage III NSCLC**



M. Hoffmann<sup>1</sup>, J. Taugner<sup>1</sup>, O. Roengvoraphoj<sup>2</sup>, C. Eze<sup>2</sup>, L. Käsmann<sup>2</sup>, C. Belka<sup>2</sup>, F. Manapov<sup>2</sup>; <sup>1</sup>München, DE, <sup>2</sup>Munich, DE

- 12:30 - 12:30 **97P - Pattern of first-site failure and salvage treatment in patients with inoperable stage III non-small cell lung cancer after chemoradiotherapy**  
C. Eze<sup>1</sup>, J. Taugner<sup>2</sup>, L. Käsmann<sup>1</sup>, O. Roengvoraphoj<sup>1</sup>, N. Schmidt-Hegemann<sup>2</sup>, M. Dantes<sup>1</sup>, C. Belka<sup>1</sup>, F. Manapov<sup>1</sup>; <sup>1</sup>Munich, DE, <sup>2</sup>München, DE
- 12:30 - 12:30 **98P - Implications for UK practice of the use of durvalumab in stage III NSCLC**  
M.S. Iqbal<sup>1</sup>, P. Atherton<sup>1</sup>, C. Macgregor<sup>2</sup>, A. Wieczorek<sup>3</sup>, J. Singer<sup>4</sup>, J. Walther<sup>5</sup>, F. Little<sup>6</sup>, S. Harden<sup>7</sup>, C. Peedell<sup>8</sup>, A. Cyriac<sup>9</sup>, S. Chowdhury<sup>4</sup>, M. Bayne<sup>10</sup>, K. Yip<sup>11</sup>, A. Britten<sup>12</sup>, C. Powell<sup>13</sup>, J. Brock<sup>12</sup>, S. Datta<sup>14</sup>, T. Sevitt<sup>15</sup>, A. Mehta<sup>16</sup>, A. Greystoke<sup>17</sup>; <sup>1</sup>Newcastle Upon Tyne, GB, <sup>2</sup>Inverness, GB, <sup>3</sup>Cottingham, GB, <sup>4</sup>Harlow, GB, <sup>5</sup>Taunton, GB, <sup>6</sup>Edinburgh, GB, <sup>7</sup>Cambridge, GB, <sup>8</sup>Middlesbrough, GB, <sup>9</sup>Southend, GB, <sup>10</sup>Poole, GB, <sup>11</sup>Ipswich, GB, <sup>12</sup>Brighton, GB, <sup>13</sup>Swansea, GB, <sup>14</sup>Peterborough, GB, <sup>15</sup>Maidstone, GB, <sup>16</sup>Guildford, GB, <sup>17</sup>Newcastle Upon Tyne, Tyne and Wear/GB
- 12:30 - 12:30 **99P - Efficacy and safety of adjuvant chemotherapy in lung cancer: Real-world evidence**  
F. Roitberg<sup>1</sup>, M.F. Neffá<sup>1</sup>, R. Bonadio<sup>1</sup>, G. Harada<sup>1</sup>, E. Mendoza<sup>2</sup>, M. Mak<sup>1</sup>, T. Takahashi<sup>1</sup>, R. Martins<sup>1</sup>, C. Mesquita<sup>1</sup>, F. Santini<sup>1</sup>, P. de Araújo<sup>1</sup>, L. Lauricella<sup>1</sup>, G. Prado<sup>1</sup>, T. Takagaki<sup>1</sup>, E. de Mello<sup>1</sup>, F. Gabrielli<sup>1</sup>, H. de Andrade Carvalho<sup>1</sup>, R. Terra<sup>1</sup>, G. de Castro Jr<sup>3</sup>; <sup>1</sup>Sao Paulo, BR, <sup>2</sup>Quito, EC, <sup>3</sup>São Paulo, BR
- 12:30 - 12:30 **100P - A new PET-CT score for locally-advanced inoperable NSCLC stage III patients treated with chemoradiotherapy**  
O. Roengvoraphoj<sup>1</sup>, C. Eze<sup>1</sup>, J. Taugner<sup>2</sup>, A. Gjika<sup>2</sup>, A. Tufman<sup>1</sup>, L. Käsmann<sup>1</sup>, I. Hadi<sup>2</sup>, E. Mille<sup>2</sup>, C. Belka<sup>1</sup>, F. Manapov<sup>1</sup>; <sup>1</sup>Munich, DE, <sup>2</sup>München, DE
- 12:30 - 12:30 **101TiP - PACIFIC-R: First real-world study of patients with unresectable, stage III NSCLC treated with durvalumab after chemoradiotherapy**  
N. Girard<sup>1</sup>, F. Mornex<sup>2</sup>, D. Christoph<sup>3</sup>, R. Fietkau<sup>4</sup>, A. Filippi<sup>5</sup>, J. Field<sup>6</sup>, P. Garrido Lopez<sup>7</sup>, F. McDonald<sup>8</sup>, S. Peters<sup>9</sup>, A. Klein<sup>10</sup>, M. Licour<sup>11</sup>, M. Garassino<sup>12</sup>; <sup>1</sup>Paris, FR, <sup>2</sup>Pierre Bénite, FR, <sup>3</sup>Essen, DE, <sup>4</sup>Erlangen, DE, <sup>5</sup>Pavia, IT, <sup>6</sup>Liverpool, GB, <sup>7</sup>Madrid, ES, <sup>8</sup>London, GB, <sup>9</sup>Lausanne, CH, <sup>10</sup>Cambridge, GB, <sup>11</sup>Gaithersburg, US, <sup>12</sup>Milan, IT
- 12:30 - 12:30 **121P - Risk of not receiving second-line therapy is high in EGFR mt&&**  
J. Roeper<sup>1</sup>, A. Lueers<sup>2</sup>, M. Falk<sup>3</sup>, S. Schatz<sup>4</sup>, M. Tiemann<sup>4</sup>, C. Wesseler<sup>4</sup>, G.H. Wiest<sup>4</sup>, S. Sackmann<sup>5</sup>, D. Ukena<sup>5</sup>, L. Heukamp<sup>6</sup>, F. Griesinger<sup>2</sup>; <sup>1</sup>Berlin, DE, <sup>2</sup>Oldenburg, DE, <sup>3</sup>Hamburg, Hamburg/DE, <sup>4</sup>Hamburg, DE, <sup>5</sup>Bremen, DE, <sup>6</sup>Köln, DE
- 12:30 - 12:30 **122P - Osimertinib as first-line (1L) treatment for epidermal growth factor receptor (EGFR) mutation-positive advanced non-small cell lung cancer (NSCLC): Final efficacy and safety results from two phase I expansion cohorts**



J.C. Yang<sup>1</sup>, S. Ramalingam<sup>2</sup>, C. Lee<sup>3</sup>, T. Kurata<sup>4</sup>, D. Kim<sup>5</sup>, T. John<sup>6</sup>, N. Nogami<sup>7</sup>, Y. Ohe<sup>8</sup>, Y. Rukazenkov<sup>9</sup>, M. Murphy<sup>10</sup>, P. Jänne<sup>11</sup>; <sup>1</sup>Taipei City, TW, <sup>2</sup>Atlanta, US, <sup>3</sup>Kogarah, NSW/AU, <sup>4</sup>Osaka, JP, <sup>5</sup>Seoul, KR, <sup>6</sup>Heidelberg, AU, <sup>7</sup>Matsuyama, JP, <sup>8</sup>Tokyo, JP, <sup>9</sup>Macclesfield, Cheshire/GB, <sup>10</sup>Cambridge, GB, <sup>11</sup>Boston, MA/US

- 12:30 - 12:30 **123P - Long term survival analysis of osimertinib in stage IV NSCLC patients harbored acquired EGFR T790M mutation: A real-world study in China**  
S. Wang, B. Han; Shanghai, CN
- 12:30 - 12:30 **124P - The effect of proton pump inhibitors (PPI) on dacomitinib (DACO) pharmacokinetics and efficacy in non-small cell lung cancer (NSCLC) patients with activating epidermal growth factor receptor (EGFR) mutation**  
J. Li, D. Nickens, K. Wilner, W. Tan; San Diego, US
- 12:30 - 12:30 **125P - Elderly patients treated with afatinib in clinical practice: Results from the prospective non-interventional study GIDEON**  
W. Brückl<sup>1</sup>, E. Laack<sup>2</sup>, C. Kortsik<sup>3</sup>, H. Schaefer<sup>4</sup>, M. Reck<sup>5</sup>, A. Maerten<sup>6</sup>, C. Hoffmann<sup>6</sup>; <sup>1</sup>Nürnberg, DE, <sup>2</sup>Berlin, DE, <sup>3</sup>Mainz, DE, <sup>4</sup>Völklingen, DE, <sup>5</sup>Grosshansdorf, DE, <sup>6</sup>Ingelheim Am Rhein, DE
- 12:30 - 12:30 **126P - Regional retrospective analysis of outcomes of EGFR mutated non-squamous non-small cell lung cancer (NSCLC) patients in West Yorkshire**  
D. Sharma<sup>1</sup>, F. Slevin<sup>1</sup>, K. Clarke<sup>1</sup>, K. Franks<sup>2</sup>, M. Snee<sup>1</sup>, P. Jain<sup>1</sup>; <sup>1</sup>Leeds, GB, <sup>2</sup>Leeds, Yorkshire/GB
- 12:30 - 12:30 **127P - Obesity has an impact on the efficacy of EGFR-TKI in NSCLC patients harbouring EGFR mutation: A real-world study**  
Z. Ding, Y. Chen, Y. Hong, Y. Fu, L. Tong, Q. Li, P. Lin; Chengdu, CN
- 12:30 - 12:30 **128P - Frequency and types of EGFR mutation in Moroccan patients with non-small cell lung cancer**  
M. Sow, H. El Yacoubi<sup>1</sup>, B. Moukafih, S. Balde, G. Akimana, S. Elkhoyaali, H. Abahssain, H. Mrabti, I. Elghissassi, H. Errihani; Rabat, MA
- 12:30 - 12:30 **129P - Anlotinib can overcome acquired resistance to EGFR-TKIs via FGFR1 signaling in non-small cell lung cancer**  
Z. Lian, W. Du, J. Zhu, Y. Zeng, L. zeyi, J. Huang; Suzhou, CN
- 12:30 - 12:30 **130P - Relationship of clinicopathological characteristics, EGFR genotyping and prognosis in non-small cell lung cancer patients with malignant pleural effusion**  
J. Zhang, Z. Zhou, Y. Su, T. Yu; Nanning, CN
- 12:30 - 12:30 **131P - Upfront whole brain radiotherapy for multiple brain metastases in patients with EGFR-mutant lung adenocarcinoma**  
C. Li, J. Guo, L. Zhao, F. Hu, W. Nie, H. Wang, X. Zheng, Y. Shen, P. Gu, Y. Zhang, X. Zhang; Shanghai, CN



- 12:30 - 12:30 **132P - New insights into acquired resistance mechanisms to third-generation EGFR tyrosine kinase inhibitor therapy in lung cancer**  
J. Fassunke<sup>1</sup>, C. Heydt<sup>2</sup>, S. Michels<sup>2</sup>, B. Van Veggel<sup>3</sup>, F. Müller<sup>2</sup>, M. Keul<sup>4</sup>, M.A. Dammert<sup>2</sup>, A. Schmitt<sup>2</sup>, E. Smit<sup>3</sup>, S. Kast<sup>4</sup>, J. Wolf<sup>1</sup>, R. Buettner<sup>1</sup>, M. Sos<sup>2</sup>, D. Rauh<sup>4</sup>, S. Merkelbach-Bruse<sup>2</sup>; <sup>1</sup>Cologne, DE, <sup>2</sup>Köln, DE, <sup>3</sup>Amsterdam, NL, <sup>4</sup>Dortmund, DE
- 12:30 - 12:30 **133P - A study evaluating the different treatment modalities for EGFR mutation positive advanced NSCLC patients that acquire c-MET amplification after EGFR TKI therapy resistant**  
J. Qu, L. Liu, J. Heng, C. Zhou, Y. Xiong, W. Jiang, N. Yang; Changsha, CN
- 12:30 - 12:30 **134P - Mutational spectrum of acquired resistance to reversible versus irreversible EGFR tyrosine kinase inhibitors**  
S. Wagener-Rydzek<sup>1</sup>, C. Heydt<sup>2</sup>, J. Sueptitz<sup>2</sup>, S. Michels<sup>2</sup>, M. Falk<sup>3</sup>, C. Alidousty<sup>2</sup>, J. Fassunke<sup>1</sup>, M. Tiemann<sup>4</sup>, L. Heukamp<sup>2</sup>, J. Wolf<sup>1</sup>, R. Buettner<sup>1</sup>, S. Merkelbach-Bruse<sup>2</sup>; <sup>1</sup>Cologne, DE, <sup>2</sup>Köln, DE, <sup>3</sup>Hamburg, Hamburg/DE, <sup>4</sup>Hamburg, DE
- 12:30 - 12:30 **135P - EGFR & PD L1: An (im)perfect union**  
U. Batra<sup>1</sup>, M. Sharma<sup>2</sup>, P. Jain<sup>2</sup>, S. Bothra<sup>2</sup>, S. Pasricha<sup>3</sup>; <sup>1</sup>New Delhi, Rohini/IN, <sup>2</sup>New Delhi, IN, <sup>3</sup>Delhi, IN
- 12:30 - 12:30 **136P - Correlation of molecular status and anatomic sites of metastases at diagnosis of EGFR positive non-small cell lung cancer (NSCLC): A single institution experience**  
K. Krpina, B. Budimir, S. Kukulj, A. Marušić, M. Jakopović, M. Samaržija; Zagreb, HR
- 12:30 - 12:30 **137P - Detection and clinicopathologic features of ctDNA in T790M-positive advanced lung adenocarcinomas patients after failure of treatment with first- and second-generation EGFR-TKIs**  
W. he, Z. Zhou, T. Yu, H. Zhao, Y. Su, P. Zeng; Nanning, CN
- 12:30 - 12:30 **138P - PD-L1 confers primary resistance to EGFR-TKI in EGFR mutant non-small cell lung cancer via inducing EMT phenotype**  
Y. Zhang, T. Liu, Y. Zeng, J. Zhu, W. Du, L. zeyi, J. Huang; Suzhou, CN
- 12:30 - 12:30 **139P - Real-world immuno-oncology (IO) therapy treatment patterns and outcomes in patients with anaplastic lymphoma kinase positive (ALK&#x0002B;) non-small cell lung cancer (NSCLC) in the United States**  
X. Pan<sup>1</sup>, M. Lin<sup>2</sup>, Y. Yin<sup>1</sup>, P. Hou<sup>1</sup>, P. Baumann<sup>1</sup>, M. Jahanzeb<sup>3</sup>; <sup>1</sup>Cambridge, MA/US, <sup>2</sup>Cambridge, US, <sup>3</sup>Miami, FL/US
- 12:30 - 12:30 **140P - Brigatinib experience on the ALK project**  
F. Gomes<sup>1</sup>, N. Tokaca<sup>2</sup>, K. Yip<sup>3</sup>, S. Ghosh<sup>2</sup>, T. Newsom-Davis<sup>2</sup>, A. Greystoke<sup>4</sup>, H. Mills<sup>2</sup>, S. Ahmed<sup>5</sup>, A. Harle<sup>1</sup>, G. Ayre<sup>6</sup>, R. Shah<sup>7</sup>, S. Popat<sup>2</sup>, F. Blackhall<sup>1</sup>, Y. Summers<sup>1</sup>; <sup>1</sup>Manchester, GB, <sup>2</sup>London, GB, <sup>3</sup>Ipswich, GB, <sup>4</sup>Newcastle Upon Tyne, Tyne and Wear/GB, <sup>5</sup>Leicester, GB, <sup>6</sup>Bristol, GB, <sup>7</sup>Maidstone, Kent/GB





- 12:30 - 12:30 **141P - Effect of central nervous system (CNS) metastases in a real-world multicenter cohort study of Spanish ALK-positive non-small cell lung cancer (NSCLC) patients (p)**  
L. Angelats<sup>1</sup>, M.R. Garcia Campelo<sup>2</sup>, R. Bernabe Caro<sup>3</sup>, E. Arriola Aperrribay<sup>4</sup>, V. Calvo de Juan<sup>5</sup>, A. Barba Joaquín<sup>4</sup>, N. Vinolas Segarra<sup>4</sup>, M. Gil Moreno<sup>6</sup>, L. Vilà Martinez<sup>7</sup>, O.J. Juan Vidal<sup>8</sup>, N. Vilariño Quintela<sup>4</sup>, M. Cobo<sup>9</sup>, E. Sais<sup>10</sup>, M. Domine Gomez<sup>11</sup>, N. Fernandez Nuñez<sup>12</sup>, J. Coves Sarto<sup>13</sup>, R. Marse Fabregat<sup>14</sup>, A.M. Esteve Gomez<sup>1</sup>, D. Rodríguez-Abreu<sup>15</sup>, E. Carcereny Costa<sup>16</sup>; <sup>1</sup>Badalona, ES, <sup>2</sup>Coruna, ES, <sup>3</sup>Sevilla, ES, <sup>4</sup>Barcelona, ES, <sup>5</sup>Majadahonda, Madrid/ES, <sup>6</sup>Barcelona, Barcelona/ES, <sup>7</sup>Sabadell, Barcelona/ES, <sup>8</sup>Valencia, ES, <sup>9</sup>Malaga, ES, <sup>10</sup>Girona, ES, <sup>11</sup>Madrid, ES, <sup>12</sup>Lugo, ES, <sup>13</sup>Palma De Mallorca, Islas Baleares/ES, <sup>14</sup>Palma De Mallorca, ES, <sup>15</sup>Las Palmas, ES, <sup>16</sup>Badalona, Barcelona/ES
- 12:30 - 12:30 **142P - Clinical management of advanced lung adenocarcinoma with ALK rearrangement: Real-world treatment outcomes and long-term survival**  
B. Zhang, S. Wang, J. Xu, Y. Zhang, X. Zhang, J. Qian, J. Lu, R. Qiao, W. Nie, L. Zhang, Y. Zhao, M. Hu, W. Zhang, B. Han; Shanghai, CN
- 12:30 - 12:30 **143P - Role of radiotherapy in management of brain metastases in anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC): A single-center retrospective study**  
Y. Zhao, B. Zhang, Y. Zhang, S. Wang, J. Qian, B. Han; Shanghai, CN
- 12:30 - 12:30 **144P - Clinical and treatment features associated with improved 5-year survival rate in ALK-positive lung cancer treated with ALK-TKIs**  
A. Passaro, A. Prelaj, G. Spitaleri, E. Del Signore, G. Rossi, E. Guerini-Rocco, M. Barberis, C. Catania, F. de Marinis; Milan, IT
- 12:30 - 12:30 **145P - Clinicopathological characteristics and outcome of advanced ROS1-positive non-small cell lung cancer in Asian patients**  
C.Y.X. Kho, D. Lim, D.S.W. Tan, W.L. Tan, T. Rajasekaran, A. Jain, C.K. Toh, M. Ang, E.H. Tan, Q.S. Ng; Singapore, SG
- 12:30 - 12:30 **146P - Clinical significance of ROS1 deletions detected by FISH and response to crizotinib**  
F. Dall'Olio, G. Lamberti, E. Capizzi, E. Gruppioni, F. Sperandi, A. Altimari, F. Giunchi, M. Fiorentino, A. Ardizzoni; Bologna, IT
- 12:30 - 12:30 **147P - Impact on KRAS-subtypes and TP53 mutations on the prognostic value of KRAS/KEAP1 mutations in non-small cell lung cancer (NSCLC)**  
M. Scheffler<sup>1</sup>, R. Frank<sup>2</sup>, M. Ihle<sup>2</sup>, D. Abdulla<sup>1</sup>, S. Koleczko<sup>2</sup>, L. Nogova<sup>2</sup>, A. Holzem<sup>2</sup>, T. Chanra<sup>1</sup>, R. Riedel<sup>1</sup>, S. Michels<sup>2</sup>, R. Fischer<sup>2</sup>, A. Kron<sup>1</sup>, S. Merkelbach-Bruse<sup>2</sup>, R. Buettner<sup>2</sup>, J. Wolf<sup>1</sup>; <sup>1</sup>Cologne, DE, <sup>2</sup>Köln, DE
- 12:30 - 12:30 **148P - KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic non-squamous NSCLC**



M. Cinausero<sup>1</sup>, N. Laprovitera<sup>2</sup>, G. De Maglio<sup>1</sup>, L. Gerratana<sup>1</sup>, M. Riefolo<sup>2</sup>, M. Macerelli<sup>1</sup>, M. Fiorentino<sup>2</sup>, E. Porcellini<sup>2</sup>, V. Buoro<sup>1</sup>, F. Gelsomino<sup>2</sup>, A. Squadrilli<sup>3</sup>, G. Fasola<sup>1</sup>, M. Tiseo<sup>3</sup>, M. Ferracin<sup>2</sup>, A. Ardizzoni<sup>2</sup>; <sup>1</sup>Udine, IT, <sup>2</sup>Bologna, IT, <sup>3</sup>Parma, IT

- 12:30 - 12:30 **149P - Efficacy of tyrosine kinase inhibitors (TKIs) in advanced lung adenosquamous carcinoma**  
M. Hu, B. Zhang, S. Wang, Y. Shen, J. Qian, Y. Zhao, B. Han; Shanghai, CN
- 12:30 - 12:30 **150P - Characterization of patients with metastatic non-small cell lung cancer obtaining long term benefit from immunotherapy**  
G. Galli<sup>1</sup>, C. Proto<sup>2</sup>, D. Signorelli<sup>1</sup>, M. Imbimbo<sup>1</sup>, R. Ferrara<sup>2</sup>, A. Prelaj<sup>2</sup>, A. De Toma<sup>2</sup>, G. Randon<sup>2</sup>, B. Trevisan<sup>2</sup>, M. Ganzinelli<sup>2</sup>, N. Zilembo<sup>2</sup>, M. Garassino<sup>1</sup>, G. Lo Russo<sup>2</sup>; <sup>1</sup>Milan, IT, <sup>2</sup>Milano, IT
- 12:30 - 12:30 **151P - Safety and tolerability of pembrolizumab or placebo plus pemetrexed and platinum as first-line therapy in Japanese patients (PTS) with metastatic non-squamous non-small cell lung cancer (NSCLC) enrolled in the phase III KEYNOTE-189 study**  
H. Horinouchi<sup>1</sup>, N. Nogami<sup>2</sup>, H. Saka<sup>3</sup>, M. Nishio<sup>1</sup>, T. Tokito<sup>4</sup>, T. Takahashi<sup>5</sup>, K. Kasahara<sup>6</sup>, Y. Hattori<sup>7</sup>, E. Ichihara<sup>8</sup>, N. Adachi<sup>1</sup>, T. Sawada<sup>1</sup>, T. Shimamoto<sup>1</sup>, K. Noguchi<sup>1</sup>, M..C. Pietanza<sup>9</sup>, T. Kurata<sup>10</sup>; <sup>1</sup>Tokyo, JP, <sup>2</sup>Matsuyama, JP, <sup>3</sup>Nagoya, JP, <sup>4</sup>Kurume, JP, <sup>5</sup>Shizuoka, Shizuoka/Jp, <sup>6</sup>Kanazawa, JP, <sup>7</sup>Akashi, JP, <sup>8</sup>Okayama, JP, <sup>9</sup>Kenilworth, NJ/US, <sup>10</sup>Osaka, JP
- 12:30 - 12:30 **152P - Correlation among different KRAS alterations, genetic co-mutations and PD-L1 expression in patients treated with immunotherapy in metastatic NSCLC**  
L. Gianoncelli<sup>1</sup>, G. Spitaleri<sup>1</sup>, A. Passaro<sup>1</sup>, C. Fumagalli<sup>1</sup>, P. Trillo Aliaga<sup>1</sup>, E. Del Signore<sup>2</sup>, V. Stati<sup>1</sup>, E. Ferraro<sup>3</sup>, E. Guerini-Rocco<sup>1</sup>, C. Catania<sup>1</sup>, M. Barberis<sup>1</sup>, F. de Marinis<sup>1</sup>; <sup>1</sup>Milan, IT, <sup>2</sup>Roma, IT, <sup>3</sup>Rozzano, (MI)/IT
- 12:30 - 12:30 **153P - Chemotherapy with immune-checkpoint inhibitors in first-line treatment metastatic NSCLC patients: Systematic review and literature-based meta-analysis**  
A. Addeo<sup>1</sup>, G. Banna<sup>2</sup>, G. Metro<sup>3</sup>, M. Di Maio<sup>4</sup>; <sup>1</sup>Geneva, CH, <sup>2</sup>Catania, IT, <sup>3</sup>Perugia, (PG)/IT, <sup>4</sup>Torino, IT
- 12:30 - 12:30 **154P - Renal toxicity from platinum/pemetrexed and pembrolizumab in the era of combination therapy**  
D. Dumoulin<sup>1</sup>, S. Visser<sup>2</sup>, R. Cornelissen<sup>3</sup>, J. Aerts<sup>4</sup>; <sup>1</sup>Barendrecht, NL, <sup>2</sup>Breda, NL, <sup>3</sup>Rotterdam, NL, <sup>4</sup>Rotterdam, Noord Brabant/NL
- 12:30 - 12:30 **155P - Association of immune-related adverse events (irAEs) and immunotherapy (IT) benefit in advanced non-small cell lung cancer (NSCLC)**  
C. Saavedra Serrano, A. Barquín García, E. Corral de la Fuente, J.J. Serrano Domingo, V. Albarrán Artahona, R. Martín Huertas, A. Gómez Rueda, M.E. Olmedo García; Madrid, ES



- 12:30 - 12:30 **156P - Peripheral blood biomarkers as prognostic factors for immunotherapy in advanced non-small cell lung cancer (aNSCLC) patients**  
A. Prelaj<sup>1</sup>, S.E. Rebutzi<sup>2</sup>, P. Pizzutilo<sup>3</sup>, M. Bilancia<sup>3</sup>, M. Montrone<sup>3</sup>, F. Pesola<sup>3</sup>, V. Longo<sup>3</sup>, G. Del Bene<sup>3</sup>, V. Lapadula<sup>3</sup>, F. Cassano<sup>3</sup>, P. Petrillo<sup>3</sup>, D. Bafunno<sup>3</sup>, N. Varesano<sup>3</sup>, V. Lamorgese<sup>3</sup>, A. Mastranrdea<sup>3</sup>, D. Ricci<sup>3</sup>, A. Catino<sup>3</sup>, D. Galetta<sup>3</sup>; <sup>1</sup>Milan, IT, <sup>2</sup>Genova, IT, <sup>3</sup>Bari, IT
- 12:30 - 12:30 **157P - Prognostic impact of the use of antibiotics in patients with advanced non-small cell lung cancer (NSCLC) receiving PD-(L)1 targeting monoclonal antibodies**  
A. Schett<sup>1</sup>, S. Rothschild<sup>1</sup>, L. Mauti<sup>2</sup>, S. Schmid<sup>2</sup>, C. Appenzeller<sup>2</sup>, A. Curioni-Fontecedro<sup>3</sup>, M. Frueh<sup>2</sup>, M. Joerger<sup>2</sup>; <sup>1</sup>Basel, CH, <sup>2</sup>St. Gallen, CH, <sup>3</sup>Zurich, CH
- 12:30 - 12:30 **158P - Immune-related adverse events (irAEs) in advanced non-small cell lung cancer (aNSCLC): Platelet-to-lymphocyte ratio (PLR) predicts the risk of development and relapse**  
A. Pavan<sup>1</sup>, L. Calvetti<sup>2</sup>, A. Dal Maso<sup>1</sup>, I. Attili<sup>1</sup>, G. Pasello<sup>1</sup>, G. Aprile<sup>3</sup>, V. Guarneri<sup>1</sup>, P. Conte<sup>1</sup>, L. Bonanno<sup>1</sup>; <sup>1</sup>Padova, IT, <sup>2</sup>Verona, IT, <sup>3</sup>Vicenza, IT
- 12:30 - 12:30 **159P - Initial serum tumor marker dynamics predict progression-free and overall survival in single PD-1/PD-L1 inhibitor treated advanced NSCLC**  
D. Lang, A. Horner, E. Brehm, K. Akbari, B. Hergan, K. Langer, C. Asel, M. Scala, B. Kaiser, B. Lamprecht; Linz, AT
- 12:30 - 12:30 **160P - EPSILoN score: Validation cohort of a prognostic score in advanced non-small cell lung cancer (aNSCLC) patients treated with immunotherapy**  
A. Prelaj<sup>1</sup>, G. Lo Russo<sup>2</sup>, D. Signorelli<sup>1</sup>, R. Ferrara<sup>2</sup>, M. Imbimbo<sup>1</sup>, G. Galli<sup>1</sup>, A. De Toma<sup>2</sup>, G. Randon<sup>2</sup>, M. Brambilla<sup>1</sup>, B. Trevisan<sup>2</sup>, M. Ganzinelli<sup>2</sup>, N. Zilembo<sup>2</sup>, F. De Braud<sup>1</sup>, M. Garassino<sup>1</sup>, C. Proto<sup>2</sup>; <sup>1</sup>Milan, IT, <sup>2</sup>Milano, IT
- 12:30 - 12:30 **161P - Tumor mutational burden assessed by a targeted NGS assay predicts clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer**  
P. Jermann<sup>1</sup>, I. Alborelli<sup>1</sup>, K. Leonards<sup>1</sup>, S. Rothschild<sup>1</sup>, L. Leuenberger<sup>1</sup>, S. Savic Prince<sup>1</sup>, K. Mertz<sup>2</sup>, S. Poechtrager<sup>2</sup>, A. Zippelius<sup>1</sup>, L. Quagliata<sup>1</sup>, L. Bubendorf<sup>1</sup>; <sup>1</sup>Basel, CH, <sup>2</sup>Liestal, CH
- 12:30 - 12:30 **162P - Monitoring of blood serum amyloid (SAA) to predict outcome of first-line pembrolizumab (P) in patients (pts) with advanced non-small cell lung cancer (ANSCCLC)**  
V. Di Noia<sup>1</sup>, E. D'Argento<sup>1</sup>, E. Vita<sup>1</sup>, M. Ferrara<sup>1</sup>, P. Damiano<sup>1</sup>, M. Ribelli<sup>1</sup>, A. Cannella<sup>1</sup>, A. Virtuoso<sup>1</sup>, G. Tortora<sup>1</sup>, E. Bria<sup>2</sup>; <sup>1</sup>Rome, IT, <sup>2</sup>Roma, IT
- 12:30 - 12:30 **163P - Immuno-oncological treatment and tumor load in non-small cell lung cancer (NSCLC): Case-control analysis of overall survival (OS) in routine clinical practice**  
M. Faehling, B. Schwenk, M. Kopp, S. Fallscheer, S. Kramberg, R. Eckert; Esslingen, DE





- 12:30 - 12:30 **164P - PD-L1 expression affect the efficacy of pemetrexed maintenance therapy in real-world patients with advanced non-squamous NSCLC**  
Y. Qin, L. Jiang, Y. Li, L. Ren, Y. Wang, Y. Gong, F. Peng, J. Zhu, Z. Ding, Y. Liu, M. Yu, Y. Lu, M. Huang; Chengdu, CN
- 12:30 - 12:30 **165P - Clinical benefit of anti PD-1/PD-L1 plus chemotherapy versus chemotherapy alone in first-line treatment in advanced non-small cell lung cancer: A meta-analysis**  
T. Landre<sup>1</sup>, G. Des Guetz<sup>2</sup>, A. Vergnenegre<sup>3</sup>, C. Chouaid<sup>4</sup>; <sup>1</sup>Sevrans, FR, <sup>2</sup>Bobigny, CEDEX/FR, <sup>3</sup>Limoges, CEDEX/FR, <sup>4</sup>Créteil, CEDEX 12/FR
- 12:30 - 12:30 **166P - Correlation of various clinical, imaging and laboratory parameters with outcome in patients with metastatic non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs): Results from a prospective, observational, single institution study**  
K. Rounis<sup>1</sup>, C. Papadaki<sup>1</sup>, D. Makrakis<sup>1</sup>, A. Monastirioti<sup>1</sup>, L. Vamvakas<sup>2</sup>, K. Kalbakis<sup>1</sup>, D. Mavroudis<sup>1</sup>, S. Aggelaki<sup>1</sup>; <sup>1</sup>Heraklion, GR, <sup>2</sup>Heraklion, Crete/GR
- 12:30 - 12:30 **167P - Prognostic significance of neutrophil/lymphocyte ratio in patients undergoing treatment with nivolumab for recurrent non-small cell lung cancer**  
B. Rapoport<sup>1</sup>, D. Vorobiof<sup>2</sup>, L. Langenhoven<sup>3</sup>, J. Hall<sup>4</sup>, R. Van Eeden<sup>1</sup>, T. Smit<sup>1</sup>, S.W. Chan<sup>5</sup>, M. Botha<sup>6</sup>, J. Raats<sup>3</sup>, M. De Necker<sup>7</sup>, H. Duvenhage<sup>8</sup>; <sup>1</sup>Sandton, ZA, <sup>2</sup>Bnei Atarot, Gauteng/IL, <sup>3</sup>Cape Town, ZA, <sup>4</sup>Cape Town, Western Cape/ZA, <sup>5</sup>Sandton, Gauteng/ZA, <sup>6</sup>George, Western Cape/ZA, <sup>7</sup>Pretoria, ZA, <sup>8</sup>Woodmead, ZA
- 12:30 - 12:30 **168P - Dynamic changes of platelet-to-lymphocyte ratio predict efficacy of PD-1/PD-L1 inhibitors in NSCLC**  
F. Zhou, A. Xiong, C. Zhou; Shanghai, CN
- 12:30 - 12:30 **169P\_PR - Benefit of immunotherapy (IT) in advanced non-small cell lung cancer (NSCLC) in elderly patients (EP)**  
E. Corral de la Fuente, A. Barquín García, C. Saavedra Serrano, M.E. Olmedo García, R. Martín Huertas, J.J. Serrano Domingo, V. Albarrán Artahona, A. Gómez Rueda; Madrid, ES
- 12:30 - 12:30 **170P - Advanced non-small cell lung cancer patients with low tumor mutation burden might derive benefit from anti-programmed cell death (PD)-1 and anti-programmed deathligand 1 (PD-L1) blockade**  
W. Nie<sup>1</sup>, M. Xu<sup>1</sup>, L. Gan<sup>1</sup>, Y. Zhang<sup>2</sup>, B. Han<sup>1</sup>; <sup>1</sup>Shanghai, CN, <sup>2</sup>Chongqing, CN
- 12:30 - 12:30 **171P - Previous exposure to bevacizumab indicated inferior benefits from PD-1/PD-L1 inhibitors in nonsquamous NSCLC**  
F. Zhou, Y. Pan, C. Zhou; Shanghai, CN
- 12:30 - 12:30 **172P - A multi-center, randomized, double-blind, parallel, two-group phase III clinical study on the efficacy and safety of QL1101 or bevacizumab in combination with paclitaxel and carboplatin in the first-line treatment of non-squamous non-small cell lung cancer**



B. Han<sup>1</sup>, K. Li<sup>2</sup>, T. Chu<sup>1</sup>, M. Bi<sup>3</sup>, H. Zhang<sup>4</sup>, Y. Yu<sup>5</sup>, J. Shi<sup>6</sup>, X. Zhang<sup>7</sup>, Z. Chen<sup>8</sup>, C. Han<sup>9</sup>, T. Bai<sup>9</sup>; <sup>1</sup>Shanghai, CN, <sup>2</sup>Tianjin, CN, <sup>3</sup>Bengbu, CN, <sup>4</sup>Xi'an, CN, <sup>5</sup>Harbin, CN, <sup>6</sup>Linyi, CN, <sup>7</sup>Qingdao, CN, <sup>8</sup>Hefei, CN, <sup>9</sup>Jinan, CN

- 12:30 - 12:30 **173P - Stereotactic radiotherapy concurrent to immune or targeted therapy for oligometastatic NSCLC: Clinical scenarios affecting survival**  
S. Kroeze<sup>1</sup>, C. Fritz<sup>1</sup>, D. Kaul<sup>2</sup>, O. Blanck<sup>3</sup>, K. Kahl<sup>4</sup>, F. Roeder<sup>5</sup>, S. Siva<sup>6</sup>, J. Verhoeff<sup>7</sup>, A. Grosu<sup>8</sup>, M. Schymalla<sup>9</sup>, M. Glatzer<sup>10</sup>, M. Szuets<sup>11</sup>, M. Geier<sup>12</sup>, G. Skazikis<sup>13</sup>, I. Sackerer<sup>14</sup>, F. Lohaus<sup>15</sup>, F. Eckert<sup>16</sup>, M. Guckenberger<sup>17</sup>; <sup>1</sup>Zurich, CH, <sup>2</sup>Berlin, DE, <sup>3</sup>Gustow, DE, <sup>4</sup>Augsburg, DE, <sup>5</sup>München, DE, <sup>6</sup>Melbourne, AU, <sup>7</sup>Utrecht, NL, <sup>8</sup>Freiburg, DE, <sup>9</sup>Marburg, DE, <sup>10</sup>St. Gallen, CH, <sup>11</sup>Rostock, DE, <sup>12</sup>Linz, AT, <sup>13</sup>Villingen-Schwenningen, DE, <sup>14</sup>Freising, DE, <sup>15</sup>Dresden, DE, <sup>16</sup>Tübingen, DE, <sup>17</sup>Zürich, CH
- 12:30 - 12:30 **174P - NSCLC stages IIa-IIIc: Tumor related IGRT yields better local control than kV-guidance to anatomic structures**  
F. Zehentmayr<sup>1</sup>, J. Karner<sup>1</sup>, K. Wurstbauer<sup>2</sup>, R. Wass<sup>3</sup>, G. Fastner<sup>1</sup>, L. Rettenbacher<sup>1</sup>, M. Studnicka<sup>1</sup>, C. Pirich<sup>1</sup>, P. Kopp<sup>1</sup>, F. Sedlmayer<sup>1</sup>; <sup>1</sup>Salzburg, AT, <sup>2</sup>Feldkirch, AT, <sup>3</sup>Linz, AT
- 12:30 - 12:30 **175P - Permanent pleural catheter (PPC) for malignant pleural effusion (PE) in advanced non-small cell lung cancer (NSCLC)**  
M. Martinez Kareaga<sup>1</sup>, N. Urbieta-Macazaga<sup>2</sup>, C. Sanchez-Vieco<sup>3</sup>, L. Tomás-López<sup>3</sup>, I. Intxaurbe-Etxebarria<sup>3</sup>, B. Mareque<sup>3</sup>, N. Torregó<sup>3</sup>, A. Narro<sup>3</sup>, L. Puntí<sup>3</sup>, I. Guillen<sup>3</sup>; <sup>1</sup>Vitoria-Gasteiz, ES, <sup>2</sup>San Sebastian, ES, <sup>3</sup>Vitoria, ES
- 12:30 - 12:30 **176P - Real-world treatment patterns for metastatic non-small cell lung cancer at IRST Italy**  
M. Altini<sup>1</sup>, I. Massa<sup>1</sup>, W. Balzi<sup>1</sup>, N. Gentili<sup>1</sup>, F. Foca<sup>1</sup>, V. Danesi<sup>1</sup>, S. Manunta<sup>1</sup>, M. Burgio<sup>1</sup>, P. Cravero<sup>1</sup>, F. Ejzykowicz<sup>2</sup>, S. Chandwani<sup>2</sup>, A. Delmonte<sup>1</sup>; <sup>1</sup>Meldola, IT, <sup>2</sup>Rahway, NJ/US
- 12:30 - 12:30 **177P - Real-world experience of ALK positive NSCLC from India**  
M. Malhotra, V. Noronha, A. Joshi, V. Patil, S. Wadhwa, K. Prabhash; Mumbai, IN
- 12:30 - 12:30 **178P - Feasibility of O-(2-[18F]fluoroethyl)-L-tyrosine (FET) PET for treatment monitoring of brain metastases in lung cancer patients**  
D. Abdulla<sup>1</sup>, M. Ruge<sup>1</sup>, M. Scheffler<sup>1</sup>, L. Nogova<sup>2</sup>, S. Koleczko<sup>2</sup>, T. Persigehl<sup>1</sup>, S. Grau<sup>1</sup>, A. Drzezga<sup>1</sup>, C. Kobe<sup>1</sup>, R. Buettner<sup>2</sup>, N. Galldiks<sup>1</sup>, J. Wolf<sup>1</sup>; <sup>1</sup>Cologne, DE, <sup>2</sup>Köln, DE
- 12:30 - 12:30 **179P - Treatment (tx) characteristics of patients (pts) with locally advanced or metastatic non-small cell lung cancer (NSCLC) receiving atezolizumab (atezo) monotherapy in US clinical practice**  
M. Frueh<sup>1</sup>, O. Rahma<sup>2</sup>, R. Pachynski<sup>3</sup>, J. Mazieres<sup>4</sup>, J. Goldschmidt Jr.<sup>5</sup>, T. Ton<sup>6</sup>, S. Mhatre<sup>6</sup>, C. Chuo<sup>6</sup>, J. Martinalbo<sup>7</sup>, J. Davies<sup>8</sup>, R. Juergens<sup>9</sup>; <sup>1</sup>St. Gallen, CH, <sup>2</sup>Boston, MA/US, <sup>3</sup>St. Louis, MO/US, <sup>4</sup>Toulouse, FR, <sup>5</sup>Blacksburg, VA/US, <sup>6</sup>South San Francisco, CA/US, <sup>7</sup>Basel, CH, <sup>8</sup>Welwyn Garden City, GB, <sup>9</sup>Hamilton, ON/CA



- 12:30 - 12:30 **180TiP - An open-label, randomized, phase I/II trial of IO102 and pembrolizumab, or IO102, pembrolizumab and chemotherapy, as first-line treatment for patients with metastatic non-small cell lung cancer**  
J. Spicer<sup>1</sup>, M. Provencio<sup>2</sup>, P. Garrido Lopez<sup>2</sup>, J. Bosch-Barrera<sup>3</sup>, F.J. de Castro Carpeño<sup>2</sup>, E. Felip<sup>4</sup>, J. Trigo<sup>5</sup>, S. Viteri<sup>4</sup>, E. Coart<sup>6</sup>, E. Schmidt<sup>7</sup>, A. Christiansen<sup>8</sup>, M. Zocca<sup>8</sup>, M. Andersen<sup>8</sup>, E. Ehrnrooth<sup>8</sup>, L. Paz-Ares<sup>2</sup>; <sup>1</sup>London, GB, <sup>2</sup>Madrid, ES, <sup>3</sup>Girona, ES, <sup>4</sup>Barcelona, ES, <sup>5</sup>Malaga, ES, <sup>6</sup>Ottignies, BE, <sup>7</sup>Kenilworth, NJ/US, <sup>8</sup>Copenhagen, DK
- 12:30 - 12:30 **181TiP - Phase II study of crizotinib in Japanese patients with advanced non-small cell lung cancer harboring a MET gene alteration: Co-MET study**  
M. Shimokawa<sup>1</sup>, K. Nosaki<sup>1</sup>, T. Seto<sup>2</sup>, K. Ohashi<sup>3</sup>, M. Morise<sup>4</sup>, Y. Fujiwara<sup>5</sup>, J. Sakakibara<sup>6</sup>, H. Murakami<sup>7</sup>, S. Yano<sup>8</sup>, M. Satouchi<sup>9</sup>, S. Matsumoto<sup>10</sup>, K. Goto<sup>10</sup>, K. Yoh<sup>10</sup>; <sup>1</sup>Fukuoka, JP, <sup>2</sup>Fukuoka, Fukuoka/JP, <sup>3</sup>Okayama, JP, <sup>4</sup>Nagoya, JP, <sup>5</sup>Tokyo, JP, <sup>6</sup>Sapporo, JP, <sup>7</sup>Shizuoka, JP, <sup>8</sup>Kanazawa, JP, <sup>9</sup>Akashi, JP, <sup>10</sup>Kashiwa, Chiba/JP
- 12:30 - 12:30 **182TiP - A phase II trial of tepotinib in patients with non-small cell lung cancer (NSCLC) harboring MET alterations: The VISION study**  
P. Paik<sup>1</sup>, A. Cortot<sup>2</sup>, E. Felip<sup>3</sup>, H. Sakai<sup>4</sup>, J. Mazieres<sup>5</sup>, L. Horn<sup>6</sup>, F. Griesinger<sup>7</sup>, R. Bruns<sup>8</sup>, J. Scheele<sup>8</sup>, J. Straub<sup>8</sup>, R. Veillon<sup>9</sup>; <sup>1</sup>New York City, NY/US, <sup>2</sup>Lille, FR, <sup>3</sup>Barcelona, ES, <sup>4</sup>Saitama, JP, <sup>5</sup>Toulouse, FR, <sup>6</sup>Nashville, TN/US, <sup>7</sup>Oldenburg, DE, <sup>8</sup>Darmstadt, DE, <sup>9</sup>Pessac, FR
- 12:30 - 12:30 **183TiP - A phase II study of [fam-] trastuzumab deruxtecan (DS-8201a) in HER2-overexpressing or -mutated advanced non-small cell lung cancer**  
D. Planchard<sup>1</sup>, B. Li<sup>2</sup>, H. Murakami<sup>3</sup>, R. Shiga<sup>4</sup>, C. Lee<sup>5</sup>, K. Wang<sup>5</sup>, P. Jänne<sup>6</sup>; <sup>1</sup>Villejuif, FR, <sup>2</sup>New York, NY/US, <sup>3</sup>Shizuoka, JP, <sup>4</sup>Tokyo, JP, <sup>5</sup>Basking Ridge, NJ/US, <sup>6</sup>Boston, MA/US
- 12:30 - 12:30 **184TiP - FIND: A phase II study to evaluate the efficacy of erdafitinib in FGFR-altered squamous NSCLC**  
L. Nogova<sup>1</sup>, F. Malchers<sup>1</sup>, A. Hillmer<sup>2</sup>, S. Merkelbach-Bruse<sup>1</sup>, A. Pinto<sup>1</sup>, C. Woempner<sup>1</sup>, R. Riedel<sup>3</sup>, M. Scheffler<sup>3</sup>, S. Michels<sup>1</sup>, P. De Porre<sup>4</sup>, A. Santiago-Walker<sup>5</sup>, R. Fischer<sup>1</sup>, D. Abdulla<sup>3</sup>, R. Thomas<sup>1</sup>, R. Buettner<sup>1</sup>, J. Wolf<sup>3</sup>; <sup>1</sup>Köln, DE, <sup>2</sup>Mainz, DE, <sup>3</sup>Cologne, DE, <sup>4</sup>Beerse, BE, <sup>5</sup>Spring House, US
- 12:30 - 12:30 **185TiP - RATIONALE 001: Tislelizumab (BGB-A317) &#x0002B; concurrent chemoradiotherapy (cCRT) followed by tislelizumab monotherapy in patients (pts) with newly diagnosed locally advanced, unresectable, stage III non-small cell lung cancer (NSCLC)**  
L. Paz-Ares<sup>1</sup>, S. Senan<sup>2</sup>, D. Planchard<sup>3</sup>, L. Wang<sup>4</sup>, A. Cheong<sup>5</sup>, R. Slepets<sup>5</sup>, M. Nguyen<sup>5</sup>, E. Vokes<sup>6</sup>; <sup>1</sup>Madrid, ES, <sup>2</sup>Amsterdam, NL, <sup>3</sup>Villejuif, FR, <sup>4</sup>Shenzhen, CN, <sup>5</sup>Summit, NJ/US, <sup>6</sup>Chicago, IL/US
- 12:30 - 12:30 **186TiP - An open-label, randomized phase III study of early switch maintenance vs delayed second-line nivolumab in advanced stage squamous non-small cell lung cancer (NSCLC) patients after standard first-line platinum-based chemotherapy: EDEN trial**



F. Gelsomino<sup>1</sup>, M. Tiseo<sup>2</sup>, L. Boni<sup>3</sup>, L. Cavanna<sup>4</sup>, A. Camerini<sup>5</sup>, R. Chiari<sup>6</sup>, C. Verusio<sup>7</sup>, M. Tognetto<sup>1</sup>, A. Ardizzoni<sup>1</sup>; <sup>1</sup>Bologna, IT, <sup>2</sup>Parma, IT, <sup>3</sup>Firenze, IT, <sup>4</sup>Piacenza, IT, <sup>5</sup>Lido Di Camaiore, (LU)/IT, <sup>6</sup>Perugia, IT, <sup>7</sup>Saronno, (VA)/IT

- 12:30 - 12:30 **187TiP - Tumor treating fields concurrent with standard of care therapy for stage IV NSCLC following platinum failure: Phase III LUNAR study**  
U. Weinberg<sup>1</sup>, O. Farber<sup>2</sup>, M. Giladi<sup>2</sup>, Z. Bomzon<sup>2</sup>, E. Kirson<sup>2</sup>; <sup>1</sup>Luzern, CH, <sup>2</sup>Haifa, IL
- 12:30 - 12:30 **188TiP - Metformin &#x0002B;- cyclic fasting mimicking diet in combination with platinum-pemetrexed chemotherapy for advanced LKB1 inactive lung adenocarcinoma: The FAME trial**  
G. Galli<sup>1</sup>, D. Signorelli<sup>1</sup>, C. Vernieri<sup>1</sup>, M. Ganzinelli<sup>2</sup>, M. Moro<sup>1</sup>, A. Fabbri<sup>1</sup>, E. Tamborini<sup>2</sup>, M. Marabese<sup>1</sup>, E. Caiola<sup>1</sup>, M. Brogginini<sup>1</sup>, L. Hollander<sup>1</sup>, R. Gallucci<sup>1</sup>, C. Gavazzi<sup>1</sup>, A.M. Rizzo<sup>2</sup>, P. Corsetto<sup>2</sup>, G. Pruneri<sup>1</sup>, F. de Braud<sup>1</sup>, G. Sozzi<sup>1</sup>, V. Torri<sup>3</sup>, M. Garassino<sup>1</sup>; <sup>1</sup>Milan, IT, <sup>2</sup>Milano, IT, <sup>3</sup>No City Provided, NA
- 12:30 - 12:30 **190P - ERGR-TKIs combined with chemotherapy delays intracranial progression in EGFR-mutant lung adenocarcinoma patients**  
C. Li, B. Zhang, J. Guo, F. Hu, W. Nie, X. Zheng, Y. Lou, Y. Shen, X. Zhang; Shanghai, CN
- 12:30 - 12:30 **191P - Assessment of toxicity and clinical outcomes with SBRT in lung metastases: A single institute experience**  
V. Pareek, Mumbai, IN
- 12:30 - 12:30 **192P - Characterization and potential role of PD-L1 positive lung cancer stem cells in lymph nodes metastasis**  
A. Raniszewska, E. Rutkowska, R. Sokolowski, J. Domagala-Kulawik; Warsaw, PL
- 12:30 - 12:30 **193P - Management of cN2 NSCLC patients treated with radical radiotherapy: Relapse with or without brain metastases**  
F. McKay, S. Ansel, C. Lowrie, P. McLoone, N. Mohammed; Glasgow, GB
- 12:30 - 12:30 **195TiP - Phase III METIS study: Tumor treating fields (150&#x02009;kHz) and radiosurgery for supra- and/or infratentorial brain metastases (1-10) from non-small cell lung cancer (NSCLC)**  
M. Mehta<sup>1</sup>, V. Gondi<sup>2</sup>, M. Ahluwalia<sup>3</sup>, P. Brown<sup>4</sup>; <sup>1</sup>Chicago, IL/US, <sup>2</sup>Warrenville, IL/US, <sup>3</sup>Cleveland, OH/US, <sup>4</sup>Rochester, MN/US
- 12:30 - 12:30 **197P - Effect of surgical treatment on the survival in patients with malignant pleural mesothelioma**  
R. Baez-Saldana<sup>1</sup>, M.T. Marmolejo-Torres<sup>2</sup>, M. Iñiguez-García<sup>2</sup>, J.A. Berrios Mejía<sup>2</sup>, U. Rumbo-Nava<sup>2</sup>, O. Arrieta-Rodríguez<sup>2</sup>; <sup>1</sup>Ciudad De México, MX, <sup>2</sup>Mexico City, MX
- 12:30 - 12:30 **198P - Efficacy of 150&#x02009;kHz tumor treating fields (TTFields) and cisplatin or pemetrexed for the treatment of mesothelioma cells in vitro**





U. Weinberg<sup>1</sup>, M. Munster<sup>2</sup>, K. Gotlib<sup>2</sup>, R. Schneiderman<sup>2</sup>, Y. Porat<sup>2</sup>, T. Voloshin Sela<sup>2</sup>, S. Davidi<sup>2</sup>, A. Shteingauz<sup>2</sup>, N. Kaynan<sup>2</sup>, E. Zeevi<sup>2</sup>, M. Giladi<sup>2</sup>, E. Kirson<sup>2</sup>, A. Kinzel<sup>3</sup>, Y. Palti<sup>2</sup>; <sup>1</sup>Luzern, CH, <sup>2</sup>Haifa, IL, <sup>3</sup>München, DE

- 12:30 - 12:30 **199P - Safety meta-analysis of clinical trials delivering TTFields to the upper torso**  
G.L. Ceresoli<sup>1</sup>, M. Pless<sup>2</sup>; <sup>1</sup>Bergamo, IT, <sup>2</sup>Winterthur, CH
- 12:30 - 12:30 **200P - Implementation of artificial intelligence (AI) for lung cancer clinical trial matching in a tertiary cancer center**  
K. Leventakos<sup>1</sup>, J. Helgeson<sup>1</sup>, A. Mansfield<sup>1</sup>, E. Deering<sup>1</sup>, A. Schwecke<sup>1</sup>, A. Adjei<sup>1</sup>, J. Molina<sup>1</sup>, C. Hocum<sup>1</sup>, T. Halfdanarson<sup>1</sup>, R. Marks<sup>1</sup>, K. Parikh<sup>1</sup>, K. Pomerleau<sup>1</sup>, S. Coverdill<sup>2</sup>, M. Rammage<sup>2</sup>, T. Haddad<sup>1</sup>; <sup>1</sup>Rochester, MN/US, <sup>2</sup>Cambridge, MA/US
- 12:30 - 12:30 **201P - Psychosocial and financial impact on family of lung cancer patients: A cancer research center experience**  
S. GODARA, S. Beniwal; Bikaner, IN
- 12:30 - 12:30 **202P - Information for lung cancer patients and their caregivers: A systematic analysis of the online landscape**  
P. Naish<sup>1</sup>, E. Purdy<sup>2</sup>; <sup>1</sup>Cambridge, GB, <sup>2</sup>London, GB
- 12:30 - 12:30 **203P - Retrospective study about lung carcinoid: Our experience in a Spanish hospital**  
D. Sanchez Cabrero, P. Cruz, J. de Castro, O. Higuera, A. Pertejo, I. Esteban, L. Gutierrez, J. Villamayor, L. Ostios, D. Viñal, J. Miranda; Madrid, ES
- 12:30 - 12:30 **204P - Diagnostic value of concomitant use of radial probe endobronchial ultrasound with guide sheath and transbronchial biopsy in lung cancer**  
S.C. Lee<sup>1</sup>, S. Kwak<sup>2</sup>, M.S. Park<sup>2</sup>, Y.S. Kim<sup>2</sup>, J. Chang<sup>2</sup>, S.H. Lee<sup>2</sup>, C.H. Han<sup>1</sup>, S.M. Lee<sup>1</sup>, C.J. Kim<sup>1</sup>; <sup>1</sup>Goyang, KR, <sup>2</sup>Seoul, KR
- 12:30 - 12:30 **205P - Non-small cell lung cancer in the elderly: A retrospective study comparing first-line treatment with single-agent vs combination chemotherapy vs tyrosine kinase inhibitor**  
É. Cipriano, A. Tavares, A. Soares, F. Estevinho, C. Sottomayor; Matosinhos, PT
- 12:30 - 12:30 **206P - Implementation of PD-L1 analysis among patients with non-small cell lung cancer in a single center**  
I. TSIROUPROU, V. Tsartsianidou, S. Papaemmanouil, N. Pastelli, S. Lampaki, E. Eleftheriadou, K. Domvri, T. Kontakiotis, D. Spyrtatos; Thessaloniki (exohi), GR
- 12:30 - 12:30 **207P - Primary mucinous carcinomas of the lung: Clinical characteristics and treatment outcomes**  
A. Thottian<sup>1</sup>, G. Babu<sup>2</sup>, L. Dasappa<sup>2</sup>, L. Jacob<sup>2</sup>, S. Babu<sup>2</sup>, K.N. Lokesh<sup>3</sup>, A. Rudresha<sup>3</sup>, L. Rajeev<sup>2</sup>, S. Saldanha<sup>2</sup>, G. Gv<sup>2</sup>; <sup>1</sup>Delhi, Delhi/IN, <sup>2</sup>Bangalore, IN, <sup>3</sup>Bangalore, Karnatka/IN



- 12:30 - 12:30 **208P - Sarcopenia as prognostic factor in lung cancer patients: A systematic review and meta-analysis**  
J. Büntzel<sup>1</sup>, J. Heinz<sup>1</sup>, C. Röver<sup>1</sup>, A. Bleckmann<sup>1</sup>, C. Bauer<sup>2</sup>, A. Emmert<sup>1</sup>; <sup>1</sup>Göttingen, DE, <sup>2</sup>Fulda, DE
- 12:30 - 12:30 **209P - Feasibility and utility of transbronchial cryobiopsy in primary lung cancer: Prospective, single arm study**  
K. Kirita<sup>1</sup>, H. Udagawa<sup>2</sup>, S. Matsumoto<sup>1</sup>, K. Yoh<sup>1</sup>, S. Niho<sup>1</sup>, K. Goto<sup>1</sup>; <sup>1</sup>Kashiwa, Chiba/JP, <sup>2</sup>Kashiwa, JP
- 12:30 - 12:30 **210TiP - Evaluation of safety and efficacy of minocycline combined with tyrosine kinase inhibitors in patients of EGFR mutated metastatic lung cancer**  
A. Thottian<sup>1</sup>, G. Babu<sup>2</sup>, L. Dasappa<sup>2</sup>, L. Jacob<sup>2</sup>, S. Babu<sup>2</sup>, K.N. Lokesh<sup>3</sup>, A. Rudresha<sup>3</sup>, S. Saldanha<sup>2</sup>, G. Gv<sup>2</sup>, R. Lk<sup>2</sup>; <sup>1</sup>Delhi, Delhi/IN, <sup>2</sup>Bangalore, IN, <sup>3</sup>Bangalore, Karnatka/IN
- 13:00 - 14:00 MSD - Industry Satellite Symposium Room A**  
 Moderation: N. Leighl, Toronto, CA
- 13:00 - 13:05 **Welcome and introduction**  
N. Leighl, Toronto, CA
- 13:05 - 13:20 **IO combinations in first-line NSCLC**  
D. Rodríguez-Abreu, Las Palmas, ES
- 13:20 - 13:35 **Role of monotherapy in first-line NSCLC**  
N. Leighl, Toronto, CA
- 13:35 - 13:50 **Patient profiles/cases**  
S. Liu, Washington, DC/US
- 13:50 - 14:00 **Q&A and Closing Remarks**  
N. Leighl, Toronto, CA
- 14:10 - 14:40 Microbiome in cancer immunotherapy Room B**  
 Moderation: P. Garrido Lopez, Madrid, ES
- 14:10 - 14:10 **Session DOI**
- 14:10 - 14:40 **Microbiome in cancer immunotherapy**  
L. Zitvogel, Villejuif, CEDEX/FR



**14:45 - 16:15 Management of side effects and toxicities** **Room A**  
Moderation: D. Isla<sup>1</sup>, B. Besse<sup>2</sup>; <sup>1</sup>Zaragoza, ES, <sup>2</sup>Villejuif, CEDEX/FR

14:45 - 14:45 **Session DOI**

14:45 - 15:00 **Management of I-O toxicities: An introduction**  
D. Isla, Zaragoza, ES

15:00 - 15:15 **Management of pulmonary toxicities: Clinical case**  
M. Garassino, Milan, IT

15:15 - 15:30 **Management of endocrine toxicities: Clinical case**  
J. Haanen, Amsterdam, NL

15:30 - 15:45 **Management of GI toxicities: Clinical case**  
M. Sebastian, Frankfurt Am Main, DE

15:45 - 16:15 **Q&A**

**14:45 - 16:15 SCLC: What are the challenges and how can we face them?** **Room C**  
Moderation: F.H. Blackhall<sup>1</sup>, C. Le Pechoux<sup>2</sup>; <sup>1</sup>Manchester, GB, <sup>2</sup>Villejuif, CEDEX/FR

14:45 - 14:45 **Session DOI**

14:45 - 15:05 **The pathologist's point of view**  
F. Lopez-Rios, Madrid, ES

15:05 - 15:25 **The medical oncologist's point of view**  
F. Blackhall, Manchester, GB

15:25 - 15:45 **The radiation oncologist's point of view**  
C. Le Pechoux, Villejuif, CEDEX/FR

15:45 - 16:05 **The surgeon's point of view**  
M. Casiraghi, Milan, IT

16:05 - 16:15 **Q&A**





- 14:45 - 16:15 ESMO-IASLC Best Abstracts** **Room B**  
Moderation: P. Garrido Lopez<sup>1</sup>, J. Wolf<sup>2</sup>; <sup>1</sup>Madrid, ES, <sup>2</sup>Cologne, DE
- 14:45 - 14:45 **Session DOI**
- 14:45 - 15:00 **LBA1\_PR - Nivolumab (nivo) plus ipilimumab (ipi), nivo, or placebo (pbo) as maintenance therapy in patients (pts) with extensive disease small cell lung cancer (ED-SCLC) after first-line (1L) platinum-based chemotherapy (chemo): Results from the double-blind, randomized phase III CheckMate 451 study**  
T. Owonikoko<sup>1</sup>, H.R. Kim<sup>2</sup>, R. Govindan<sup>3</sup>, N. Ready<sup>4</sup>, M. Reck<sup>5</sup>, S. Peters<sup>6</sup>, S. Dakhil<sup>7</sup>, A. Navarro<sup>8</sup>, J. Rodriguez-Cid<sup>9</sup>, M. Schenker<sup>10</sup>, J. Lee<sup>2</sup>, V. Gutierrez<sup>11</sup>, I. Percent<sup>12</sup>, D. Morgensztern<sup>3</sup>, J. Fairchild<sup>13</sup>, C. Baudelet<sup>13</sup>, K. Park<sup>2</sup>; <sup>1</sup>Atlanta, GA/US, <sup>2</sup>Seoul, KR, <sup>3</sup>St. Louis, MO/US, <sup>4</sup>Durham, NC/US, <sup>5</sup>Grosshansdorf, DE, <sup>6</sup>Lausanne, CH, <sup>7</sup>Wichita, KS/US, <sup>8</sup>Barcelona, ES, <sup>9</sup>Mexico City, MX, <sup>10</sup>Craiova, Dolj/RO, <sup>11</sup>Malaga, ES, <sup>12</sup>Punta Gorda, FL/US, <sup>13</sup>Princeton, NJ/US
- 15:00 - 15:15 **LBA3 - Efficacy and safety of first-line durvalumab (D) ± tremelimumab (T) vs platinum-based chemotherapy (CT) based on clinical characteristics in patients with metastatic (m) NSCLC: Results from MYSTIC**  
B.C. Cho<sup>1</sup>, N. Reinmuth<sup>2</sup>, K.H. Lee<sup>3</sup>, M. Ahn<sup>1</sup>, A. Luft<sup>4</sup>, M. Van den Heuvel<sup>5</sup>, M. Cobo Dols<sup>6</sup>, A. Smolin<sup>7</sup>, D. Vicente<sup>8</sup>, V. Moiseyenko<sup>4</sup>, S. Antonia<sup>9</sup>, S. Le Moulec<sup>10</sup>, G. Robinet<sup>11</sup>, R. Natale<sup>12</sup>, E. Garon<sup>13</sup>, K. Nakagawa<sup>14</sup>, F. Liu<sup>15</sup>, P. Thiyagarajah<sup>16</sup>, S. Peters<sup>17</sup>, N. Rizvi<sup>18</sup>; <sup>1</sup>Seoul, KR, <sup>2</sup>Gauting, DE, <sup>3</sup>Cheongju, KR, <sup>4</sup>Saint-Petersburg, RU, <sup>5</sup>Amsterdam, NL, <sup>6</sup>Málaga, ES, <sup>7</sup>Moscow, RU, <sup>8</sup>Seville, ES, <sup>9</sup>Tampa, FL/US, <sup>10</sup>Paris, CEDEX 5/FR, <sup>11</sup>Brest, Cedex 2/FR, <sup>12</sup>Los Angeles, US, <sup>13</sup>Santa Monica, CA/US, <sup>14</sup>Osaka, JP, <sup>15</sup>Gaithersburg, US, <sup>16</sup>Cambridge, GB, <sup>17</sup>Lausanne, CH, <sup>18</sup>New York, US
- 15:15 - 15:30 **Invited Discussant LBA1\_PR and LBA3**  
L. Paz-Ares, Madrid, ES
- 15:30 - 15:45 **1020 - Final analysis of the phase III KEYNOTE-042 study: Pembrolizumab (Pembro) versus platinum-based chemotherapy (Chemo) as first-line therapy for patients (Pts) with PD-L1-positive locally advanced/metastatic NSCLC**  
T.S.K. Mok<sup>1</sup>, Y. Wu<sup>2</sup>, I. Kudaba<sup>3</sup>, D. Kowalski<sup>4</sup>, B.C. Cho<sup>5</sup>, H. Turna<sup>6</sup>, G. de Castro Jr<sup>7</sup>, V. Srimuninnimit<sup>8</sup>, K. Laktionov<sup>9</sup>, I. Bondarenko<sup>10</sup>, K. Kubota<sup>11</sup>, C. Caglevic<sup>12</sup>, B. Karaszewska<sup>13</sup>, T. Dang<sup>14</sup>, L. Yin<sup>14</sup>, J. Penrod<sup>14</sup>, G. Lopes<sup>15</sup>; <sup>1</sup>Shatin, HK, <sup>2</sup>Guangdong, CN, <sup>3</sup>Riga, LV, <sup>4</sup>Warsaw, PL, <sup>5</sup>Seoul, KR, <sup>6</sup>Istanbul, TR, <sup>7</sup>São Paulo, BR, <sup>8</sup>Bangkok, TH, <sup>9</sup>Moscow, RU, <sup>10</sup>Dnipro, UA, <sup>11</sup>Tokyo, JP, <sup>12</sup>Santiago, CL, <sup>13</sup>Konin, PL, <sup>14</sup>Kenilworth, NJ/US, <sup>15</sup>Miami, FL/US
- 15:45 - 16:00 **1030\_PR - Safety and efficacy of pembrolizumab (Pembro) monotherapy in elderly patients (Pts) with PD-L1-positive advanced NSCLC: Pooled analysis from KEYNOTE-010, -024, and -042**



K. Nosaki<sup>1</sup>, Y. Hosomi<sup>2</sup>, H. Saka<sup>3</sup>, P. Baas<sup>4</sup>, G. de Castro Jr<sup>5</sup>, M. Reck<sup>6</sup>, Y. Wu<sup>7</sup>, J. Brahmer<sup>8</sup>, E. Felip<sup>9</sup>, T. Sawada<sup>2</sup>, K. Noguchi<sup>2</sup>, S.R. Han<sup>2</sup>, B. Piperdi<sup>10</sup>, D. Kush<sup>10</sup>, G. Lopes<sup>11</sup>; <sup>1</sup>Fukuoka, JP, <sup>2</sup>Tokyo, JP, <sup>3</sup>Nagoya, JP, <sup>4</sup>Amsterdam, NL, <sup>5</sup>São Paulo, BR, <sup>6</sup>Grosshansdorf, DE, <sup>7</sup>Guangdong, CN, <sup>8</sup>Baltimore, US, <sup>9</sup>Barcelona, ES, <sup>10</sup>Kenilworth, NJ/US, <sup>11</sup>Miami, FL/US

16:00 - 16:15 **Invited Discussant 1020 and 1030\_PR**

S. Popat, London, GB

**16:15 - 16:45 Coffee break**

**Hall 1**

**16:40 - 17:40 Mini Oral session II**

**Room C**

Moderation: F. Cappuzzo<sup>1</sup>, D. Isla<sup>2</sup>, S. Peters<sup>3</sup>; <sup>1</sup>Ravenna, IT, <sup>2</sup>Zaragoza, ES, <sup>3</sup>Lausanne, CH

16:40 - 16:40 **Session DOI**

16:40 - 16:45 **10 - Impact of MET variants on PD-L1 expression in pleomorphic lung carcinoma**

A. Januszewski, Y.Z. Zhang, W. Chang, U. Laggner, A. Bowman, T. Adefila-Ideozu, I. Vivanco, M. Moffatt, W. Cookson, N. Gupta, A.G. Nicholson, A. Bowcock, S. Popat; London, GB

16:45 - 16:50 **850 - Prevalence of programmed death ligand-1 (PD-L1) by demographic, disease and sample characteristics in unresectable, stage III NSCLC (PACIFIC)**

D. Planchard<sup>1</sup>, M. Garassino<sup>2</sup>, L. Paz-Ares<sup>3</sup>, C. Faivre-Finn<sup>4</sup>, A. Spira<sup>5</sup>, Y. Gu<sup>6</sup>, C. Wadsworth<sup>7</sup>, J. Whiteley<sup>8</sup>, M. Scott<sup>8</sup>, A. Boothman<sup>9</sup>, M. Ratcliffe<sup>7</sup>, J. Walker<sup>10</sup>, P. Dennis<sup>6</sup>, S. Antonia<sup>11</sup>; <sup>1</sup>Villejuif, FR, <sup>2</sup>Milan, IT, <sup>3</sup>Madrid, ES, <sup>4</sup>Manchester, GB, <sup>5</sup>Fairfax, US, <sup>6</sup>Gaithersburg, MD/US, <sup>7</sup>Macclesfield, GB, <sup>8</sup>Cambridge, GB, <sup>9</sup>Melbourn, GB, <sup>10</sup>Zoetermeer, NL, <sup>11</sup>Tampa, FL/US

16:50 - 16:55 **1160 - Health-related quality of life (HRQoL) of non-small cell lung cancer (NSCLC) patients treated with nivolumab in real-life: The EVIDENS study**

M. Pérol<sup>1</sup>, A. Dixmier<sup>2</sup>, F. Barlesi<sup>3</sup>, D. Debieuvre<sup>4</sup>, C. Raspaud<sup>5</sup>, J.B. Auliac<sup>6</sup>, N. Benoit<sup>7</sup>, P. Bombaron<sup>8</sup>, D. Moro-Sibilot<sup>9</sup>, B. Asselain<sup>10</sup>, F. Cotté<sup>11</sup>, P. Lamoureux<sup>12</sup>, N. Karam<sup>11</sup>, N. Ozan<sup>11</sup>, C. Calvet<sup>11</sup>, B. Bryan<sup>13</sup>, V. Allan<sup>13</sup>, C. Audigier Valette<sup>14</sup>; <sup>1</sup>Lyon, CEDEX/FR, <sup>2</sup>Orleans, FR, <sup>3</sup>Marseille, CEDEX 20/FR, <sup>4</sup>Mulhouse, FR, <sup>5</sup>Toulouse, FR, <sup>6</sup>Mantes La Jolie, FR, <sup>7</sup>Amiens, FR, <sup>8</sup>Lyon, CEDEX 8/FR, <sup>9</sup>Grenoble, FR, <sup>10</sup>Paris, FR, <sup>11</sup>Rueil-Malmaison, FR, <sup>12</sup>Vandoeuvre Les Nancy, FR, <sup>13</sup>Uxbridge, GB, <sup>14</sup>Toulon, CEDEX/FR

16:55 - 17:00 **1170 - Racial disparities in characteristics and prognosis in Asian versus white patients receiving atezolizumab: An ancillary analysis of POPLAR and OAK studies**

J. Qian, W. Nie, J. Lu, L. Zhang, Y. Zhang, B. Zhang, S. Wang, M. Hu, J. Xu, Y. Lou, Y. Dong, Y. Niu, B. Yan, R. Zhong, W. Zhang, T. Chu, H. Zhong, B. Han; Shanghai, CN



- 17:00 - 17:05 **1180 - Blood tumor mutational burden as a predictor of clinical benefit in non-small cell lung cancer patients treated with docetaxel: Secondary analysis of the OAK and POPLAR randomized clinical trials**  
W. Nie, J. Qian, B. Han; Shanghai, CN
- 17:05 - 17:10 **1190 - Efficacy and safety of nintedanib + docetaxel in lung adenocarcinoma patients (pts) following treatment with immune checkpoint inhibitors (ICIs): First results of the ongoing non-interventional study (NIS) VARGADO**  
C. Grohe<sup>1</sup>, W. Gleiber<sup>2</sup>, S. Haas<sup>3</sup>, H. Mueller-Huesmann<sup>4</sup>, M. Schulze<sup>5</sup>, J. Atz<sup>6</sup>, R. Kaiser<sup>6</sup>;  
<sup>1</sup>Berlin, DE, <sup>2</sup>Frankfurt Am Main, DE, <sup>3</sup>Neumünster, DE, <sup>4</sup>Paderborn, DE, <sup>5</sup>Zittau, DE, <sup>6</sup>Ingelheim Am Rhein, DE
- 17:10 - 17:15 **1890 - EGFR-TKIs plus bevacizumab demonstrated survival benefit than EGFR-TKIs alone in EGFR-mutant NSCLC patients with multiple brain metastases**  
T. Jiang, C. Zhou; Shanghai, CN
- 17:15 - 17:40 **Discussion led by moderators**
- 16:45 - 17:45 Multiple lung tumour nodules Room B**  
Moderation: M.S. Tsao<sup>1</sup>, J. Zugazagoitia<sup>2</sup>; <sup>1</sup>Toronto, Ontario/CA, <sup>2</sup>New Haven, US
- 16:45 - 16:45 **Session DOI**
- 16:45 - 17:05 **Treatment options from the medical oncologist's perspective**  
J. Zugazagoitia, New Haven, US
- 17:05 - 17:25 **Surgical decision: To operate or not to operate?**  
T. Mitsudomi, Osaka, JP
- 17:25 - 17:45 **The role of the pathologist: Multiple primaries vs metastatic disease**  
M. Tsao, Toronto, Ontario/CA



<b>16:45 - 17:45</b>	<b>Should we upfront NGS as a standard?</b>	<b>Room A</b>
	Moderation: N. Normanno <sup>1</sup> , L. Bubendorf <sup>2</sup> ; <sup>1</sup> Napoli, IT, <sup>2</sup> Basel, CH	
16:45 - 16:45	<b>Session DOI</b>	
16:45 - 16:55	<b>Introduction and first vote</b> <u>L. Bubendorf</u> , Basel, CH	
16:55 - 17:15	<b>Yes</b> <u>F. Shepherd</u> , Toronto, Ontario/CA	
17:15 - 17:35	<b>No</b> <u>K. Kerr</u> , Aberdeen, GB	
17:35 - 17:45	<b>Second vote and conclusions</b> <u>N. Normanno</u> , Napoli, IT	
<b>18:00 - 19:00</b>	<b>Boehringer Ingelheim - Industry Satellite Symposium</b>	<b>Room A</b>
	Moderation: V. Gregorc, Milan, IT	
18:00 - 18:05	<b>Meeting welcome and introductions</b> <u>V. Gregorc</u> , Milan, IT	
18:05 - 18:20	<b>Prolonging the chemotherapy-free period in EGFRM+ NSCLC</b> <u>N. Girard</u> , Paris, FR	
18:20 - 18:30	<b>Q&amp;A: Treating EGFRM+ NSCLC</b> <u>V. Gregorc</u> , Milan, IT	
18:30 - 18:45	<b>Recent changes and sequencing strategies in non-mutated, non-squamous advanced NSCLC</b> <u>M. Reck</u> , Grosshansdorf, DE	
18:45 - 18:55	<b>Q&amp;A: Treating non-mutated, non-squamous NSCLC</b> <u>V. Gregorc</u> , Milan, IT	
18:55 - 19:00	<b>Meeting close</b> <u>V. Gregorc</u> , Milan, IT	



**18:00 - 19:00 Medscape Oncology - Industry Satellite Symposium** **Room C**  
Moderation: S. Peters, Lausanne, CH

18:00 - 18:05 **Introduction**

S. Peters, Lausanne, CH

18:05 - 18:20 **Testing for ALK-positive disease: The state of the art**

R. Califano, Manchester, GB

18:20 - 18:35 **The expanding treatment armamentarium in ALK-positive NSCLC: The evidence**

M. Garassino, Milan, IT

18:35 - 18:45 **Case challenge 1: First-line options - Considerations for treatment choice**

M. Garassino, Milan, IT

18:45 - 18:55 **Case challenge 2: Second-line treatment selection - How do we choose?**

R. Califano, Manchester, GB

18:55 - 19:00 **Conclusions and key points**

S. Peters, Lausanne, CH





12.04.2019

**08:30 - 10:00 Biomarker development in I-O** **Room B**  
Moderation: N. Normanno<sup>1</sup>, S. Ramon y Cajal<sup>2</sup>; <sup>1</sup>Napoli, IT, <sup>2</sup>Barcelona, ES

08:30 - 08:30 **Session DOI**

08:30 - 08:55 **Biomarkers for I-O**  
L. Bubendorf, Basel, CH

08:55 - 09:20 **Role of biomarkers in resistance**  
R.A. Soo, Singapore, SG

09:20 - 09:45 **How to implement immuno biomarkers in clinical practice**  
S. Ramon y Cajal, Barcelona, ES

09:45 - 10:00 **Q&A**

**08:30 - 10:00 Proffered Paper session III** **Room A**  
Moderation: T.S.K. Mok<sup>1</sup>, N. Leigh<sup>2</sup>; <sup>1</sup>Shatin, HK, <sup>2</sup>Toronto, CA

08:30 - 08:30 **Session DOI**

08:30 - 08:42 **840 - Phase I study of gefitinib (G) + durvalumab (D) for locally advanced/metastatic non-small cell lung cancer (NSCLC) harbouring epidermal growth factor receptor (EGFR) sensitising mutations**

B. Creelan<sup>1</sup>, T. Yeh<sup>2</sup>, S. Kim<sup>3</sup>, N. Nogami<sup>4</sup>, D. Kim<sup>3</sup>, L. Chow<sup>5</sup>, S. Kanda<sup>6</sup>, R. Taylor<sup>7</sup>, W. Tang<sup>8</sup>, M. Tang<sup>8</sup>, H. Angell<sup>7</sup>, M. Roudier<sup>7</sup>, M. Marotti<sup>7</sup>, D. Gibbons<sup>9</sup>; <sup>1</sup>Tampa, FL/US, <sup>2</sup>Boston, MA/US, <sup>3</sup>Seoul, KR, <sup>4</sup>Matsuyama City, JP, <sup>5</sup>Seattle, WA/US, <sup>6</sup>Tokyo, JP, <sup>7</sup>Cambridge, GB, <sup>8</sup>Gaithersburg, MD/US, <sup>9</sup>Houston, TX/US

08:42 - 08:54 **1040 - IMpower150: An exploratory analysis of efficacy outcomes in patients with EGFR mutations**

M. Reck<sup>1</sup>, R. Jotte<sup>2</sup>, T.S.K. Mok<sup>3</sup>, D. Lim<sup>4</sup>, F. Cappuzzo<sup>5</sup>, F. Orlandi<sup>6</sup>, D. Stroyakovskiy<sup>7</sup>, N. Nogami<sup>8</sup>, D. Rodríguez-Abreu<sup>9</sup>, D. Moro-Sibilot<sup>10</sup>, C. Thomas<sup>11</sup>, F. Barlesi<sup>12</sup>, G. Finley<sup>13</sup>, M. Nishio<sup>14</sup>, A. Lee<sup>15</sup>, G. Shankar<sup>15</sup>, W. Yu<sup>15</sup>, M. Socinski<sup>16</sup>; <sup>1</sup>Grosshansdorf, DE, <sup>2</sup>Denver, CO/US, <sup>3</sup>Shatin, HK, <sup>4</sup>Singapore, SG, <sup>5</sup>Ravenna, IT, <sup>6</sup>Santiago, CL, <sup>7</sup>Moscow, RU, <sup>8</sup>Matsuyama, JP, <sup>9</sup>Las Palmas, ES, <sup>10</sup>Grenoble, FR, <sup>11</sup>Scarborough, ME/US, <sup>12</sup>Marseille, CEDEX 20/FR, <sup>13</sup>Pittsburgh, PA/US, <sup>14</sup>Tokyo, JP, <sup>15</sup>South San Francisco, CA/US, <sup>16</sup>Orlando, FL/US



- 08:54 - 09:06 **1050 - Osimertinib for patients (pts) with leptomeningeal metastases (LM) associated with EGFRm advanced NSCLC: The AURA LM study**  
M. Ahn<sup>1</sup>, C. Chiu<sup>2</sup>, Y. Cheng<sup>3</sup>, J. Han<sup>4</sup>, S. Goldberg<sup>5</sup>, A. Greystoke<sup>6</sup>, J. Crawford<sup>7</sup>, Y. Zhao<sup>8</sup>, X. Huang<sup>9</sup>, M. Johnson<sup>9</sup>, K. Vishwanathan<sup>10</sup>, A. Mendoza-Naranjo<sup>9</sup>, T.S.K. Mok<sup>11</sup>;  
1Seoul, KR, 2Taipei, TW, 3Changchun, Jilin/CN, 4Goyang, KR/KR, 5New Haven, US,  
6Newcastle Upon Tyne, Tyne and Wear/GB, 7Durham, NC/US, 8Zhengzhou, CN,  
9Cambridge, GB, 10Waltham, US, 11Shatin, HK
- 09:06 - 09:21 **Invited Discussant 840, 1040 and 1050**  
P. Jänne, Boston, MA/US
- 09:21 - 09:33 **1060 - Brigatinib (BRG) vs crizotinib (CRZ) in the phase III ALTA-1L trial**  
R. Califano<sup>1</sup>, M. Hochmair<sup>2</sup>, C. Gridelli<sup>3</sup>, A. Delmonte<sup>4</sup>, M.R. Garcia Campelo<sup>5</sup>, A. Bearz<sup>6</sup>,  
F. Griesinger<sup>7</sup>, A. Morabito<sup>8</sup>, E. Felip<sup>9</sup>, S. Ghosh<sup>10</sup>, M. Tiseo<sup>11</sup>, J. Haney<sup>12</sup>, D. Kerstein<sup>12</sup>,  
S. Popat<sup>10</sup>, D. Camidge<sup>13</sup>; 1Manchester, GB, 2Vienna, AT, 3Avellino, IT, 4Meldola, IT,  
5Coruna, ES, 6Aviano, IT, 7Oldenburg, DE, 8Naples, IT, 9Barcelona, ES, 10London, GB,  
11Parma, IT, 12Cambridge, MA/US, 13Aurora, CO/US
- 09:33 - 09:45 **1070 - Crizotinib in advanced ROS1-rearranged non-small cell lung cancer (NSCLC): Overall survival (OS) and updated safety from PROFILE 1001**  
A. Shaw<sup>1</sup>, G. Riely<sup>2</sup>, Y. Bang<sup>3</sup>, D. Kim<sup>3</sup>, D. Camidge<sup>4</sup>, G. Shapiro<sup>1</sup>, T. Usari<sup>5</sup>, S. Wang<sup>6</sup>, K.  
Wilner<sup>7</sup>, J. Clark<sup>1</sup>, S. Ou<sup>8</sup>; 1Boston, MA/US, 2New York, NY/US, 3Seoul, KR, 4Aurora,  
CO/US, 5Milano, IT, 6La Jolla, CA/US, 7San Diego, US, 8Orange, CA/US
- 09:45 - 10:00 **Invited Discussant 1060 and 1070**  
N. Leighl, Toronto, CA



<b>08:30 - 10:00</b>	<b>Advanced nursing roles in LCC</b> Moderation: D. Kelly <sup>1</sup> , M. Culligan <sup>2</sup> ; <sup>1</sup> London, GB, <sup>2</sup> Baltimore, MD/US	<b>Room K</b>
08:30 - 08:30	<b>Session DOI</b>	
08:30 - 08:35	<b>Introduction</b> <u>D. Kelly</u> , London, GB	
08:35 - 08:55	<b>Advanced nursing practices in thoracic surgery: Improving patient outcomes</b> <u>M. Culligan</u> , Baltimore, MD/US	
08:55 - 09:15	<b>Developing advanced practice lung cancer nurses</b> <u>M. Eicher</u> , Lausanne, CH	
09:15 - 09:35	<b>Evaluation and challenges of advanced practice lung cancer nurses in current context</b> <u>A. Tod</u> , Sheffield, GB	
09:35 - 09:55	<b>RECaN: What this project has taught us about advanced roles?</b> <u>D. Kelly</u> , London, GB	
09:55 - 10:00	<b>Conclusions</b> <u>M. Culligan</u> , Baltimore, MD/US	
<b>10:00 - 10:30</b>	<b>Coffee break</b>	<b>Hall 1</b>



<b>10:30 - 12:00</b>	<b>The accessibility and sustainability of lung cancer care</b> Moderation: A. Baird, Dublin, IE	<b>Room C</b>
10:30 - 10:30	<b>Session DOI</b>	
10:30 - 10:35	<b>Introduction</b> <u>A. Baird</u> , Dublin, IE	
10:35 - 10:55	<b>Accessibility in low and middle-income countries</b> <u>E. Szmytke</u> , Bern, CH	
10:55 - 11:15	<b>Accessibility and sustainability of new expensive treatment</b> <u>M. Tran Minh</u> , Helsinki, FI	
11:15 - 11:35	<b>What can LuCE achieve in terms of lobbying?</b> <u>S. Vallone</u> , Orbassano, IT	
11:35 - 11:55	<b>Importance of access to innovative treatments and their impact on patient reported outcomes</b> <u>M. Hennink</u> , Utrecht, NL	
11:55 - 12:00	<b>Conclusions</b> <u>A. Baird</u> , Dublin, IE	



**10:30 - 12:00 Genetic heterogeneity and clonal evolution** **Room B**  
Moderation: D.S.W. Tan<sup>1</sup>, M. Peifer<sup>2</sup>; <sup>1</sup>Singapore, SG, <sup>2</sup>Cologne, DE

10:30 - 10:30 **Session DOI**

10:30 - 10:50 **Clonal evolution in lung cancer**  
N. McGranahan, London, GB

10:50 - 11:10 **Immune microenvironment and cancer evolution**  
M. Holzel, Bonn, DE

11:10 - 11:30 **Elucidating EGFR evolution**  
D.S.W. Tan, Singapore, SG

11:30 - 11:50 **Challenges in tracking clonal evolution**  
M. Peifer, Cologne, DE

11:50 - 12:00 **Q&A**

**10:30 - 12:00 Implementation of personalised lung cancer care in clinical routine** **Room A**  
Moderation: B. Besse<sup>1</sup>, J. Wolf<sup>2</sup>; <sup>1</sup>Villejuif, CEDEX/FR, <sup>2</sup>Cologne, DE

10:30 - 10:30 **Session DOI**

10:30 - 10:50 **Experiences from the German Network Genomic Medicine**  
J. Wolf, Cologne, DE

10:50 - 11:10 **Reflections from the French experience**  
B. Besse, Villejuif, CEDEX/FR

11:10 - 11:30 **How can ESMO help to implement personalised treatment in clinical practice**  
R.A. Stahel, Zurich, CH

11:30 - 11:50 **The role of IASLC in helping to implement personalised medicine**  
G. Scagliotti, Orbassano, TO/IT

11:50 - 12:00 **Q&A**





<b>10:30 - 12:00</b>	<b>Family caregivers in LCC</b> Moderation: A. Charalambous <sup>1</sup> , C.L. Degi <sup>2</sup> ; <sup>1</sup> Limassol, CY, <sup>2</sup> Cluj-Napoca, RO	<b>Room K</b>
10:30 - 10:30	<b>DOI session</b>	
10:30 - 10:35	<b>Introduction</b>	
10:35 - 11:00	<b>The experience and impact of cancer caregiving through the cancer continuum</b> <u>A. Charalambous</u> , Limassol, CY	
11:00 - 11:25	<b>What caregivers do for patients affected by cancer?</b> <u>H. Ullgren</u> , Stockholm, SE	
11:25 - 11:45	<b>Family caregivers burnout</b> <u>C. Degi</u> , Cluj-Napoca, RO	
11:45 - 12:00	<b>Conclusions and Q&amp;A</b> <u>C. Degi</u> , Cluj-Napoca, RO	
<b>12:10 - 12:40</b>	<b>A decade of targeting EGFR</b> Moderation: J. Wolf, Cologne, DE	<b>Room B</b>
12:10 - 12:10	<b>Session DOI</b>	
12:10 - 12:40	<b>A decade of targeting EGFR</b> <u>T.S.K. Mok</u> , Shatin, HK	
<b>12:30 - 13:00</b>	<b>Lunch &amp; Poster Display session</b> Moderation: B. Besse <sup>1</sup> , A.C. Dingemans <sup>2</sup> , D. De Ruysscher <sup>2</sup> , D. Planchard <sup>3</sup> , N. Peled <sup>4</sup> , R. Buettner <sup>5</sup> , T. Behrens <sup>6</sup> ; <sup>1</sup> Villejuif, CEDEX/FR, <sup>2</sup> Maastricht, NL, <sup>3</sup> Villejuif, FR, <sup>4</sup> Beer Sheva, IL, <sup>5</sup> Cologne, DE, <sup>6</sup> Bochum, DE	<b>Hall 1</b>
12:30 - 12:30	<b>3P - Notable variation of molecular testing in metastatic lung cancer in the Netherlands</b> <u>C. Epskamp-Kuijpers</u> <sup>1</sup> , M. Van den Heuvel <sup>2</sup> , L. Overbeek <sup>3</sup> , A. Van Lindert <sup>1</sup> , R. Damhuis <sup>1</sup> , S. Willems <sup>1</sup> ; <sup>1</sup> Utrecht, NL, <sup>2</sup> Nijmegen, NL, <sup>3</sup> Houten, NL	
12:30 - 12:30	<b>4P - Correlation between folate receptor alpha (FR<math>\alpha</math>) expression and clinicopathological features in lung adenocarcinoma</b>	



N. Tamura<sup>1</sup>, Y. Fujiwara<sup>1</sup>, T. Hashimoto<sup>1</sup>, H. Shiraishi<sup>1</sup>, S. Kitano<sup>2</sup>, T. Shimizu<sup>1</sup>, N. Yamamoto<sup>1</sup>, N. Motoi<sup>1</sup>; <sup>1</sup>Tokyo, JP, <sup>2</sup>Tokyo, NY/JP

- 12:30 - 12:30 **5P - The circular RNA circXPO1 promotes tumor growth in lung adenocarcinoma**  
O. Huang, M. Qiu; Beijing, CN
- 12:30 - 12:30 **6P - Correlation of epidermal growth factor receptor mutation status in plasma and tissue samples of patients with lung cancer**  
C. Son, Busan, KR
- 12:30 - 12:30 **7P - Immunomodulatory effects of Tumor Treating Fields (TTFields) on lung cancer models**  
U. Weinberg<sup>1</sup>, N. Kaynan<sup>2</sup>, T. Voloshin Sela<sup>2</sup>, S. Davidi<sup>2</sup>, Y. Porat<sup>2</sup>, A. Shteingauz<sup>2</sup>, M. Munster<sup>2</sup>, R. Schneiderman<sup>2</sup>, C. Tempel Brami<sup>2</sup>, E. Zeevi<sup>2</sup>, K. Gotlib<sup>2</sup>, S. Cahal<sup>2</sup>, M. Giladi<sup>2</sup>, E. Kirson<sup>2</sup>, A. Kinzel<sup>3</sup>, Y. Palti<sup>2</sup>; <sup>1</sup>Luzern, CH, <sup>2</sup>Haifa, IL, <sup>3</sup>München, DE
- 12:30 - 12:30 **8P - Role of chemokines in resectable non-small cell lung cancer (NSCLC)**  
M. Drosslerová, M. Šterclová, M. Vašáková, A. Tašková, V. Hytych, P. Horažďovský, E. Richterová, M. Smětáková, L. Havel; Prague, CZ
- 12:30 - 12:30 **9P - Clinical validation of an NGS-based assay for detecting multiple genomic alterations in Chinese patients with non-small cell lung cancer**  
H. Ge<sup>1</sup>, X. Chen<sup>2</sup>, L. Ruan<sup>1</sup>, Q. Gao<sup>1</sup>, X. Yang<sup>1</sup>, W. Shi<sup>1</sup>, X. Li<sup>1</sup>, G. Zhu<sup>1</sup>; <sup>1</sup>Xiamen, CN, <sup>2</sup>Fuzhou, CN
- 12:30 - 12:30 **10P - The prevalence and prognostic significance of JAK2 mutation subtypes in non-small cell lung cancer from Chinese populations**  
W. Wang<sup>1</sup>, C. Xu<sup>2</sup>, Q. Zhang<sup>2</sup>, W. Zhuang<sup>2</sup>, Y. Zhu<sup>1</sup>, Z. Huang<sup>2</sup>, G. Chen<sup>2</sup>, M. Fang<sup>1</sup>, T. Lv<sup>3</sup>, Y. Song<sup>3</sup>; <sup>1</sup>Zhenjiang, CN, <sup>2</sup>Fuzhou, CN, <sup>3</sup>Nanjing, CN
- 12:30 - 12:30 **11P - Autophagy inhibition potentiates the anti-angiogenic property of multikinase inhibitor anlotinib through JAK2/STAT3/VEGFA signaling in non-small cell lung cancer cells**  
L. Liang, K. Hui, C. Hu, Y. Wen, X. Jiang; Lianyungang, CN
- 12:30 - 12:30 **12P - Clinicopathologic characteristics of patients with TP63 mutations in Chinese non-small cell lung cancer**  
Q. Zhang<sup>1</sup>, C. Xu<sup>1</sup>, W. Wang<sup>2</sup>, W. Zhuang<sup>1</sup>, Z. Huang<sup>1</sup>, G. Chen<sup>1</sup>, M. Fang<sup>2</sup>, T. Lv<sup>3</sup>, Y. Song<sup>3</sup>; <sup>1</sup>Fuzhou, CN, <sup>2</sup>Zhenjiang, CN, <sup>3</sup>Nanjing, CN
- 12:30 - 12:30 **13P - The micro-environmental cross talk between mast cells and lung cancer cells through cell-to-cell contact**  
R. Shemesh<sup>1</sup>, Y. Gorzalczany<sup>1</sup>, R. Sagi-Eisenberg<sup>1</sup>, S. Geva<sup>1</sup>, L.R. Roisman<sup>2</sup>, N. Peled<sup>2</sup>; <sup>1</sup>Tel Aviv, IL, <sup>2</sup>Beer Sheva, IL



- 12:30 - 12:30 **14P - The characteristics of MET exon 14 skipping mutations in Chinese non-small cell lung cancer: A retrospective analysis**  
Y. Zhu<sup>1</sup>, C. Xu<sup>2</sup>, W. Wang<sup>1</sup>, Q. Zhang<sup>2</sup>, W. Zhuang<sup>2</sup>, G. Chen<sup>2</sup>, M. Fang<sup>1</sup>, T. Lv<sup>3</sup>, Y. Song<sup>3</sup>;  
<sup>1</sup>Zhenjiang, CN, <sup>2</sup>Fuzhou, CN, <sup>3</sup>Nanjing, CN
- 12:30 - 12:30 **15P - TTF1 status in non-small cell lung cancer adenocarcinoma: A prognostic factor**  
J.F. Cordoba Ortega<sup>1</sup>, A. Salud<sup>2</sup>, S. Morales<sup>2</sup>, J. Veas<sup>2</sup>, A. Rodriguez<sup>2</sup>; <sup>1</sup>Lleida, ES,  
<sup>2</sup>Lerida, ES
- 12:30 - 12:30 **17P - REDOXI-miRNA of Keap1/Nrf2 axis in lung tumors**  
F. Fabrizio, A. Sparaneo, S. Castellana, T. Mazza, D. Trombetta, P. Graziano, A. Rossi, V. Fazio, L.A. Muscarella; San Giovanni Rotondo, IT
- 12:30 - 12:30 **18P - Immunohistochemical expression of PD-L1 in early and late stage non-small cell lung cancer: Correlation with clinicopathological and molecular features**  
E. Kokkotou, V. Rapti, D. Grapsa, P. Bakakos, S. Papadopoulos, M. Bobos, K. Iliadis, K. Syrigos; Athens, GR
- 12:30 - 12:30 **19P - FOXP3<sup>3</sup>, the major isoform of FOXP3, promotes proliferation, migration, and invasion in non-small cell lung cancer**  
H. JIA<sup>1</sup>, H. Qi<sup>2</sup>, J. Peng<sup>2</sup>, M. Li<sup>2</sup>, G. Chen<sup>1</sup>; <sup>1</sup>Shatin, HK, <sup>2</sup>Hong Kong, HK
- 12:30 - 12:30 **20P - Atypical hyperplasia of bronchial epithelial cells induced by chronic exposure to PM 2.5 in mice**  
T.F. Hou, Q.H. Chen; Beijing, CN
- 12:30 - 12:30 **22P - Paclitaxel/ carboplatin/ bevacizumab in non-small cell lung cancer patients induces peripheral effector CD8 T cell proliferation that could be prone for treatment with checkpoint inhibitors**  
D. Dumoulin<sup>1</sup>, P. de Goeje<sup>2</sup>, M. Poncin<sup>2</sup>, K. Bezemer<sup>2</sup>, H. Groen<sup>3</sup>, E. Smit<sup>4</sup>, A. Dingemans<sup>5</sup>, A. Kunert<sup>2</sup>, R. Hendriks<sup>2</sup>, J. Aerts<sup>6</sup>; <sup>1</sup>Barendrecht, NL, <sup>2</sup>Rotterdam, NL, <sup>3</sup>Groningen, NL, <sup>4</sup>Amsterdam, NL, <sup>5</sup>Maastricht, NL, <sup>6</sup>Rotterdam, Noord Brabant/NL
- 12:30 - 12:30 **23P - Immunosenescence (iSenescence) correlates with progression (PD) to PD-(L)1 inhibitors (IO) and not to platinum-chemotherapy (PCT) in advanced non-small cell lung cancer (aNSCLC) patients (pts)**  
R. Ferrara<sup>1</sup>, M. Naigeon<sup>2</sup>, E. Auclin<sup>2</sup>, B. Duchemann<sup>3</sup>, L. Cassard<sup>1</sup>, J.J. Medhi<sup>2</sup>, L. Boselli<sup>2</sup>, J. Grivel<sup>2</sup>, A. Desnoyer<sup>2</sup>, L. Mezquita<sup>1</sup>, L. Hendriks<sup>4</sup>, D. Planchard<sup>1</sup>, C. Caramella<sup>1</sup>, J. Remon-Masip<sup>5</sup>, S. Sangaletti<sup>6</sup>, M. Garassino<sup>7</sup>, B. Besse<sup>8</sup>, N. Chaput<sup>8</sup>;  
<sup>1</sup>Villejuif, FR, <sup>2</sup>Paris, FR, <sup>3</sup>Bobigny, CEDEX/FR, <sup>4</sup>Maastricht, NL, <sup>5</sup>Barcelona, ES, <sup>6</sup>Milano, IT, <sup>7</sup>Milan, IT, <sup>8</sup>Villejuif, CEDEX/FR
- 12:30 - 12:30 **24P - A new bioinformatic pipeline allows the design of small, targeted gene panels for efficient TMB estimation**



P. Manca<sup>1</sup>, I. Mallona<sup>2</sup>, D. Santini<sup>3</sup>, G. Tonini<sup>3</sup>, C. Rolfo<sup>4</sup>, M. Robinson<sup>2</sup>, F. Pantano<sup>3</sup>;  
<sup>1</sup>Rome, IT, <sup>2</sup>Zürich, CH, <sup>3</sup>Roma, IT, <sup>4</sup>Baltimore, US

- 12:30 - 12:30    **25P - Lung tumorspheres as a drug screening platform against cancer stem cells**  
A. Herreros Pomares<sup>1</sup>, H. Amado<sup>1</sup>, S. Calabuig Fariñas<sup>1</sup>, E. Escorihuela<sup>1</sup>, J. Murga<sup>2</sup>, S. Torres<sup>1</sup>, E. Durendez-Saez<sup>1</sup>, F. Zhang<sup>1</sup>, A. Blasco<sup>1</sup>, A. Navarro<sup>1</sup>, C. Sampedro<sup>1</sup>, E. Jantus-Lewintre<sup>1</sup>, C. Camps<sup>1</sup>; <sup>1</sup>Valencia, ES, <sup>2</sup>Castellón, ES
- 12:30 - 12:30    **26P - Potentialities of liquid biopsy in advanced non-small cell lung cancer (aNSCLC): Early evaluation of sentinel mutations in plasma and outcome of patients treated with immunotherapy**  
L. Bonanno, E. Zulato, I. Attili, A. Pavan, P. Del Bianco, G. Nardo, A. Boscolo Bragadin, L. Pasqualini, F. Calabrese, M. Fassan, G. Pasello, V. Guarneri, A. Amadori, P. Conte, S. Indraccolo; Padova, IT
- 12:30 - 12:30    **27P - Comparison of three different gene panels for determination of tumor mutational burden by next generation sequencing**  
R. Pappesch, C. Heydt, J. Rehker, S. Merkelbach-Bruse; Köln, DE
- 12:30 - 12:30    **28P - Applicability of ctDNA at diagnosis and during the monitoring of EGFR-mutated patients**  
S. Calabuig Fariñas, A. Blasco, E. Durendez-Saez, A. Fernández, M. Mosqueda, E. Escorihuela, A. Herreros Pomares, F. Aparisi, J. Garde, M. Shahin, E. Jantus-Lewintre, C. Camps; Valencia, ES
- 12:30 - 12:30    **29P - Pretreatment T790M mutation detection by ultrasensitive PCR assay as predictor of efficacy in non-small lung cancer (NSCLC) patients treated with 1<sup>st</sup> or 2<sup>nd</sup> generation EGFR tyrosine kinase inhibitors (TKIs)**  
O.J. Juan Vidal, J. Simarro, D. Lorente Estelles, G. Pérez-Simó, N. Mancheno, R. Murria, J. Gomez Codina, B. Laiz, S. Palanca; Valencia, ES
- 12:30 - 12:30    **30P - Prognostic significance of IGF-1 signaling pathway in patients with advanced non-small cell lung cancer**  
I. Kotsantis, P. Economopoulou, A. Psyrri, E. Maratou, D. Pectasides, H. Gogas, N. Kentepozidis, G. Mountzios, G. Dimitriadis, S. Giannouli; Athens, GR
- 12:30 - 12:30    **31P - Do two lungs form an integrated immune system? Learning from BALF examination in lung cancer**  
J. Domagala-Kulawik, T. Skirecki, D. Dziedzic, M. Polubiec-Kownacka, T. Kryczka, I. Kwiecien; Warsaw, PL
- 12:30 - 12:30    **32P - Exosomes in NSCLC: Analysis of its cargo as a source of biomarkers**  
E. Durendez-Saez<sup>1</sup>, S. Calabuig Fariñas<sup>1</sup>, C. Suarez<sup>2</sup>, M. Mosqueda<sup>1</sup>, S. Gallach<sup>1</sup>, E. Escorihuela<sup>1</sup>, A. Moreno<sup>1</sup>, N. Dong<sup>1</sup>, A. Herreros Pomares<sup>1</sup>, E. de la Cueva<sup>1</sup>, A. Martinez-Romero<sup>1</sup>, E. Serna<sup>1</sup>, J.M. Paramio<sup>2</sup>, E. Jantus-Lewintre<sup>1</sup>, C. Camps<sup>1</sup>; <sup>1</sup>Valencia, ES, <sup>2</sup>Madrid, ES



- 12:30 - 12:30 **33P - Prognostic value of CD8-positive tumor stroma-infiltrating lymphocytes and PD-L1 positive tumor cells at initial biopsy in patients with locally advanced NSCLC treated with chemoradiotherapy**  
K. Gennen<sup>1</sup>, L. Käsmann<sup>1</sup>, C. Eze<sup>1</sup>, M. Dantes<sup>1</sup>, O. Roengvoraphoj<sup>1</sup>, J. Taugner<sup>2</sup>, J. Neumann<sup>2</sup>, A. Tufman<sup>1</sup>, M. Orth<sup>2</sup>, S. Reu<sup>3</sup>, C. Belka<sup>1</sup>, F. Manapov<sup>1</sup>; <sup>1</sup>Munich, DE, <sup>2</sup>München, DE, <sup>3</sup>Würzburg, DE
- 12:30 - 12:30 **34P - Impacts of HDAC2 inhibition on lung cancer treatment**  
Y. Yeh<sup>1</sup>, C. Wu<sup>2</sup>, J. Lai<sup>2</sup>, C. Huang<sup>2</sup>, Y. Wei<sup>2</sup>, M. Huang<sup>2</sup>; <sup>1</sup>Kaohsiung City, TW, <sup>2</sup>Kaohsiung, TW
- 12:30 - 12:30 **35P - Clinicopathological characteristics with genetic profiling and prognostic analysis of primary lymphoepithelioma-like carcinoma in Chinese south-eastern population**  
Y. Shen, F. Hu, B. Zhang, B. Han; Shanghai, CN
- 12:30 - 12:30 **36P - Can a BALF profile distinguish hot vs cold lung tumors?**  
J. Domagala-Kulawik, D. Dziejczak, M. Polubiec-Kownacka, T. Kryczka, I. Kwiecien; Warsaw, PL
- 12:30 - 12:30 **37P - Genetic variation of lymphotoxin beta receptor (LT $\beta$ ;R) rs10849448 (A/G) is associated with risk for lung cancer and metastatic spread to adrenals**  
F. Dimitrakopoulos<sup>1</sup>, A. Antonacopoulou<sup>2</sup>, A. Kottorou<sup>1</sup>, V. Tzelepi<sup>2</sup>, N. Panagopoulos<sup>2</sup>, M. Kalofonou<sup>3</sup>, D. Dougenis<sup>2</sup>, A. Koutras<sup>2</sup>, T. Makatsoris<sup>1</sup>, H. Kalofonos<sup>2</sup>; <sup>1</sup>Patras, Rion/GR, <sup>2</sup>Patras, GR, <sup>3</sup>London, GB
- 12:30 - 12:30 **38P - Hedgehog pathway activation might mediate pemetrexed resistance in NSCLC cells**  
Y. Liu, R. Kiefl, R. Huber, A. Tufman, D. Kauffmann-Guerrero; Munich, DE
- 12:30 - 12:30 **39P - High dose apatinib in the reversal of immunosuppressive tumor microenvironment for irradiation therapy in lung carcinoma**  
L. Liang, C. Hu, Y. Wen, W. Zhuang, L. Wang, Y. Xia, K. Hui, X. Jiang; Lianyungang, CN
- 12:30 - 12:30 **40P - The metabolic phenotypes of non-small cell lung cancer cells in association with clinical treatment strategies**  
T. Kuo<sup>1</sup>, T. Hsiao<sup>2</sup>, P. Yang<sup>1</sup>; <sup>1</sup>Taipei, TW, <sup>2</sup>Taichung, TW
- 12:30 - 12:30 **41P - Diagnostic accuracy of droplet digital PCR (ddPCR) and amplification refractory mutation system PCR (ARMS-PCR) for detecting EGFR mutation in cell-free DNA of advanced lung cancer: A meta-analysis**  
C. Li, Q. He, H. Liang, J. He, W. Liang; Guangzhou, CN
- 12:30 - 12:30 **44P - Temporal trends in treatment (Tx) and overall survival (OS) among patients (pts) with incident NSCLC in the UK: A real-oncology database analysis from the I-O Optimise initiative**





M. Snee<sup>1</sup>, S. Cheeseman<sup>1</sup>, M. Thompson<sup>2</sup>, M. Riaz<sup>1</sup>, L. Lacoïn<sup>3</sup>, W. Sopwith<sup>1</sup>, C. Chaib<sup>4</sup>, M. Daumont<sup>5</sup>, J. Penrod<sup>6</sup>, J. O'Donnell<sup>6</sup>, G. Hall<sup>1</sup>; <sup>1</sup>Leeds, GB, <sup>2</sup>London, GB, <sup>3</sup>Ladeuze, BE, <sup>4</sup>Madrid, ES, <sup>5</sup>Braine-L'alleud, BE, <sup>6</sup>Princeton, NJ/US

- 12:30 - 12:30 **45P - Treatment (Tx) patterns and overall survival (OS) in patients (pts) with stage III&#x02013;IV NSCLC in Portugal: An IPO-PORTO database analysis from the I-O Optimise initiative**  
M. Soares<sup>1</sup>, L. Antunes<sup>1</sup>, P. Redondo<sup>1</sup>, M. Borges<sup>1</sup>, R. Hermans<sup>2</sup>, D. Patel<sup>2</sup>, F. Grimson<sup>2</sup>, R. Munro<sup>2</sup>, C. Chaib<sup>3</sup>, L. Lacoïn<sup>4</sup>, M. Daumont<sup>5</sup>, J. Penrod<sup>6</sup>, J. O'Donnell<sup>6</sup>, M. Bento<sup>1</sup>, F.R. Goncalves<sup>1</sup>; <sup>1</sup>Porto, PT, <sup>2</sup>London, GB, <sup>3</sup>Madrid, ES, <sup>4</sup>Ladeuze, BE, <sup>5</sup>Braine-L'alleud, BE, <sup>6</sup>Princeton, NJ/US
- 12:30 - 12:30 **46P - Evolution of overall survival (OS) in patients (pts) with incident NSCLC in Denmark and Sweden: A SCAN-LEAF study analysis from the I-O Optimise initiative**  
J. Sørensen<sup>1</sup>, S. Ekman<sup>2</sup>, O.T. Brustugun<sup>3</sup>, P. Horvat<sup>4</sup>, D. Patel<sup>4</sup>, M. Rosenlund<sup>2</sup>, A. Mette Kejs<sup>1</sup>, A. Juarez-Garcia<sup>5</sup>, M. Daumont<sup>6</sup>, L. Lacoïn<sup>7</sup>, J. Penrod<sup>8</sup>, J. O'Donnell<sup>8</sup>, M. Planck<sup>9</sup>; <sup>1</sup>Copenhagen, DK, <sup>2</sup>Stockholm, SE, <sup>3</sup>Oslo, NO, <sup>4</sup>London, GB, <sup>5</sup>Uxbridge, GB, <sup>6</sup>Braine-L'alleud, BE, <sup>7</sup>Ladeuze, BE, <sup>8</sup>Princeton, NJ/US, <sup>9</sup>Lund, SE
- 12:30 - 12:30 **47P - Treatment (Tx) patterns and overall survival (OS) in patients (pts) with NSCLC in Sweden: A SCAN-LEAF study analysis from the I-O Optimise initiative**  
S. Ekman<sup>1</sup>, J. Sørensen<sup>2</sup>, O.T. Brustugun<sup>3</sup>, P. Horvat<sup>4</sup>, D. Patel<sup>4</sup>, M. Rosenlund<sup>1</sup>, A. Mette Kejs<sup>2</sup>, A. Juarez-Garcia<sup>5</sup>, M. Daumont<sup>6</sup>, L. Lacoïn<sup>7</sup>, J. Penrod<sup>8</sup>, J. O'Donnell<sup>8</sup>, M. Planck<sup>9</sup>; <sup>1</sup>Stockholm, SE, <sup>2</sup>Copenhagen, DK, <sup>3</sup>Oslo, NO, <sup>4</sup>London, GB, <sup>5</sup>Uxbridge, GB, <sup>6</sup>Braine-L'alleud, BE, <sup>7</sup>Ladeuze, BE, <sup>8</sup>Princeton, NJ/US, <sup>9</sup>Lund, SE
- 12:30 - 12:30 **48P - Education and lung cancer: A Mendelian randomisation study**  
H. Zhou, Y. Zhang, J. Liu, Y. Yang, W. Fang, S. Hong, G. Chen, S. Zhao, Z. Zhang, J. Shen, W. Xian, Y. Huang, H. Zhao, L. Zhang; Guangzhou, CN
- 12:30 - 12:30 **49P - A Mendelian randomization study of the effects of Crohn's disease on lung cancer**  
J. Liu, H. Zhou, Y. Zhang, W. Fang, Y. Yang, S. Hong, G. Chen, S. Zhao, J. Shen, W. Xian, Y. Huang, H. Zhao, L. Zhang; Guangzhou, CN
- 12:30 - 12:30 **50P - Reduced-, and no-dose thin-section radiologic examinations: Comparison of capability for nodule detection in patients having pulmonary nodules**  
W. Tang, Q. Peng, Y. Huang, N. Wu, H. Ouyang; Beijing, CN
- 12:30 - 12:30 **51P - Invasive diagnostic investigation-related complications and its impact on treatment initiation in lung cancer patients in a rapid access lung lesion clinic in regional Australia**  
K. Mccann<sup>1</sup>, W. Faisal<sup>2</sup>; <sup>1</sup>Ballarat, VIC/AU, <sup>2</sup>Ballarat, AU
- 12:30 - 12:30 **52P - Concordance, decision impact, and satisfaction for a computerized clinical decision support system in treatment of lung cancer patients**



K.A. Lee<sup>1</sup>, W. Felix<sup>2</sup>, G. Jackson<sup>3</sup>; <sup>1</sup>Jupiter, US, <sup>2</sup>Boston, MA/US, <sup>3</sup>Nashville, TN/US

- 12:30 - 12:30 **53P - Pulmonary tuberculosis: A hurdle to overcome for early lung cancer diagnosis in TB burden countries**  
M.S. Akter, S. Ahmed; Dhaka, BD
- 12:30 - 12:30 **56P - CT image standardization is superior to larger but heterogeneous data for robust radiomic models**  
D. Vuong<sup>1</sup>, M. Bogowicz<sup>1</sup>, J. Unkelbach<sup>1</sup>, R. Foerster<sup>1</sup>, S. Denzler<sup>1</sup>, A. Xyrafas<sup>2</sup>, M. Pless<sup>3</sup>, S. Thierstein<sup>2</sup>, S. Peters<sup>4</sup>, M. Guckenberger<sup>1</sup>, S. Tanadini-Lang<sup>1</sup>; <sup>1</sup>Zürich, CH, <sup>2</sup>Bern, CH, <sup>3</sup>Winterthur, CH, <sup>4</sup>Lausanne, CH
- 12:30 - 12:30 **57P - Non-small cell lung carcinoma (NSCLC) patients with baseline brain imaging: A prospective observational study**  
G. NARESH, P.S. Malik, S. Khurana, S. Pathy, M. Yadav, D. Jain, H. Kancharla; New Delhi, IN
- 12:30 - 12:30 **58P - Evaluation of a care path for patients with lung tumors and co-existing interstitial lung disease**  
M. Ronden-Kianoush, E. Nossent, C. Dickhoff, S. Nijman, I. Bahce, S. Senan, F. Spoelstra; Amsterdam, NL
- 12:30 - 12:30 **59P - Comparison of internal target volume delineation using CT datasets of four-dimensional computed tomography in lung cancer radiotherapy**  
S. Bushra, A. Tibdewal, N. Mummudi, R. Kinhikar, Y. Ghadi, J.P. Agarwal; Mumbai, IN
- 12:30 - 12:30 **60P - Nomogram for patients with stage I small cell lung cancer: A competing risk analysis**  
J. Liu, H. Zhou, Y. Zhang, W. Fang, Y. Yang, S. Hong, G. Chen, S. Zhao, X. Chen, Z. Zhang, W. Xian, J. Shen, Y. Huang, H. Zhao, L. Zhang; Guangzhou, CN
- 12:30 - 12:30 **61P - Value of post-radiotherapy for limited stage small cell lung cancer on basis of a prognostic scoring model**  
J. Yu, W. Ouyang, J. Hu, J. Zhang, C. Xie; Wuhan, CN
- 12:30 - 12:30 **62P - External validation of a survival score for limited stage small cell lung cancer treated with chemoradiotherapy**  
L. Käsmann<sup>1</sup>, R. Abdo<sup>2</sup>, J. Taugner<sup>2</sup>, C. Eze<sup>1</sup>, M. Dantes<sup>1</sup>, O. Roengvoraphoj<sup>1</sup>, C. Belka<sup>1</sup>, F. Manapov<sup>1</sup>; <sup>1</sup>Munich, DE, <sup>2</sup>München, DE
- 12:30 - 12:30 **63P - Real-life experience with the implementation of DLL3 staining and the subsequent treatment with rovalpituzumab tesirine in heavily pretreated SCLC patients**  
M. Hochmair, C. Weinlinger, H. Fabikan, R. Koger, D. Krenbeck, F. Huemer, O. Illini, M. Kulaksiz, A. Valipour, O. Burghuber; Vienna, AT



- 12:30 - 12:30 **64P - Timing of treatment with concurrent chemoradiotherapy (CRT) and impact on progression free survival (PFS) in limited stage small cell lung cancer (LSSCLC)**  
L. McSorley<sup>1</sup>, C. Goggin<sup>2</sup>, N. Elhadi<sup>2</sup>, P. O'Dea<sup>2</sup>, J. Sui<sup>3</sup>, D. Kelly<sup>3</sup>, C. Brady<sup>4</sup>, D. O'Mahony<sup>4</sup>; <sup>1</sup>Galway, IE, <sup>2</sup>Cork, IE, <sup>3</sup>Dublin, IE, <sup>4</sup>Cork, Cork/IE
- 12:30 - 12:30 **65P - Experience of prophylactic cranial irradiation in extensive stage small cell lung cancer at a regional cancer center in India**  
R. Jat, R. Rai, S. Jakhar, S. Beniwal, N. Sharma, H. Kumar; Bikaner, IN
- 12:30 - 12:30 **66P - Treatment (tx) characteristics and clinical outcomes in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) treated with carboplatin (carbo) or cisplatin (cis) in combination with etoposide (etop) in US clinical practice**  
M. Sebastian<sup>1</sup>, F. Barlesi<sup>2</sup>, R. Califano<sup>3</sup>, A. Mansfield<sup>4</sup>, F. Blackhall<sup>3</sup>, E. Flahavan<sup>5</sup>, J. Davies<sup>5</sup>, P. Arnold<sup>6</sup>, S. Morris<sup>6</sup>, M. Reck<sup>7</sup>; <sup>1</sup>Frankfurt Am Main, DE, <sup>2</sup>Marseille, CEDEX 20/FR, <sup>3</sup>Manchester, GB, <sup>4</sup>Rochester, MN/US, <sup>5</sup>Welwyn Garden City, GB, <sup>6</sup>Basel, CH, <sup>7</sup>Grosshansdorf, DE
- 12:30 - 12:30 **67TiP - ADRIATIC: A phase III trial of durvalumab &#x000B1; tremelimumab after concurrent chemoradiation for patients with limited stage small cell lung cancer**  
S. Senan<sup>1</sup>, N. Shire<sup>2</sup>, G. Mak<sup>3</sup>, W. Yao<sup>3</sup>, H. Jiang<sup>4</sup>; <sup>1</sup>Amsterdam, NL, <sup>2</sup>Gaithersburg, US, <sup>3</sup>Gaithersburg, MD/US, <sup>4</sup>Shanghai, CN
- 12:30 - 12:30 **73P - Utilization rates of stereotactic body radiation therapy for the treatment of stage I NSCLC in three European countries**  
R. Damhuis<sup>1</sup>, S. Senan<sup>2</sup>, A. Khakwani<sup>3</sup>, S. Harden<sup>4</sup>, A. Helland<sup>5</sup>, T. Strand<sup>5</sup>; <sup>1</sup>Utrecht, NL, <sup>2</sup>Amsterdam, NL, <sup>3</sup>Nottingham, GB, <sup>4</sup>Cambridge, GB, <sup>5</sup>Oslo, NO
- 12:30 - 12:30 **74P - Is there any prognostic significance of the level of change in SUVmax after SBRT in patients with early stage NSCLC?**  
G. Yaprak<sup>1</sup>, A. Ozen<sup>2</sup>, F. Tugrul<sup>2</sup>, S. Ozugur<sup>1</sup>, N. Isik<sup>1</sup>; <sup>1</sup>Istanbul, TR, <sup>2</sup>Eskisehir, TR
- 12:30 - 12:30 **75P - Thoracic ultrasound can be a trustable tool in untouchable lung nodule surgery**  
H. Zhang, Berlin, CN
- 12:30 - 12:30 **76P - Endobronchial surgery and photodynamic therapy for early central lung cancer treatment**  
S. Pirogov, L. Telegina, V. Sokolov, T. Karmakova, E. Filonenko, O. Pikin, A. Kaprin; Moscow, RU
- 12:30 - 12:30 **77P - The prognostic impact of the international association for the study of lung cancer (IASLC) definitions on completeness of surgical resection for non-small cell lung cancer (NSCLC)**



M. Gagliasso<sup>1</sup>, C. Cartia<sup>2</sup>, A. Maraschi<sup>2</sup>, R. Rapanà<sup>2</sup>, S. Sobrero<sup>2</sup>, A. Sandri<sup>2</sup>, G. Migliaretti<sup>2</sup>, F. Ardisson<sup>2</sup>; <sup>1</sup>Cuneo, IT, <sup>2</sup>Orbassano, IT

- 12:30 - 12:30 **78P - Lung resection for cancer in patients with heart disease: Management and postoperative outcome**  
F. Caushi, I. Skenduli, A. Hatibi, A. Mezini, S. Telo, S. Bala, E. Shima, A. Cani; Tirana, AL
- 12:30 - 12:30 **79P - Tissue microarray analysis on prognostic value of coexpression of RUNX3 and trimethylated histone H3 lysine 27 in surgically resected patients with stage I non-small cell lung cancer**  
X. Chen, Y. Deng, Y. Shi; Fuzhou, CN
- 12:30 - 12:30 **80P - High blood platelets levels (BPL): A prognostic factor in patients with early or locally advanced non-small cell lung cancer (NSCLC)**  
J.F. Cordoba Ortega<sup>1</sup>, A. Salud<sup>2</sup>, S. Morales<sup>2</sup>, J. Veas<sup>2</sup>, A. Rodriguez<sup>2</sup>; <sup>1</sup>Lleida, ES, <sup>2</sup>Lerida, ES
- 12:30 - 12:30 **81P - Higher PD-L1 expression correlates with lymphocyte infiltration in early non-small cell lung cancer**  
P. Rocha, M. Rodrigo, L. Moliner, M. Hardy-Werbin, D. Casadevall Aguilar, X. Durán, O. Arpí, S. Clavé, M. Salido, X. Riera, S. Menendez, Á. Taus, L. Pijuan, L. Comerma, E. Arriola Aperribay; Barcelona, ES
- 12:30 - 12:30 **82TiP - IMpower030: Phase III study evaluating neoadjuvant treatment of resectable stage II-IIIB non-small cell lung cancer (NSCLC) with atezolizumab (atezo) & chemotherapy**  
S. Peters<sup>1</sup>, A. Kim<sup>2</sup>, B. Solomon<sup>3</sup>, D. Gandara<sup>4</sup>, R. Dziadziuszko<sup>5</sup>, A. Brunelli<sup>6</sup>, M. Garassino<sup>7</sup>, M. Reck<sup>8</sup>, L. Wang<sup>9</sup>, I. To<sup>9</sup>, S. Sun<sup>9</sup>, B. Gitlitz<sup>9</sup>, A. Sandler<sup>10</sup>, N. Rizvi<sup>11</sup>; <sup>1</sup>Lausanne, CH, <sup>2</sup>Los Angeles, CA/US, <sup>3</sup>Melbourne, VIC/AU, <sup>4</sup>Sacramento, CA/US, <sup>5</sup>Gdańsk, PL, <sup>6</sup>Leeds, GB, <sup>7</sup>Milan, IT, <sup>8</sup>Grosshansdorf, DE, <sup>9</sup>South San Francisco, CA/US, <sup>10</sup>South San Francisco, OR/US, <sup>11</sup>New York, NY/US
- 12:30 - 12:30 **87P - Time-series of peripheral blood biomarkers as biomarkers for immunotherapy in advanced non-small cell lung cancer (aNSCLC) patients**  
A. Prelaj<sup>1</sup>, S.E. Rebuzzi<sup>2</sup>, P. Pizzutilo<sup>3</sup>, M. Bilancia<sup>3</sup>, M. Montrone<sup>3</sup>, F. Pesola<sup>3</sup>, V. Longo<sup>3</sup>, G. Del Bene<sup>3</sup>, V. Lapadula<sup>3</sup>, F. Cassano<sup>3</sup>, P. Petrillo<sup>3</sup>, D. Bafunno<sup>3</sup>, N. Varesano<sup>3</sup>, V. Lamorgese<sup>3</sup>, A. Mastranrdea<sup>3</sup>, D. Ricci<sup>3</sup>, A. Catino<sup>3</sup>, D. Galetta<sup>3</sup>; <sup>1</sup>Milan, IT, <sup>2</sup>Genova, IT, <sup>3</sup>Bari, IT
- 12:30 - 12:30 **89P - Treatment patterns and long-term survival for unresected stage III non-small cell lung cancer patients: A nationwide register study in Denmark**  
A. Green<sup>1</sup>, K. Olsen<sup>2</sup>, M. Bliddal<sup>2</sup>, H. Christensen<sup>1</sup>, E. Jakobsen<sup>2</sup>; <sup>1</sup>Copenhagen, DK, <sup>2</sup>Odense C, DK
- 12:30 - 12:30 **90P - Real-world treatment patterns, clinical practice and outcomes for locally advanced, non resectable, non-small cell lung cancer from the French ESME Lung database**





N. Girard<sup>1</sup>, M. Pérol<sup>2</sup>, G. Simon<sup>1</sup>, C. Audigier Valette<sup>3</sup>, R. Gervais<sup>4</sup>, D. Debieuvre<sup>5</sup>, R. Schott<sup>6</sup>, X. Quantin<sup>7</sup>, B. Coudert<sup>8</sup>, H. Lena<sup>9</sup>, M. Carton<sup>1</sup>, M. Robain<sup>1</sup>, T. Filleron<sup>10</sup>, C. Chouaid<sup>11</sup>; <sup>1</sup>Paris, FR, <sup>2</sup>Lyon, CEDEX/FR, <sup>3</sup>Toulon, CEDEX/FR, <sup>4</sup>Caen, CEDEX 5/FR, <sup>5</sup>Mulhouse, FR, <sup>6</sup>Strasbourg, CEDEX/FR, <sup>7</sup>Montpellier, CEDEX 5/FR, <sup>8</sup>Dijon, Cedex/FR, <sup>9</sup>Rennes, CEDEX/FR, <sup>10</sup>Toulouse, CEDEX 3/FR, <sup>11</sup>Créteil, CEDEX 12/FR

- 12:30 - 12:30 **91P - Prognosis of EGFR-mutant advanced lung adenocarcinoma patients with different intrathoracic metastatic patterns**  
F. Hu<sup>1</sup>, B. Zhang<sup>1</sup>, C. Li<sup>1</sup>, J. Xu<sup>1</sup>, H. Wang<sup>1</sup>, P. Gu<sup>1</sup>, X. Zheng<sup>1</sup>, W. Nie<sup>1</sup>, Y. Shen<sup>1</sup>, H. Zhang<sup>1</sup>, P. Hu<sup>2</sup>, X. Zhang<sup>1</sup>; <sup>1</sup>Shanghai, CN, <sup>2</sup>Zhenjiang, CN
- 12:30 - 12:30 **92P - A prospective study on the association of dose-volume histogram parameters with oesophagitis, radiation pneumonitis, radiation induced pulmonary fibrosis after receiving chemoradiation for NSCLC**  
S. Bhowal, K. Chatterjee, J. Dey; Kolkata, IN
- 12:30 - 12:30 **93P - Heterogeneity score in inoperable stage III non-small cell lung cancer patients treated with definitive chemoradiotherapy: A single centre analysis**  
J. Taugner<sup>1</sup>, L. Käsmann<sup>2</sup>, C. Eze<sup>2</sup>, M. Dantes<sup>2</sup>, O. Roengvoraphoj<sup>2</sup>, K. Gennen<sup>2</sup>, M. Karin<sup>2</sup>, A. Tufman<sup>2</sup>, C. Belka<sup>2</sup>, F. Manapov<sup>2</sup>; <sup>1</sup>München, DE, <sup>2</sup>Munich, DE
- 12:30 - 12:30 **94P - Challenges in the management of stage III non-small cell lung cancer (NSCLC) within multidisciplinary team (MDT): A lung cancer center experience**  
K. Harbeque, N. Mejri, H. El Benna, S. Labidi, N. Daoud, H. Boussen; Ariana, TN
- 12:30 - 12:30 **95P - The role of patient performance status and its changes before and after completion of multimodal treatment for inoperable stage III NSCLC**  
L. Käsmann<sup>1</sup>, J. Taugner<sup>2</sup>, C. Eze<sup>1</sup>, O. Roengvoraphoj<sup>1</sup>, M. Dantes<sup>1</sup>, K. Gennen<sup>1</sup>, M. Karin<sup>1</sup>, A. Tufman<sup>1</sup>, C. Belka<sup>1</sup>, F. Manapov<sup>1</sup>; <sup>1</sup>Munich, DE, <sup>2</sup>München, DE
- 12:30 - 12:30 **96P - Impact of thrombocytosis and neutrophil-to-lymphocyte ratio before start of chemoradiotherapy on patient survival in inoperable stage III NSCLC**  
M. Hoffmann<sup>1</sup>, J. Taugner<sup>1</sup>, O. Roengvoraphoj<sup>2</sup>, C. Eze<sup>2</sup>, L. Käsmann<sup>2</sup>, C. Belka<sup>2</sup>, F. Manapov<sup>2</sup>; <sup>1</sup>München, DE, <sup>2</sup>Munich, DE
- 12:30 - 12:30 **97P - Pattern of first-site failure and salvage treatment in patients with inoperable stage III non-small cell lung cancer after chemoradiotherapy**  
C. Eze<sup>1</sup>, J. Taugner<sup>2</sup>, L. Käsmann<sup>1</sup>, O. Roengvoraphoj<sup>1</sup>, N. Schmidt-Hegemann<sup>2</sup>, M. Dantes<sup>1</sup>, C. Belka<sup>1</sup>, F. Manapov<sup>1</sup>; <sup>1</sup>Munich, DE, <sup>2</sup>München, DE
- 12:30 - 12:30 **98P - Implications for UK practice of the use of durvalumab in stage III NSCLC**





M.S. Iqbal<sup>1</sup>, P. Atherton<sup>1</sup>, C. Macgregor<sup>2</sup>, A. Wieczorek<sup>3</sup>, J. Singer<sup>4</sup>, J. Walther<sup>5</sup>, F. Little<sup>6</sup>, S. Harden<sup>7</sup>, C. Peedell<sup>8</sup>, A. Cyriac<sup>9</sup>, S. Chowdhury<sup>4</sup>, M. Bayne<sup>10</sup>, K. Yip<sup>11</sup>, A. Britten<sup>12</sup>, C. Powell<sup>13</sup>, J. Brock<sup>12</sup>, S. Datta<sup>14</sup>, T. Sevitt<sup>15</sup>, A. Mehta<sup>16</sup>, A. Greystoke<sup>17</sup>; <sup>1</sup>Newcastle Upon Tyne, GB, <sup>2</sup>Inverness, GB, <sup>3</sup>Cottingham, GB, <sup>4</sup>Harlow, GB, <sup>5</sup>Taunton, GB, <sup>6</sup>Edinburgh, GB, <sup>7</sup>Cambridge, GB, <sup>8</sup>Middlesbrough, GB, <sup>9</sup>Southend, GB, <sup>10</sup>Poole, GB, <sup>11</sup>Ipswich, GB, <sup>12</sup>Brighton, GB, <sup>13</sup>Swansea, GB, <sup>14</sup>Peterborough, GB, <sup>15</sup>Maidstone, GB, <sup>16</sup>Guildford, GB, <sup>17</sup>Newcastle Upon Tyne, Tyne and Wear/GB

12:30 - 12:30

**99P - Efficacy and safety of adjuvant chemotherapy in lung cancer: Real-world evidence**

F. Roitberg<sup>1</sup>, M.F. Neffá<sup>1</sup>, R. Bonadio<sup>1</sup>, G. Harada<sup>1</sup>, E. Mendoza<sup>2</sup>, M. Mak<sup>1</sup>, T. Takahashi<sup>1</sup>, R. Martins<sup>1</sup>, C. Mesquita<sup>1</sup>, F. Santini<sup>1</sup>, P. de Araújo<sup>1</sup>, L. Lauricella<sup>1</sup>, G. Prado<sup>1</sup>, T. Takagaki<sup>1</sup>, E. de Mello<sup>1</sup>, F. Gabrielli<sup>1</sup>, H. de Andrade Carvalho<sup>1</sup>, R. Terra<sup>1</sup>, G. de Castro Jr<sup>3</sup>; <sup>1</sup>Sao Paulo, BR, <sup>2</sup>Quito, EC, <sup>3</sup>São Paulo, BR

12:30 - 12:30

**100P - A new PET-CT score for locally-advanced inoperable NSCLC stage III patients treated with chemoradiotherapy**

O. Roengvoraphoj<sup>1</sup>, C. Eze<sup>1</sup>, J. Taugner<sup>2</sup>, A. Gjika<sup>2</sup>, A. Tufman<sup>1</sup>, L. Käsmann<sup>1</sup>, I. Hadi<sup>2</sup>, E. Mille<sup>2</sup>, C. Belka<sup>1</sup>, F. Manapov<sup>1</sup>; <sup>1</sup>Munich, DE, <sup>2</sup>München, DE

12:30 - 12:30

**101TiP - PACIFIC-R: First real-world study of patients with unresectable, stage III NSCLC treated with durvalumab after chemoradiotherapy**

N. Girard<sup>1</sup>, F. Mornex<sup>2</sup>, D. Christoph<sup>3</sup>, R. Fietkau<sup>4</sup>, A. Filippi<sup>5</sup>, J. Field<sup>6</sup>, P. Garrido Lopez<sup>7</sup>, F. McDonald<sup>8</sup>, S. Peters<sup>9</sup>, A. Klein<sup>10</sup>, M. Licour<sup>11</sup>, M. Garassino<sup>12</sup>; <sup>1</sup>Paris, FR, <sup>2</sup>Pierre Bénite, FR, <sup>3</sup>Essen, DE, <sup>4</sup>Erlangen, DE, <sup>5</sup>Pavia, IT, <sup>6</sup>Liverpool, GB, <sup>7</sup>Madrid, ES, <sup>8</sup>London, GB, <sup>9</sup>Lausanne, CH, <sup>10</sup>Cambridge, GB, <sup>11</sup>Gaithersburg, US, <sup>12</sup>Milan, IT

12:30 - 12:30

**121P - Risk of not receiving second-line therapy is high in EGFR mt&&**

J. Roeper<sup>1</sup>, A. Lueers<sup>2</sup>, M. Falk<sup>3</sup>, S. Schatz<sup>4</sup>, M. Tiemann<sup>4</sup>, C. Wesseler<sup>4</sup>, G.H. Wiest<sup>4</sup>, S. Sackmann<sup>5</sup>, D. Ukena<sup>5</sup>, L. Heukamp<sup>6</sup>, F. Griesinger<sup>2</sup>; <sup>1</sup>Berlin, DE, <sup>2</sup>Oldenburg, DE, <sup>3</sup>Hamburg, Hamburg/DE, <sup>4</sup>Hamburg, DE, <sup>5</sup>Bremen, DE, <sup>6</sup>Köln, DE

12:30 - 12:30

**122P - Osimertinib as first-line (1L) treatment for epidermal growth factor receptor (EGFR) mutation-positive advanced non-small cell lung cancer (NSCLC): Final efficacy and safety results from two phase I expansion cohorts**

J.C. Yang<sup>1</sup>, S. Ramalingam<sup>2</sup>, C. Lee<sup>3</sup>, T. Kurata<sup>4</sup>, D. Kim<sup>5</sup>, T. John<sup>6</sup>, N. Nogami<sup>7</sup>, Y. Ohe<sup>8</sup>, Y. Rukazenzov<sup>9</sup>, M. Murphy<sup>10</sup>, P. Jänne<sup>11</sup>; <sup>1</sup>Taipei City, TW, <sup>2</sup>Atlanta, US, <sup>3</sup>Kogarah, NSW/AU, <sup>4</sup>Osaka, JP, <sup>5</sup>Seoul, KR, <sup>6</sup>Heidelberg, AU, <sup>7</sup>Matsuyama, JP, <sup>8</sup>Tokyo, JP, <sup>9</sup>Macclesfield, Cheshire/GB, <sup>10</sup>Cambridge, GB, <sup>11</sup>Boston, MA/US

12:30 - 12:30

**123P - Long term survival analysis of osimertinib in stage IV NSCLC patients harbored acquired EGFR T790M mutation: A real-word study in China**

S. Wang, B. Han; Shanghai, CN

12:30 - 12:30

**124P - The effect of proton pump inhibitors (PPI) on dacomitinib (DACO) pharmacokinetics and efficacy in non-small cell lung cancer (NSCLC) patients with activating epidermal growth factor receptor (EGFR) mutation**



J. Li, D. Nickens, K. Wilner, W. Tan; San Diego, US

- 12:30 - 12:30 **125P - Elderly patients treated with afatinib in clinical practice: Results from the prospective non-interventional study GIDEON**  
W. Brückl<sup>1</sup>, E. Laack<sup>2</sup>, C. Kortsik<sup>3</sup>, H. Schaefer<sup>4</sup>, M. Reck<sup>5</sup>, A. Maerten<sup>6</sup>, C. Hoffmann<sup>6</sup>;  
<sup>1</sup>Nürnberg, DE, <sup>2</sup>Berlin, DE, <sup>3</sup>Mainz, DE, <sup>4</sup>Völklingen, DE, <sup>5</sup>Grosshansdorf, DE,  
<sup>6</sup>Ingelheim Am Rhein, DE
- 12:30 - 12:30 **126P - Regional retrospective analysis of outcomes of EGFR mutated non-squamous non-small cell lung cancer (NSCLC) patients in West Yorkshire**  
D. Sharma<sup>1</sup>, F. Slevin<sup>1</sup>, K. Clarke<sup>1</sup>, K. Franks<sup>2</sup>, M. Snee<sup>1</sup>, P. Jain<sup>1</sup>; <sup>1</sup>Leeds, GB, <sup>2</sup>Leeds, Yorkshire/GB
- 12:30 - 12:30 **127P - Obesity has an impact on the efficacy of EGFR-TKI in NSCLC patients harbouring EGFR mutation: A real-world study**  
Z. Ding, Y. Chen, Y. Hong, Y. Fu, L. Tong, Q. Li, P. Lin; Chengdu, CN
- 12:30 - 12:30 **128P - Frequency and types of EGFR mutation in Moroccan patients with non-small cell lung cancer**  
M. Sow, H. El Yacoubi<sup>1</sup>, B. Moukafih, S. Balde, G. Akimana, S. Elkhoyaali, H. Abahssain, H. Mrabti, I. Elghissassi, H. Errihani; Rabat, MA
- 12:30 - 12:30 **129P - Anlotinib can overcome acquired resistance to EGFR-TKIs via FGFR1 signaling in non-small cell lung cancer**  
Z. Lian, W. Du, J. Zhu, Y. Zeng, L. zeyi, J. Huang; Suzhou, CN
- 12:30 - 12:30 **130P - Relationship of clinicopathological characteristics, EGFR genotyping and prognosis in non-small cell lung cancer patients with malignant pleural effusion**  
J. Zhang, Z. Zhou, Y. Su, T. Yu; Nanning, CN
- 12:30 - 12:30 **131P - Upfront whole brain radiotherapy for multiple brain metastases in patients with EGFR-mutant lung adenocarcinoma**  
C. Li, J. Guo, L. Zhao, F. Hu, W. Nie, H. Wang, X. Zheng, Y. Shen, P. Gu, Y. Zhang, X. Zhang; Shanghai, CN
- 12:30 - 12:30 **132P - New insights into acquired resistance mechanisms to third-generation EGFR tyrosine kinase inhibitor therapy in lung cancer**  
J. Fassunke<sup>1</sup>, C. Heydt<sup>2</sup>, S. Michels<sup>2</sup>, B. Van Veggel<sup>3</sup>, F. Müller<sup>2</sup>, M. Keul<sup>4</sup>, M.A. Dammert<sup>2</sup>, A. Schmitt<sup>2</sup>, E. Smit<sup>3</sup>, S. Kast<sup>4</sup>, J. Wolf<sup>1</sup>, R. Buettner<sup>1</sup>, M. Sos<sup>2</sup>, D. Rauh<sup>4</sup>, S. Merkelbach-Bruse<sup>2</sup>; <sup>1</sup>Cologne, DE, <sup>2</sup>Köln, DE, <sup>3</sup>Amsterdam, NL, <sup>4</sup>Dortmund, DE
- 12:30 - 12:30 **133P - A study evaluating the different treatment modalities for EGFR mutation positive advanced NSCLC patients that acquire c-MET amplification after EGFR TKI therapy resistant**  
J. Qu, L. Liu, J. Heng, C. Zhou, Y. Xiong, W. Jiang, N. Yang; Changsha, CN



- 12:30 - 12:30 **134P - Mutational spectrum of acquired resistance to reversible versus irreversible EGFR tyrosine kinase inhibitors**  
S. Wagener-Rydzek<sup>1</sup>, C. Heydt<sup>2</sup>, J. Sueptitz<sup>2</sup>, S. Michels<sup>2</sup>, M. Falk<sup>3</sup>, C. Alidousty<sup>2</sup>, J. Fassunke<sup>1</sup>, M. Tiemann<sup>4</sup>, L. Heukamp<sup>2</sup>, J. Wolf<sup>1</sup>, R. Buettner<sup>1</sup>, S. Merkelbach-Bruse<sup>2</sup>; <sup>1</sup>Cologne, DE, <sup>2</sup>Köln, DE, <sup>3</sup>Hamburg, Hamburg/DE, <sup>4</sup>Hamburg, DE
- 12:30 - 12:30 **135P - EGFR &#x0026; PD L1: An (im)perfect union**  
U. Batra<sup>1</sup>, M. Sharma<sup>2</sup>, P. Jain<sup>2</sup>, S. Bothra<sup>2</sup>, S. Pasricha<sup>3</sup>; <sup>1</sup>New Delhi, Rohini/IN, <sup>2</sup>New Delhi, IN, <sup>3</sup>Delhi, IN
- 12:30 - 12:30 **136P - Correlation of molecular status and anatomic sites of metastases at diagnosis of EGFR positive non-small cell lung cancer (NSCLC): A single institution experience**  
K. Krpina, B. Budimir, S. Kukulj, A. Marušić, M. Jakopović, M. Samaržija; Zagreb, HR
- 12:30 - 12:30 **137P - Detection and clinicopathologic features of ctDNA in T790M-positive advanced lung adenocarcinomas patients after failure of treatment with first- and second-generation EGFR-TKIs**  
W. he, Z. Zhou, T. Yu, H. Zhao, Y. Su, P. Zeng; Nanning, CN
- 12:30 - 12:30 **138P - PD-L1 confers primary resistance to EGFR-TKI in EGFR mutant non-small cell lung cancer via inducing EMT phenotype**  
Y. Zhang, T. Liu, Y. Zeng, J. Zhu, W. Du, L. zeyi, J. Huang; Suzhou, CN
- 12:30 - 12:30 **139P - Real-world immuno-oncology (IO) therapy treatment patterns and outcomes in patients with anaplastic lymphoma kinase positive (ALK&#x0026;) non-small cell lung cancer (NSCLC) in the United States**  
X. Pan<sup>1</sup>, M. Lin<sup>2</sup>, Y. Yin<sup>1</sup>, P. Hou<sup>1</sup>, P. Baumann<sup>1</sup>, M. Jahanzeb<sup>3</sup>; <sup>1</sup>Cambridge, MA/US, <sup>2</sup>Cambridge, US, <sup>3</sup>Miami, FL/US
- 12:30 - 12:30 **140P - Brigatinib experience on the ALK project**  
F. Gomes<sup>1</sup>, N. Tokaca<sup>2</sup>, K. Yip<sup>3</sup>, S. Ghosh<sup>2</sup>, T. Newsom-Davis<sup>2</sup>, A. Greystoke<sup>4</sup>, H. Mills<sup>2</sup>, S. Ahmed<sup>5</sup>, A. Harle<sup>1</sup>, G. Ayre<sup>6</sup>, R. Shah<sup>7</sup>, S. Popat<sup>2</sup>, F. Blackhall<sup>1</sup>, Y. Summers<sup>1</sup>; <sup>1</sup>Manchester, GB, <sup>2</sup>London, GB, <sup>3</sup>Ipswich, GB, <sup>4</sup>Newcastle Upon Tyne, Tyne and Wear/GB, <sup>5</sup>Leicester, GB, <sup>6</sup>Bristol, GB, <sup>7</sup>Maidstone, Kent/GB
- 12:30 - 12:30 **141P - Effect of central nervous system (CNS) metastases in a real-world multicenter cohort study of Spanish ALK-positive non-small cell lung cancer (NSCLC) patients (p)**



L. Angelats<sup>1</sup>, M.R. Garcia Campelo<sup>2</sup>, R. Bernabe Caro<sup>3</sup>, E. Arriola Aperrribay<sup>4</sup>, V. Calvo de Juan<sup>5</sup>, A. Barba Joaquín<sup>4</sup>, N. Vinolas Segarra<sup>4</sup>, M. Gil Moreno<sup>6</sup>, L. Vilà Martinez<sup>7</sup>, O.J. Juan Vidal<sup>8</sup>, N. Vilariño Quintela<sup>4</sup>, M. Cobo<sup>9</sup>, E. Sais<sup>10</sup>, M. Domine Gomez<sup>11</sup>, N. Fernandez Nuñez<sup>12</sup>, J. Coves Sarto<sup>13</sup>, R. Marse Fabregat<sup>14</sup>, A.M. Esteve Gomez<sup>1</sup>, D. Rodríguez-Abreu<sup>15</sup>, E. Carcereny Costa<sup>16</sup>; <sup>1</sup>Badalona, ES, <sup>2</sup>Coruna, ES, <sup>3</sup>Sevilla, ES, <sup>4</sup>Barcelona, ES, <sup>5</sup>Majadahonda, Madrid/ES, <sup>6</sup>Barcelona, Barcelona/ES, <sup>7</sup>Sabadell, Barcelona/ES, <sup>8</sup>Valencia, ES, <sup>9</sup>Malaga, ES, <sup>10</sup>Girona, ES, <sup>11</sup>Madrid, ES, <sup>12</sup>Lugo, ES, <sup>13</sup>Palma De Mallorca, Islas Baleares/ES, <sup>14</sup>Palma De Mallorca, ES, <sup>15</sup>Las Palmas, ES, <sup>16</sup>Badalona, Barcelona/ES

- 12:30 - 12:30 **142P - Clinical management of advanced lung adenocarcinoma with ALK rearrangement: Real-world treatment outcomes and long-term survival**  
B. Zhang, S. Wang, J. Xu, Y. Zhang, X. Zhang, J. Qian, J. Lu, R. Qiao, W. Nie, L. Zhang, Y. Zhao, M. Hu, W. Zhang, B. Han; Shanghai, CN
- 12:30 - 12:30 **143P - Role of radiotherapy in management of brain metastases in anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC): A single-center retrospective study**  
Y. Zhao, B. Zhang, Y. Zhang, S. Wang, J. Qian, B. Han; Shanghai, CN
- 12:30 - 12:30 **144P - Clinical and treatment features associated with improved 5-year survival rate in ALK-positive lung cancer treated with ALK-TKIs**  
A. Passaro, A. Prelaj, G. Spitaleri, E. Del Signore, G. Rossi, E. Guerini-Rocco, M. Barberis, C. Catania, F. de Marinis; Milan, IT
- 12:30 - 12:30 **145P - Clinicopathological characteristics and outcome of advanced ROS1-positive non-small cell lung cancer in Asian patients**  
C.Y.X. Kho, D. Lim, D.S.W. Tan, W.L. Tan, T. Rajasekaran, A. Jain, C.K. Toh, M. Ang, E.H. Tan, Q.S. Ng; Singapore, SG
- 12:30 - 12:30 **146P - Clinical significance of ROS1 deletions detected by FISH and response to crizotinib**  
F. Dall'Olio, G. Lamberti, E. Capizzi, E. Gruppioni, F. Sperandi, A. Altimari, F. Giunchi, M. Fiorentino, A. Ardizzoni; Bologna, IT
- 12:30 - 12:30 **147P - Impact on KRAS-subtypes and TP53 mutations on the prognostic value of KRAS/KEAP1 mutations in non-small cell lung cancer (NSCLC)**  
M. Scheffler<sup>1</sup>, R. Frank<sup>2</sup>, M. Ihle<sup>2</sup>, D. Abdulla<sup>1</sup>, S. Koleczko<sup>2</sup>, L. Nogova<sup>2</sup>, A. Holzem<sup>2</sup>, T. Chanra<sup>1</sup>, R. Riedel<sup>1</sup>, S. Michels<sup>2</sup>, R. Fischer<sup>2</sup>, A. Kron<sup>1</sup>, S. Merkelbach-Bruse<sup>2</sup>, R. Buettner<sup>2</sup>, J. Wolf<sup>1</sup>; <sup>1</sup>Cologne, DE, <sup>2</sup>Köln, DE
- 12:30 - 12:30 **148P - KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic non-squamous NSCLC**  
M. Cinausero<sup>1</sup>, N. Laprovitera<sup>2</sup>, G. De Maglio<sup>1</sup>, L. Gerratana<sup>1</sup>, M. Riefolo<sup>2</sup>, M. Macerelli<sup>1</sup>, M. Fiorentino<sup>2</sup>, E. Porcellini<sup>2</sup>, V. Buoro<sup>1</sup>, F. Gelsomino<sup>2</sup>, A. Squadrilli<sup>3</sup>, G. Fasola<sup>1</sup>, M. Tiseo<sup>3</sup>, M. Ferracin<sup>2</sup>, A. Ardizzoni<sup>2</sup>; <sup>1</sup>Udine, IT, <sup>2</sup>Bologna, IT, <sup>3</sup>Parma, IT





- 12:30 - 12:30 **149P - Efficacy of tyrosine kinase inhibitors (TKIs) in advanced lung adenosquamous carcinoma**  
M. Hu, B. Zhang, S. Wang, Y. Shen, J. Qian, Y. Zhao, B. Han; Shanghai, CN
- 12:30 - 12:30 **150P - Characterization of patients with metastatic non-small cell lung cancer obtaining long term benefit from immunotherapy**  
G. Galli<sup>1</sup>, C. Proto<sup>2</sup>, D. Signorelli<sup>1</sup>, M. Imbimbo<sup>1</sup>, R. Ferrara<sup>2</sup>, A. Prelaj<sup>2</sup>, A. De Toma<sup>2</sup>, G. Randon<sup>2</sup>, B. Trevisan<sup>2</sup>, M. Ganzinelli<sup>2</sup>, N. Zilembo<sup>2</sup>, M. Garassino<sup>1</sup>, G. Lo Russo<sup>2</sup>; <sup>1</sup>Milan, IT, <sup>2</sup>Milano, IT
- 12:30 - 12:30 **151P - Safety and tolerability of pembrolizumab or placebo plus pemetrexed and platinum as first-line therapy in Japanese patients (PTS) with metastatic non-squamous non-small cell lung cancer (NSCLC) enrolled in the phase III KEYNOTE-189 study**  
H. Horinouchi<sup>1</sup>, N. Nogami<sup>2</sup>, H. Saka<sup>3</sup>, M. Nishio<sup>1</sup>, T. Tokito<sup>4</sup>, T. Takahashi<sup>5</sup>, K. Kasahara<sup>6</sup>, Y. Hattori<sup>7</sup>, E. Ichihara<sup>8</sup>, N. Adachi<sup>1</sup>, T. Sawada<sup>1</sup>, T. Shimamoto<sup>1</sup>, K. Noguchi<sup>1</sup>, M.C. Pietanza<sup>9</sup>, T. Kurata<sup>10</sup>; <sup>1</sup>Tokyo, JP, <sup>2</sup>Matsuyama, JP, <sup>3</sup>Nagoya, JP, <sup>4</sup>Kurume, JP, <sup>5</sup>Shizuoka, Shizuoka/JP, <sup>6</sup>Kanazawa, JP, <sup>7</sup>Akashi, JP, <sup>8</sup>Okayama, JP, <sup>9</sup>Kenilworth, NJ/US, <sup>10</sup>Osaka, JP
- 12:30 - 12:30 **152P - Correlation among different KRAS alterations, genetic co-mutations and PD-L1 expression in patients treated with immunotherapy in metastatic NSCLC**  
L. Gianoncelli<sup>1</sup>, G. Spitaleri<sup>1</sup>, A. Passaro<sup>1</sup>, C. Fumagalli<sup>1</sup>, P. Trillo Aliaga<sup>1</sup>, E. Del Signore<sup>2</sup>, V. Stati<sup>1</sup>, E. Ferraro<sup>3</sup>, E. Guerini-Rocco<sup>1</sup>, C. Catania<sup>1</sup>, M. Barberis<sup>1</sup>, F. de Marinis<sup>1</sup>; <sup>1</sup>Milan, IT, <sup>2</sup>Roma, IT, <sup>3</sup>Rozzano, (MI)/IT
- 12:30 - 12:30 **153P - Chemotherapy with immune-checkpoint inhibitors in first-line treatment metastatic NSCLC patients: Systematic review and literature-based meta-analysis**  
A. Addeo<sup>1</sup>, G. Banna<sup>2</sup>, G. Metro<sup>3</sup>, M. Di Maio<sup>4</sup>; <sup>1</sup>Geneva, CH, <sup>2</sup>Catania, IT, <sup>3</sup>Perugia, (PG)/IT, <sup>4</sup>Torino, IT
- 12:30 - 12:30 **154P - Renal toxicity from platinum/pemetrexed and pembrolizumab in the era of combination therapy**  
D. Dumoulin<sup>1</sup>, S. Visser<sup>2</sup>, R. Cornelissen<sup>3</sup>, J. Aerts<sup>4</sup>; <sup>1</sup>Barendrecht, NL, <sup>2</sup>Breda, NL, <sup>3</sup>Rotterdam, NL, <sup>4</sup>Rotterdam, Noord Brabant/NL
- 12:30 - 12:30 **155P - Association of immune-related adverse events (irAEs) and immunotherapy (IT) benefit in advanced non-small cell lung cancer (NSCLC)**  
C. Saavedra Serrano, A. Barquín García, E. Corral de la Fuente, J.J. Serrano Domingo, V. Albarrán Artahona, R. Martín Huertas, A. Gómez Rueda, M.E. Olmedo García; Madrid, ES
- 12:30 - 12:30 **156P - Peripheral blood biomarkers as prognostic factors for immunotherapy in advanced non-small cell lung cancer (aNSCLC) patients**





A. Prelaj<sup>1</sup>, S.E. Rebutzi<sup>2</sup>, P. Pizzutilo<sup>3</sup>, M. Bilancia<sup>3</sup>, M. Montrone<sup>3</sup>, F. Pesola<sup>3</sup>, V. Longo<sup>3</sup>, G. Del Bene<sup>3</sup>, V. Lapadula<sup>3</sup>, F. Cassano<sup>3</sup>, P. Petrillo<sup>3</sup>, D. Bafunno<sup>3</sup>, N. Varesano<sup>3</sup>, V. Lamorgese<sup>3</sup>, A. Mastranrdea<sup>3</sup>, D. Ricci<sup>3</sup>, A. Catino<sup>3</sup>, D. Galetta<sup>3</sup>; <sup>1</sup>Milan, IT, <sup>2</sup>Genova, IT, <sup>3</sup>Bari, IT

- 12:30 - 12:30 **157P - Prognostic impact of the use of antibiotics in patients with advanced non-small cell lung cancer (NSCLC) receiving PD-(L)1 targeting monoclonal antibodies**  
A. Schett<sup>1</sup>, S. Rothschild<sup>1</sup>, L. Mauti<sup>2</sup>, S. Schmid<sup>2</sup>, C. Appenzeller<sup>2</sup>, A. Curioni-Fontecedro<sup>3</sup>, M. Frueh<sup>2</sup>, M. Joerger<sup>2</sup>; <sup>1</sup>Basel, CH, <sup>2</sup>St. Gallen, CH, <sup>3</sup>Zurich, CH
- 12:30 - 12:30 **158P - Immune-related adverse events (irAEs) in advanced non-small cell lung cancer (aNSCLC): Platelet-to-lymphocyte ratio (PLR) predicts the risk of development and relapse**  
A. Pavan<sup>1</sup>, L. Calvetti<sup>2</sup>, A. Dal Maso<sup>1</sup>, I. Attili<sup>1</sup>, G. Pasello<sup>1</sup>, G. Aprile<sup>3</sup>, V. Guarneri<sup>1</sup>, P. Conte<sup>1</sup>, L. Bonanno<sup>1</sup>; <sup>1</sup>Padova, IT, <sup>2</sup>Verona, IT, <sup>3</sup>Vicenza, IT
- 12:30 - 12:30 **159P - Initial serum tumor marker dynamics predict progression-free and overall survival in single PD-1/PD-L1 inhibitor treated advanced NSCLC**  
D. Lang, A. Horner, E. Brehm, K. Akbari, B. Hergan, K. Langer, C. Asel, M. Scala, B. Kaiser, B. Lamprecht; Linz, AT
- 12:30 - 12:30 **160P - EPSILoN score: Validation cohort of a prognostic score in advanced non-small cell lung cancer (aNSCLC) patients treated with immunotherapy**  
A. Prelaj<sup>1</sup>, G. Lo Russo<sup>2</sup>, D. Signorelli<sup>1</sup>, R. Ferrara<sup>2</sup>, M. Imbimbo<sup>1</sup>, G. Galli<sup>1</sup>, A. De Toma<sup>2</sup>, G. Randon<sup>2</sup>, M. Brambilla<sup>1</sup>, B. Trevisan<sup>2</sup>, M. Ganzinelli<sup>2</sup>, N. Zilembo<sup>2</sup>, F. De Braud<sup>1</sup>, M. Garassino<sup>1</sup>, C. Proto<sup>2</sup>; <sup>1</sup>Milan, IT, <sup>2</sup>Milano, IT
- 12:30 - 12:30 **161P - Tumor mutational burden assessed by a targeted NGS assay predicts clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer**  
P. Jermann<sup>1</sup>, I. Alborelli<sup>1</sup>, K. Leonards<sup>1</sup>, S. Rothschild<sup>1</sup>, L. Leuenberger<sup>1</sup>, S. Savic Prince<sup>1</sup>, K. Mertz<sup>2</sup>, S. Poechtrager<sup>2</sup>, A. Zippelius<sup>1</sup>, L. Quagliata<sup>1</sup>, L. Bubendorf<sup>1</sup>; <sup>1</sup>Basel, CH, <sup>2</sup>Liestal, CH
- 12:30 - 12:30 **162P - Monitoring of blood serum amyloid (SAA) to predict outcome of first-line pembrolizumab (P) in patients (pts) with advanced non-small cell lung cancer (ANSCCLC)**  
V. Di Noia<sup>1</sup>, E. D'Argento<sup>1</sup>, E. Vita<sup>1</sup>, M. Ferrara<sup>1</sup>, P. Damiano<sup>1</sup>, M. Ribelli<sup>1</sup>, A. Cannella<sup>1</sup>, A. Virtuoso<sup>1</sup>, G. Tortora<sup>1</sup>, E. Bria<sup>2</sup>; <sup>1</sup>Rome, IT, <sup>2</sup>Roma, IT
- 12:30 - 12:30 **163P - Immuno-oncological treatment and tumor load in non-small cell lung cancer (NSCLC): Case-control analysis of overall survival (OS) in routine clinical practice**  
M. Faehling, B. Schwenk, M. Kopp, S. Fallscheer, S. Kramberg, R. Eckert; Esslingen, DE
- 12:30 - 12:30 **164P - PD-L1 expression affect the efficacy of pemetrexed maintenance therapy in real-world patients with advanced non-squamous NSCLC**



Y. Qin, L. Jiang, Y. Li, L. Ren, Y. Wang, Y. Gong, F. Peng, J. Zhu, Z. Ding, Y. Liu, M. Yu, Y. Lu, M. Huang; Chengdu, CN

- 12:30 - 12:30 **165P - Clinical benefit of anti PD-1/PD-L1 plus chemotherapy versus chemotherapy alone in first-line treatment in advanced non-small cell lung cancer: A meta-analysis**  
T. Landre<sup>1</sup>, G. Des Guetz<sup>2</sup>, A. Vergnenegre<sup>3</sup>, C. Chouaid<sup>4</sup>; <sup>1</sup>Sevrans, FR, <sup>2</sup>Bobigny, CEDEX/FR, <sup>3</sup>Limoges, CEDEX/FR, <sup>4</sup>Créteil, CEDEX 12/FR
- 12:30 - 12:30 **166P - Correlation of various clinical, imaging and laboratory parameters with outcome in patients with metastatic non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs): Results from a prospective, observational, single institution study**  
K. Rounis<sup>1</sup>, C. Papadaki<sup>1</sup>, D. Makrakis<sup>1</sup>, A. Monastirioti<sup>1</sup>, L. Vamvakas<sup>2</sup>, K. Kalbakis<sup>1</sup>, D. Mavroudis<sup>1</sup>, S. Aggelaki<sup>1</sup>; <sup>1</sup>Heraklion, GR, <sup>2</sup>Heraklion, Crete/GR
- 12:30 - 12:30 **167P - Prognostic significance of neutrophil/lymphocyte ratio in patients undergoing treatment with nivolumab for recurrent non-small cell lung cancer**  
B. Rapoport<sup>1</sup>, D. Vorobiof<sup>2</sup>, L. Langenhoven<sup>3</sup>, J. Hall<sup>4</sup>, R. Van Eeden<sup>1</sup>, T. Smit<sup>1</sup>, S.W. Chan<sup>5</sup>, M. Botha<sup>6</sup>, J. Raats<sup>3</sup>, M. De Necker<sup>7</sup>, H. Duvenhage<sup>8</sup>; <sup>1</sup>Sandton, ZA, <sup>2</sup>Bnei Atarot, Gauteng/IL, <sup>3</sup>Cape Town, ZA, <sup>4</sup>Cape Town, Western Cape/ZA, <sup>5</sup>Sandton, Gauteng/ZA, <sup>6</sup>George, Western Cape/ZA, <sup>7</sup>Pretoria, ZA, <sup>8</sup>Woodmead, ZA
- 12:30 - 12:30 **168P - Dynamic changes of platelet-to-lymphocyte ratio predict efficacy of PD-1/PD-L1 inhibitors in NSCLC**  
F. Zhou, A. Xiong, C. Zhou; Shanghai, CN
- 12:30 - 12:30 **169P\_PR - Benefit of immunotherapy (IT) in advanced non-small cell lung cancer (NSCLC) in elderly patients (EP)**  
E. Corral de la Fuente, A. Barquín García, C. Saavedra Serrano, M.E. Olmedo García, R. Martín Huertas, J.J. Serrano Domingo, V. Albarrán Artahona, A. Gómez Rueda; Madrid, ES
- 12:30 - 12:30 **170P - Advanced non-small cell lung cancer patients with low tumor mutation burden might derive benefit from anti-programmed cell death (PD)-1 and anti-programmed deathligand 1 (PD-L1) blockade**  
W. Nie<sup>1</sup>, M. Xu<sup>1</sup>, L. Gan<sup>1</sup>, Y. Zhang<sup>2</sup>, B. Han<sup>1</sup>; <sup>1</sup>Shanghai, CN, <sup>2</sup>Chongqing, CN
- 12:30 - 12:30 **171P - Previous exposure to bevacizumab indicated inferior benefits from PD-1/PD-L1 inhibitors in nonsquamous NSCLC**  
F. Zhou, Y. Pan, C. Zhou; Shanghai, CN
- 12:30 - 12:30 **172P - A multi-center, randomized, double-blind, parallel, two-group phase III clinical study on the efficacy and safety of QL1101 or bevacizumab in combination with paclitaxel and carboplatin in the first-line treatment of non-squamous non-small cell lung cancer**



B. Han<sup>1</sup>, K. Li<sup>2</sup>, T. Chu<sup>1</sup>, M. Bi<sup>3</sup>, H. Zhang<sup>4</sup>, Y. Yu<sup>5</sup>, J. Shi<sup>6</sup>, X. Zhang<sup>7</sup>, Z. Chen<sup>8</sup>, C. Han<sup>9</sup>, T. Bai<sup>9</sup>; <sup>1</sup>Shanghai, CN, <sup>2</sup>Tianjin, CN, <sup>3</sup>Bengbu, CN, <sup>4</sup>Xi'an, CN, <sup>5</sup>Harbin, CN, <sup>6</sup>Linyi, CN, <sup>7</sup>Qingdao, CN, <sup>8</sup>Hefei, CN, <sup>9</sup>Jinan, CN

- 12:30 - 12:30 **173P - Stereotactic radiotherapy concurrent to immune or targeted therapy for oligometastatic NSCLC: Clinical scenarios affecting survival**  
S. Kroeze<sup>1</sup>, C. Fritz<sup>1</sup>, D. Kaul<sup>2</sup>, O. Blanck<sup>3</sup>, K. Kahl<sup>4</sup>, F. Roeder<sup>5</sup>, S. Siva<sup>6</sup>, J. Verhoeff<sup>7</sup>, A. Grosu<sup>8</sup>, M. Schymalla<sup>9</sup>, M. Glatzer<sup>10</sup>, M. Szuets<sup>11</sup>, M. Geier<sup>12</sup>, G. Skazikis<sup>13</sup>, I. Sackerer<sup>14</sup>, F. Lohaus<sup>15</sup>, F. Eckert<sup>16</sup>, M. Guckenberger<sup>17</sup>; <sup>1</sup>Zurich, CH, <sup>2</sup>Berlin, DE, <sup>3</sup>Gustow, DE, <sup>4</sup>Augsburg, DE, <sup>5</sup>München, DE, <sup>6</sup>Melbourne, AU, <sup>7</sup>Utrecht, NL, <sup>8</sup>Freiburg, DE, <sup>9</sup>Marburg, DE, <sup>10</sup>St. Gallen, CH, <sup>11</sup>Rostock, DE, <sup>12</sup>Linz, AT, <sup>13</sup>Villingen-Schwenningen, DE, <sup>14</sup>Freising, DE, <sup>15</sup>Dresden, DE, <sup>16</sup>Tübingen, DE, <sup>17</sup>Zürich, CH
- 12:30 - 12:30 **174P - NSCLC stages IIa-IIIc: Tumor related IGRT yields better local control than kV-guidance to anatomic structures**  
F. Zehentmayr<sup>1</sup>, J. Karner<sup>1</sup>, K. Wurstbauer<sup>2</sup>, R. Wass<sup>3</sup>, G. Fastner<sup>1</sup>, L. Rettenbacher<sup>1</sup>, M. Studnicka<sup>1</sup>, C. Pirich<sup>1</sup>, P. Kopp<sup>1</sup>, F. Sedlmayer<sup>1</sup>; <sup>1</sup>Salzburg, AT, <sup>2</sup>Feldkirch, AT, <sup>3</sup>Linz, AT
- 12:30 - 12:30 **175P - Permanent pleural catheter (PPC) for malignant pleural effusion (PE) in advanced non-small cell lung cancer (NSCLC)**  
M. Martinez Kareaga<sup>1</sup>, N. Urbieta-Macazaga<sup>2</sup>, C. Sanchez-Vieco<sup>3</sup>, L. Tomás-López<sup>3</sup>, I. Intxaurbe-Etxebarria<sup>3</sup>, B. Mareque<sup>3</sup>, N. Torregó<sup>3</sup>, A. Narro<sup>3</sup>, L. Puntí<sup>3</sup>, I. Guillen<sup>3</sup>; <sup>1</sup>Vitoria-Gasteiz, ES, <sup>2</sup>San Sebastian, ES, <sup>3</sup>Vitoria, ES
- 12:30 - 12:30 **176P - Real-world treatment patterns for metastatic non-small cell lung cancer at IRST Italy**  
M. Altini<sup>1</sup>, I. Massa<sup>1</sup>, W. Balzi<sup>1</sup>, N. Gentili<sup>1</sup>, F. Foca<sup>1</sup>, V. Danesi<sup>1</sup>, S. Manunta<sup>1</sup>, M. Burgio<sup>1</sup>, P. Cravero<sup>1</sup>, F. Ejzykowicz<sup>2</sup>, S. Chandwani<sup>2</sup>, A. Delmonte<sup>1</sup>; <sup>1</sup>Meldola, IT, <sup>2</sup>Rahway, NJ/US
- 12:30 - 12:30 **177P - Real-world experience of ALK positive NSCLC from India**  
M. Malhotra, V. Noronha, A. Joshi, V. Patil, S. Wadhwa, K. Prabhash; Mumbai, IN
- 12:30 - 12:30 **178P - Feasibility of O-(2-[18F]fluoroethyl)-L-tyrosine (FET) PET for treatment monitoring of brain metastases in lung cancer patients**  
D. Abdulla<sup>1</sup>, M. Ruge<sup>1</sup>, M. Scheffler<sup>1</sup>, L. Nogova<sup>2</sup>, S. Koleczko<sup>2</sup>, T. Persigehl<sup>1</sup>, S. Grau<sup>1</sup>, A. Drzezga<sup>1</sup>, C. Kobe<sup>1</sup>, R. Buettner<sup>2</sup>, N. Galldiks<sup>1</sup>, J. Wolf<sup>1</sup>; <sup>1</sup>Cologne, DE, <sup>2</sup>Köln, DE
- 12:30 - 12:30 **179P - Treatment (tx) characteristics of patients (pts) with locally advanced or metastatic non-small cell lung cancer (NSCLC) receiving atezolizumab (atezo) monotherapy in US clinical practice**  
M. Frueh<sup>1</sup>, O. Rahma<sup>2</sup>, R. Pachynski<sup>3</sup>, J. Mazieres<sup>4</sup>, J. Goldschmidt Jr.<sup>5</sup>, T. Ton<sup>6</sup>, S. Mhatre<sup>6</sup>, C. Chuo<sup>6</sup>, J. Martinalbo<sup>7</sup>, J. Davies<sup>8</sup>, R. Juergens<sup>9</sup>; <sup>1</sup>St. Gallen, CH, <sup>2</sup>Boston, MA/US, <sup>3</sup>St. Louis, MO/US, <sup>4</sup>Toulouse, FR, <sup>5</sup>Blacksburg, VA/US, <sup>6</sup>South San Francisco, CA/US, <sup>7</sup>Basel, CH, <sup>8</sup>Welwyn Garden City, GB, <sup>9</sup>Hamilton, ON/CA



- 12:30 - 12:30 **180TiP - An open-label, randomized, phase I/II trial of IO102 and pembrolizumab, or IO102, pembrolizumab and chemotherapy, as first-line treatment for patients with metastatic non-small cell lung cancer**  
J. Spicer<sup>1</sup>, M. Provencio<sup>2</sup>, P. Garrido Lopez<sup>2</sup>, J. Bosch-Barrera<sup>3</sup>, F.J. de Castro Carpeño<sup>2</sup>, E. Felip<sup>4</sup>, J. Trigo<sup>5</sup>, S. Viteri<sup>4</sup>, E. Coart<sup>6</sup>, E. Schmidt<sup>7</sup>, A. Christiansen<sup>8</sup>, M. Zocca<sup>8</sup>, M. Andersen<sup>8</sup>, E. Ehrnrooth<sup>8</sup>, L. Paz-Ares<sup>2</sup>; <sup>1</sup>London, GB, <sup>2</sup>Madrid, ES, <sup>3</sup>Girona, ES, <sup>4</sup>Barcelona, ES, <sup>5</sup>Malaga, ES, <sup>6</sup>Ottignies, BE, <sup>7</sup>Kenilworth, NJ/US, <sup>8</sup>Copenhagen, DK
- 12:30 - 12:30 **181TiP - Phase II study of crizotinib in Japanese patients with advanced non-small cell lung cancer harboring a MET gene alteration: Co-MET study**  
M. Shimokawa<sup>1</sup>, K. Nosaki<sup>1</sup>, T. Seto<sup>2</sup>, K. Ohashi<sup>3</sup>, M. Morise<sup>4</sup>, Y. Fujiwara<sup>5</sup>, J. Sakakibara<sup>6</sup>, H. Murakami<sup>7</sup>, S. Yano<sup>8</sup>, M. Satouchi<sup>9</sup>, S. Matsumoto<sup>10</sup>, K. Goto<sup>10</sup>, K. Yoh<sup>10</sup>; <sup>1</sup>Fukuoka, JP, <sup>2</sup>Fukuoka, Fukuoka/JP, <sup>3</sup>Okayama, JP, <sup>4</sup>Nagoya, JP, <sup>5</sup>Tokyo, JP, <sup>6</sup>Sapporo, JP, <sup>7</sup>Shizuoka, JP, <sup>8</sup>Kanazawa, JP, <sup>9</sup>Akashi, JP, <sup>10</sup>Kashiwa, Chiba/JP
- 12:30 - 12:30 **182TiP - A phase II trial of tepotinib in patients with non-small cell lung cancer (NSCLC) harboring MET alterations: The VISION study**  
P. Paik<sup>1</sup>, A. Cortot<sup>2</sup>, E. Felip<sup>3</sup>, H. Sakai<sup>4</sup>, J. Mazieres<sup>5</sup>, L. Horn<sup>6</sup>, F. Griesinger<sup>7</sup>, R. Bruns<sup>8</sup>, J. Scheele<sup>8</sup>, J. Straub<sup>8</sup>, R. Veillon<sup>9</sup>; <sup>1</sup>New York City, NY/US, <sup>2</sup>Lille, FR, <sup>3</sup>Barcelona, ES, <sup>4</sup>Saitama, JP, <sup>5</sup>Toulouse, FR, <sup>6</sup>Nashville, TN/US, <sup>7</sup>Oldenburg, DE, <sup>8</sup>Darmstadt, DE, <sup>9</sup>Pessac, FR
- 12:30 - 12:30 **183TiP - A phase II study of [fam-] trastuzumab deruxtecan (DS-8201a) in HER2-overexpressing or -mutated advanced non-small cell lung cancer**  
D. Planchard<sup>1</sup>, B. Li<sup>2</sup>, H. Murakami<sup>3</sup>, R. Shiga<sup>4</sup>, C. Lee<sup>5</sup>, K. Wang<sup>5</sup>, P. Jänne<sup>6</sup>; <sup>1</sup>Villejuif, FR, <sup>2</sup>New York, NY/US, <sup>3</sup>Shizuoka, JP, <sup>4</sup>Tokyo, JP, <sup>5</sup>Basking Ridge, NJ/US, <sup>6</sup>Boston, MA/US
- 12:30 - 12:30 **184TiP - FIND: A phase II study to evaluate the efficacy of erdafitinib in FGFR-altered squamous NSCLC**  
L. Nogova<sup>1</sup>, F. Malchers<sup>1</sup>, A. Hillmer<sup>2</sup>, S. Merkelbach-Bruse<sup>1</sup>, A. Pinto<sup>1</sup>, C. Woempner<sup>1</sup>, R. Riedel<sup>3</sup>, M. Scheffler<sup>3</sup>, S. Michels<sup>1</sup>, P. De Porre<sup>4</sup>, A. Santiago-Walker<sup>5</sup>, R. Fischer<sup>1</sup>, D. Abdulla<sup>3</sup>, R. Thomas<sup>1</sup>, R. Buettner<sup>1</sup>, J. Wolf<sup>3</sup>; <sup>1</sup>Köln, DE, <sup>2</sup>Mainz, DE, <sup>3</sup>Cologne, DE, <sup>4</sup>Beerse, BE, <sup>5</sup>Spring House, US
- 12:30 - 12:30 **185TiP - RATIONALE 001: Tislelizumab (BGB-A317) &#x0002B; concurrent chemoradiotherapy (cCRT) followed by tislelizumab monotherapy in patients (pts) with newly diagnosed locally advanced, unresectable, stage III non-small cell lung cancer (NSCLC)**  
L. Paz-Ares<sup>1</sup>, S. Senan<sup>2</sup>, D. Planchard<sup>3</sup>, L. Wang<sup>4</sup>, A. Cheong<sup>5</sup>, R. Slepets<sup>5</sup>, M. Nguyen<sup>5</sup>, E. Vokes<sup>6</sup>; <sup>1</sup>Madrid, ES, <sup>2</sup>Amsterdam, NL, <sup>3</sup>Villejuif, FR, <sup>4</sup>Shenzhen, CN, <sup>5</sup>Summit, NJ/US, <sup>6</sup>Chicago, IL/US
- 12:30 - 12:30 **186TiP - An open-label, randomized phase III study of early switch maintenance vs delayed second-line nivolumab in advanced stage squamous non-small cell lung cancer (NSCLC) patients after standard first-line platinum-based chemotherapy: EDEN trial**





F. Gelsomino<sup>1</sup>, M. Tiseo<sup>2</sup>, L. Boni<sup>3</sup>, L. Cavanna<sup>4</sup>, A. Camerini<sup>5</sup>, R. Chiari<sup>6</sup>, C. Verusio<sup>7</sup>, M. Tognetto<sup>1</sup>, A. Ardizzoni<sup>1</sup>; <sup>1</sup>Bologna, IT, <sup>2</sup>Parma, IT, <sup>3</sup>Firenze, IT, <sup>4</sup>Piacenza, IT, <sup>5</sup>Lido Di Camaiore, (LU)/IT, <sup>6</sup>Perugia, IT, <sup>7</sup>Saronno, (VA)/IT

- 12:30 - 12:30 **187TiP - Tumor treating fields concurrent with standard of care therapy for stage IV NSCLC following platinum failure: Phase III LUNAR study**  
U. Weinberg<sup>1</sup>, O. Farber<sup>2</sup>, M. Giladi<sup>2</sup>, Z. Bomzon<sup>2</sup>, E. Kirson<sup>2</sup>; <sup>1</sup>Luzern, CH, <sup>2</sup>Haifa, IL
- 12:30 - 12:30 **188TiP - Metformin &#x0002B;- cyclic fasting mimicking diet in combination with platinum-pemetrexed chemotherapy for advanced LKB1 inactive lung adenocarcinoma: The FAME trial**  
G. Galli<sup>1</sup>, D. Signorelli<sup>1</sup>, C. Vernieri<sup>1</sup>, M. Ganzinelli<sup>2</sup>, M. Moro<sup>1</sup>, A. Fabbri<sup>1</sup>, E. Tamborini<sup>2</sup>, M. Marabese<sup>1</sup>, E. Caiola<sup>1</sup>, M. Brogginini<sup>1</sup>, L. Hollander<sup>1</sup>, R. Gallucci<sup>1</sup>, C. Gavazzi<sup>1</sup>, A.M. Rizzo<sup>2</sup>, P. Corsetto<sup>2</sup>, G. Pruneri<sup>1</sup>, F. de Braud<sup>1</sup>, G. Sozzi<sup>1</sup>, V. Torri<sup>3</sup>, M. Garassino<sup>1</sup>; <sup>1</sup>Milan, IT, <sup>2</sup>Milano, IT, <sup>3</sup>No City Provided, NA
- 12:30 - 12:30 **190P - ERGR-TKIs combined with chemotherapy delays intracranial progression in EGFR-mutant lung adenocarcinoma patients**  
C. Li, B. Zhang, J. Guo, F. Hu, W. Nie, X. Zheng, Y. Lou, Y. Shen, X. Zhang; Shanghai, CN
- 12:30 - 12:30 **191P - Assessment of toxicity and clinical outcomes with SBRT in lung metastases: A single institute experience**  
V. Pareek, Mumbai, IN
- 12:30 - 12:30 **192P - Characterization and potential role of PD-L1 positive lung cancer stem cells in lymph nodes metastasis**  
A. Raniszewska, E. Rutkowska, R. Sokolowski, J. Domagala-Kulawik; Warsaw, PL
- 12:30 - 12:30 **193P - Management of cN2 NSCLC patients treated with radical radiotherapy: Relapse with or without brain metastases**  
F. McKay, S. Ansel, C. Lowrie, P. McLoone, N. Mohammed; Glasgow, GB
- 12:30 - 12:30 **195TiP - Phase III METIS study: Tumor treating fields (150&#x02009;kHz) and radiosurgery for supra- and/or infratentorial brain metastases (1-10) from non-small cell lung cancer (NSCLC)**  
M. Mehta<sup>1</sup>, V. Gondi<sup>2</sup>, M. Ahluwalia<sup>3</sup>, P. Brown<sup>4</sup>; <sup>1</sup>Chicago, IL/US, <sup>2</sup>Warrenville, IL/US, <sup>3</sup>Cleveland, OH/US, <sup>4</sup>Rochester, MN/US
- 12:30 - 12:30 **197P - Effect of surgical treatment on the survival in patients with malignant pleural mesothelioma**  
R. Baez-Saldana<sup>1</sup>, M.T. Marmolejo-Torres<sup>2</sup>, M. Iñiguez-García<sup>2</sup>, J.A. Berrios Mejía<sup>2</sup>, U. Rumbo-Nava<sup>2</sup>, O. Arrieta-Rodríguez<sup>2</sup>; <sup>1</sup>Ciudad De México, MX, <sup>2</sup>Mexico City, MX
- 12:30 - 12:30 **198P - Efficacy of 150&#x02009;kHz tumor treating fields (TTFields) and cisplatin or pemetrexed for the treatment of mesothelioma cells in vitro**





U. Weinberg<sup>1</sup>, M. Munster<sup>2</sup>, K. Gotlib<sup>2</sup>, R. Schneiderman<sup>2</sup>, Y. Porat<sup>2</sup>, T. Voloshin Sela<sup>2</sup>, S. Davidi<sup>2</sup>, A. Shteingauz<sup>2</sup>, N. Kaynan<sup>2</sup>, E. Zeevi<sup>2</sup>, M. Giladi<sup>2</sup>, E. Kirson<sup>2</sup>, A. Kinzel<sup>3</sup>, Y. Palti<sup>2</sup>; <sup>1</sup>Luzern, CH, <sup>2</sup>Haifa, IL, <sup>3</sup>München, DE

- 12:30 - 12:30 **199P - Safety meta-analysis of clinical trials delivering TTFields to the upper torso**  
G.L. Ceresoli<sup>1</sup>, M. Pless<sup>2</sup>; <sup>1</sup>Bergamo, IT, <sup>2</sup>Winterthur, CH
- 12:30 - 12:30 **200P - Implementation of artificial intelligence (AI) for lung cancer clinical trial matching in a tertiary cancer center**  
K. Leventakos<sup>1</sup>, J. Helgeson<sup>1</sup>, A. Mansfield<sup>1</sup>, E. Deering<sup>1</sup>, A. Schwecke<sup>1</sup>, A. Adjei<sup>1</sup>, J. Molina<sup>1</sup>, C. Hocum<sup>1</sup>, T. Halfdanarson<sup>1</sup>, R. Marks<sup>1</sup>, K. Parikh<sup>1</sup>, K. Pomerleau<sup>1</sup>, S. Coverdill<sup>2</sup>, M. Rammage<sup>2</sup>, T. Haddad<sup>1</sup>; <sup>1</sup>Rochester, MN/US, <sup>2</sup>Cambridge, MA/US
- 12:30 - 12:30 **201P - Psychosocial and financial impact on family of lung cancer patients: A cancer research center experience**  
S. GODARA, S. Beniwal; Bikaner, IN
- 12:30 - 12:30 **202P - Information for lung cancer patients and their caregivers: A systematic analysis of the online landscape**  
P. Naish<sup>1</sup>, E. Purdy<sup>2</sup>; <sup>1</sup>Cambridge, GB, <sup>2</sup>London, GB
- 12:30 - 12:30 **203P - Retrospective study about lung carcinoid: Our experience in a Spanish hospital**  
D. Sanchez Cabrero, P. Cruz, J. de Castro, O. Higuera, A. Pertejo, I. Esteban, L. Gutierrez, J. Villamayor, L. Ostios, D. Viñal, J. Miranda; Madrid, ES
- 12:30 - 12:30 **204P - Diagnostic value of concomitant use of radial probe endobronchial ultrasound with guide sheath and transbronchial biopsy in lung cancer**  
S.C. Lee<sup>1</sup>, S. Kwak<sup>2</sup>, M.S. Park<sup>2</sup>, Y.S. Kim<sup>2</sup>, J. Chang<sup>2</sup>, S.H. Lee<sup>2</sup>, C.H. Han<sup>1</sup>, S.M. Lee<sup>1</sup>, C.J. Kim<sup>1</sup>; <sup>1</sup>Goyang, KR, <sup>2</sup>Seoul, KR
- 12:30 - 12:30 **205P - Non-small cell lung cancer in the elderly: A retrospective study comparing first-line treatment with single-agent vs combination chemotherapy vs tyrosine kinase inhibitor**  
É. Cipriano, A. Tavares, A. Soares, F. Estevinho, C. Sottomayor; Matosinhos, PT
- 12:30 - 12:30 **206P - Implementation of PD-L1 analysis among patients with non-small cell lung cancer in a single center**  
I. TSIROUPROU, V. Tsartsianidou, S. Papaemmanouil, N. Pastelli, S. Lampaki, E. Eleftheriadou, K. Domvri, T. Kontakiotis, D. Spyrtatos; Thessaloniki (exohi), GR
- 12:30 - 12:30 **207P - Primary mucinous carcinomas of the lung: Clinical characteristics and treatment outcomes**  
A. Thottian<sup>1</sup>, G. Babu<sup>2</sup>, L. Dasappa<sup>2</sup>, L. Jacob<sup>2</sup>, S. Babu<sup>2</sup>, K.N. Lokesh<sup>3</sup>, A. Rudresha<sup>3</sup>, L. Rajeev<sup>2</sup>, S. Saldanha<sup>2</sup>, G. Gv<sup>2</sup>; <sup>1</sup>Delhi, Delhi/IN, <sup>2</sup>Bangalore, IN, <sup>3</sup>Bangalore, Karnatka/IN



- 12:30 - 12:30 **208P - Sarcopenia as prognostic factor in lung cancer patients: A systematic review and meta-analysis**  
J. Büntzel<sup>1</sup>, J. Heinz<sup>1</sup>, C. Röver<sup>1</sup>, A. Bleckmann<sup>1</sup>, C. Bauer<sup>2</sup>, A. Emmert<sup>1</sup>; <sup>1</sup>Göttingen, DE, <sup>2</sup>Fulda, DE
- 12:30 - 12:30 **209P - Feasibility and utility of transbronchial cryobiopsy in primary lung cancer: Prospective, single arm study**  
K. Kirita<sup>1</sup>, H. Udagawa<sup>2</sup>, S. Matsumoto<sup>1</sup>, K. Yoh<sup>1</sup>, S. Niho<sup>1</sup>, K. Goto<sup>1</sup>; <sup>1</sup>Kashiwa, Chiba/JP, <sup>2</sup>Kashiwa, JP
- 12:30 - 12:30 **210TiP - Evaluation of safety and efficacy of minocycline combined with tyrosine kinase inhibitors in patients of EGFR mutated metastatic lung cancer**  
A. Thottian<sup>1</sup>, G. Babu<sup>2</sup>, L. Dasappa<sup>2</sup>, L. Jacob<sup>2</sup>, S. Babu<sup>2</sup>, K.N. Lokesh<sup>3</sup>, A. Rudresha<sup>3</sup>, S. Saldanha<sup>2</sup>, G. Gv<sup>2</sup>, R. Lk<sup>2</sup>; <sup>1</sup>Delhi, Delhi/IN, <sup>2</sup>Bangalore, IN, <sup>3</sup>Bangalore, Karnatka/IN
- 13:00 - 14:00 Medscape Oncology - Industry Satellite Symposium Room A**  
 Moderation: L. Paz-Ares, Madrid, ES
- 13:00 - 13:10 **Welcome and introduction: Recent practice changing data - What do they mean in the real world?**  
L. Paz-Ares, Madrid, ES
- 13:10 - 13:20 **PDL1: To test or not to test?**  
K. Kerr, Aberdeen, GB
- 13:20 - 13:35 **Patient case 1: Optimizing therapy based on CCRT suitability**  
C. Le Pechoux, Villejuif, CEDEX/FR
- 13:35 - 13:50 **Patient case 2: Optimizing therapy based on CCRT suitability**  
J. Vansteenkiste, Leuven, BE
- 13:50 - 14:00 **Panel Discussion and Q&A**



**13:00 - 14:00 Pfizer Oncology - Industry Satellite Symposium** **Room C**  
Moderation: E. Felip, Barcelona, ES

13:00 - 13:05 **Introduction**  
E. Felip, Barcelona, ES

13:05 - 13:15 **Where did we start?**  
E. Felip, Barcelona, ES

13:15 - 13:35 **Where are we now and what is on the horizon?**  
S. Bajjal, Birmingham, GB

13:35 - 13:50 **How can we make balanced treatment decisions for our EGFR+ patients?**  
N. Girard, Paris, FR

13:50 - 14:00 **Q&A**  
E. Felip, Barcelona, ES

**14:30 - 16:00 Molecular board in clinical practice** **Room B**  
Moderation: E.F. Smit<sup>1</sup>, M. Sebastian<sup>2</sup>; <sup>1</sup>Amsterdam, NL, <sup>2</sup>Frankfurt Am Main, DE

14:30 - 14:30 **Session DOI**

14:30 - 14:55 **Do we need a molecular board in our hospital?**  
M. Kris, New York, NY/US

14:55 - 15:20 **Biomarkers are a rapidly changing scenario: How to face it**  
E. Smit, Amsterdam, NL

15:20 - 15:45 **Facts and myths of liquid biopsy**  
N. Normanno, Napoli, IT

15:45 - 16:00 **Q&A**



**14:30 - 16:00 Oligometastatic and oligoproliferative disease: A new era? Room A**  
Moderation: F. Barlesi<sup>1</sup>, F. McDonald<sup>2</sup>; <sup>1</sup>Marseille, CEDEX 20/FR, <sup>2</sup>London, GB

14:30 - 14:30 **Session DOI**

14:30 - 14:55 **How to define it? How to treat it?**

A. Dingemans, Maastricht, NL

14:55 - 15:20 **Local treatment in oligoproliferative disease**

F. McDonald, London, GB

15:20 - 15:45 **Treatment algorithms for oligoproliferative and oligometastatic disease**

F. Barlesi, Marseille, CEDEX 20/FR

15:45 - 16:00 **Q&A**



<b>14:30 - 16:00</b>	<b>Quality of Life (QoL) and care: New paradigms</b> Moderation: A. Aguarón Turrientes, Brussels, BE	<b>Room C</b>
14:30 - 14:30	<b>Session DOI</b>	
14:30 - 14:35	<b>Introduction</b> <u>A. Aguarón Turrientes</u> , Brussels, BE	
14:35 - 14:55	<b>Is palliative care under threat for stigma? LuCE and Hospice Casa Sperantei initiative for early integration of palliative care interventions in the plan of care of lung cancer patients</b> <u>N. Mitrea</u> , Bucharest, RO	
14:55 - 15:15	<b>How accurate are we in measuring quality of life?</b> <u>L. Magee</u> , Cambridge, GB	
15:15 - 15:35	<b>Clinical trials: Safety and pharmacovigilance</b> <u>D. Villalon</u> , Madrid, ES	
15:35 - 15:55	<b>Supporting lung cancer survivors: Living with and beyond lung cancer</b> <u>R.D. Ihlen</u> , Le Relecq Kerhuon, FR	
15:55 - 16:00	<b>Conclusions and perspectives</b> <u>A. Aguarón Turrientes</u> , Brussels, BE	





<b>14:30 - 16:00</b>	<b>Integrated care in LCC</b> Moderation: A. Fraser, Auckland, NZ	<b>Room K</b>
14:30 - 14:30	<b>Session DOI</b>	
14:30 - 14:35	<b>Introduction</b> <u>A. Fraser</u> , Auckland, NZ	
14:35 - 15:00	<b>Integrating early palliative care to oncology care: Are we there yet?</b> <u>A. Charalambous</u> , Limassol, CY	
15:00 - 15:20	<b>Advance care planning in LC: Practices and challenges</b> <u>M. Connolly</u> , Dublin, IE	
15:20 - 15:45	<b>Patient's experience of the integrated model of care</b> <u>S. Parreira</u> , Lisbon, PT	
15:45 - 16:00	<b>Conclusions and Q&amp;A</b> <u>A. Fraser</u> , Auckland, NZ	
<b>16:00 - 16:30</b>	<b>Coffee break</b>	<b>Hall 1</b>



<b>16:30 - 17:30</b>	<b>AstraZeneca - Industry Satellite Symposium</b> Moderation: V. Papadimitrakopoulou, Houston, US	<b>Room A</b>
16:30 - 16:35	<b>Welcome and programme overview</b> <u>V. Papadimitrakopoulou</u> , Houston, US	
16:35 - 16:45	<b>Considerations for first-line treatment selection for patients with metastatic EGFRm NSCLC</b> <u>M. Garassino</u> , Milan, IT	
16:45 - 16:45	<b>Panel discussion</b> <u>V. Papadimitrakopoulou</u> <sup>1</sup> , <u>N. Reinmuth</u> <sup>2</sup> ; <sup>1</sup> Houston, US, <sup>2</sup> Gauting, DE	
16:45 - 17:00	<b>What do we know? First-line osimertinib treatment and mechanisms of acquired resistance</b> <u>N. Reinmuth</u> , Gauting, DE	
17:00 - 17:00	<b>Panel discussion</b> <u>M. Garassino</u> <sup>1</sup> , <u>V. Papadimitrakopoulou</u> <sup>2</sup> ; <sup>1</sup> Milan, IT, <sup>2</sup> Houston, US	
17:00 - 17:10	<b>What's next? Clinical management of patients with progression on first-line osimertinib</b> <u>V. Papadimitrakopoulou</u> , Houston, US	
17:10 - 17:10	<b>Panel discussion</b> <u>M. Garassino</u> <sup>1</sup> , <u>N. Reinmuth</u> <sup>2</sup> ; <sup>1</sup> Milan, IT, <sup>2</sup> Gauting, DE	
17:10 - 17:25	<b>How do we manage patients who need second-line therapy? Clinical practice approach to therapy selection</b> <u>V. Papadimitrakopoulou</u> , Houston, US	
17:25 - 17:25	<b>Panel discussion</b> <u>M. Garassino</u> <sup>1</sup> , <u>N. Reinmuth</u> <sup>2</sup> ; <sup>1</sup> Milan, IT, <sup>2</sup> Gauting, DE	
17:25 - 17:30	<b>Conclusions</b> <u>V. Papadimitrakopoulou</u> , Houston, US	



**16:30 - 17:30 Bayer - Industry Satellite Symposium** **Room C**  
Moderation: L. Bubendorf, Basel, CH

16:30 - 16:35 **Welcome and introduction**  
L. Bubendorf, Basel, CH

16:35 - 16:50 **Emerging data on TRK inhibition in TRK fusion lung cancer**  
A. Drilon, New York, NY/US

16:50 - 17:05 **Testing for TRK fusion lung cancer**  
L. Bubendorf, Basel, CH

17:05 - 17:15 **Ask the experts: Patient cases from TRK inhibitor clinical trials**  
L. Bubendorf<sup>1</sup>, A. Drilon<sup>2</sup>; <sup>1</sup>Basel, CH, <sup>2</sup>New York, NY/US

17:15 - 17:30 **Q&A and close**  
L. Bubendorf<sup>1</sup>, A. Drilon<sup>2</sup>; <sup>1</sup>Basel, CH, <sup>2</sup>New York, NY/US

**16:30 - 18:00 Novel interventions in LC** **Room K**  
Moderation: A. Molassiotis<sup>1</sup>, A. Fraser<sup>2</sup>; <sup>1</sup>Shatin, Pokfulam/HK, <sup>2</sup>Auckland, NZ

16:30 - 16:30 **Session DOI**

16:30 - 16:35 **Introduction**  
A. Fraser, Auckland, NZ

16:35 - 16:55 **Patient reported-outcomes: Where nursing fits**  
C. de los Rios de la Serna, Southampton, GB

16:55 - 17:15 **Management of patients with peripheral neuropathy**  
A. Fraser, Auckland, NZ

17:15 - 17:35 **Management of cough in patients with LC**  
A. Molassiotis, Shatin, Pokfulam/HK

17:35 - 17:55 **Supporting lung cancer patients through virtual environments**  
A. Ioannou, Strovolos, CY

17:55 - 18:00 **Conclusions**  
A. Molassiotis, Shatin, Pokfulam/HK



- 17:45 - 18:45 Mini Oral session III** **Room C**  
Moderation: W. Eberhardt<sup>1</sup>, M. Guckenberger<sup>2</sup>, J. Zugazagoitia<sup>3</sup>; <sup>1</sup>Essen, DE, <sup>2</sup>Zürich, CH, <sup>3</sup>New Haven, US
- 17:45 - 17:45 **Session DOI**
- 17:45 - 17:50 **20 - Differentially regulated high-throughput CT imaging features correlate to distinct tumor immune contextures portraying a radiomic signature with prognostic impact on surgically resected NSCLC**  
G. Mazzaschi<sup>1</sup>, F. Quaini<sup>1</sup>, G. Milanese<sup>1</sup>, D. Madeddu<sup>1</sup>, G. Bocchialini<sup>2</sup>, L. Ampollini<sup>1</sup>, L. Gnetti<sup>1</sup>, C. Lagrasta<sup>1</sup>, M. Silva<sup>1</sup>, G. Roti<sup>1</sup>, N. Sverzellati<sup>1</sup>, M. Tiseo<sup>1</sup>; <sup>1</sup>Parma, IT, <sup>2</sup>Parma, Parma/PR/IT
- 17:50 - 17:55 **420 - Implementation of organized lung cancer screening program in Korea**  
Y. Kim, Gyeonggi, KR
- 17:55 - 18:00 **430 - Baseline results from a French pilot study on lung cancer screening by CT scan: DEP KP80**  
O. Leleu<sup>1</sup>, M. Auquier<sup>2</sup>, B. Chauffert<sup>3</sup>, P. Berna<sup>2</sup>, V. Petigny<sup>2</sup>, A. Ait Addi<sup>2</sup>, D. Basille<sup>2</sup>, V. Jounieaux<sup>2</sup>; <sup>1</sup>Abbeville, FR, <sup>2</sup>Amiens, FR, <sup>3</sup>Amiens, CEDEX/FR
- 18:00 - 18:05 **700 - Radiomic-based quantitative CT analysis to predict the invasiveness of pure ground-glass lung adenocarcinoma**  
F. Xv<sup>1</sup>, W. Zhu<sup>2</sup>, H. Hu<sup>2</sup>; <sup>1</sup>Hangzhou, CN, <sup>2</sup>Hangzhou, CN
- 18:05 - 18:10 **710 - Impact of underlying pulmonary diseases on treatment outcomes in early stage non-small cell lung cancer treated with definitive radiotherapy**  
H. Kim, H. Yoo, H. Pyo, H.Y. Park; Seoul, KR
- 18:10 - 18:15 **720 - Multi-centre analysis of cardiac events following radical radiotherapy for lung cancer**  
F. Sun<sup>1</sup>, K. Banfill<sup>2</sup>, J. Lilley<sup>3</sup>, B. Wheller<sup>3</sup>, L. Murray<sup>3</sup>, A. McWilliam<sup>2</sup>, M. Van Herk<sup>2</sup>, A. Abravan<sup>2</sup>, C. Faivre-Finn<sup>2</sup>, K. Franks<sup>4</sup>; <sup>1</sup>Cottingham, East Yorkshire/GB, <sup>2</sup>Manchester, GB, <sup>3</sup>Leeds, GB, <sup>4</sup>Leeds, Yorkshire/GB
- 18:15 - 18:20 **860 - The effect of prophylactic cranial irradiation (PCI) for young stage III NSCLC patients: Subgroup analyses of the NVALT-11/DLCRG-02 study**  
W. Witlox<sup>1</sup>, B. Ramaekers<sup>1</sup>, H. Groen<sup>2</sup>, A. Dingemans<sup>1</sup>, J. Praag<sup>3</sup>, J. Belderbos<sup>4</sup>, V. Van der Noort<sup>4</sup>, H. Van Tinteren<sup>4</sup>, M. Joore<sup>1</sup>, D. De Ruyscher<sup>1</sup>; <sup>1</sup>Maastricht, NL, <sup>2</sup>Groningen, NL, <sup>3</sup>Rotterdam, NL, <sup>4</sup>Amsterdam, NL
- 18:20 - 18:25 **1200 - Thromboembolic events in advanced non-small cell lung cancer**



V. Srinivasalu<sup>1</sup>, N. Subramaniam<sup>2</sup>, S. Raghuram<sup>2</sup>, S. Kolathu<sup>2</sup>, B. Ponnada<sup>2</sup>, A. Philip<sup>3</sup>, W. Jose<sup>4</sup>, K. Pavithran<sup>4</sup>; <sup>1</sup>Bangalore, IN, <sup>2</sup>Kochi, IN, <sup>3</sup>Cochin, Tamil Nadu/IN, <sup>4</sup>Kochi, Kerala/IN

18:25 - 18:45 **Discussion led by moderators**

**17:45 - 18:45 Should sequencing of ALK inhibitors be molecularly-guided? Room A**  
Moderation: T. Newsom-Davis<sup>1</sup>, D. Planchard<sup>2</sup>; <sup>1</sup>London, GB, <sup>2</sup>Villejuif, FR

17:45 - 17:45 **Session DOI**

17:45 - 17:55 **Introduction and first vote**  
T. Newsom-Davis, London, GB

17:55 - 18:15 **Yes**  
A. Shaw, Boston, MA/US

18:15 - 18:35 **No**  
N. Girard, Paris, FR

18:35 - 18:45 **Second vote and conclusions**  
D. Planchard, Villejuif, FR





13.04.2019

**08:00 - 09:30 SCLC: New targets** **Room A**  
Moderation: S. Popat<sup>1</sup>, S. Ekman<sup>2</sup>; <sup>1</sup>London, GB, <sup>2</sup>Stockholm, SE

08:00 - 08:00 **Session DOI**

08:00 - 08:20 **Molecular targets and therapies for SCLC**  
S. Ekman, Stockholm, SE

08:20 - 08:40 **Immune targets and therapies for SCLC**  
E. Felip, Barcelona, ES

08:40 - 09:00 **Genomics of SCLC: Therapeutically relevant advances**  
M. Peifer, Cologne, DE

09:00 - 09:20 **What can mice tell us about drugging SCLC?**  
A. Berns, Amsterdam, NL

09:20 - 09:30 **Q&A**

**08:30 - 09:30 Do we treat patients with I-O until progression?** **Room C**  
Moderation: S. Peters<sup>1</sup>, D. Planchard<sup>2</sup>; <sup>1</sup>Lausanne, CH, <sup>2</sup>Villejuif, FR

08:30 - 08:30 **Session DOI**

08:30 - 08:40 **Introduction and first vote**  
S. Peters, Lausanne, CH

08:40 - 09:00 **I-O until PD**  
D. Spigel, Nashville, TN/US

09:00 - 09:20 **I-O fixed-time duration**  
F. de Marinis, Milan, IT

09:20 - 09:30 **Second vote and conclusions**  
D. Planchard, Villejuif, FR



**09:40 - 11:10 Mesothelioma** **Room A**  
Moderation: S. Novello<sup>1</sup>, L. Greillier<sup>2</sup>; <sup>1</sup>Orbassano, IT, <sup>2</sup>Marseille, FR

09:40 - 09:40 **Session DOI**

09:40 - 10:00 **Epidemiology and asbestos ban: European picture**  
L. Greillier, Marseille, FR

10:00 - 10:20 **Potential biomarkers for MPM in asbestos-exposed subjects**  
F. Galateau-Sallé, Lyon, FR

10:20 - 10:40 **Treatment of localised disease**  
H. Pass, New York, NY/US

10:40 - 11:00 **Novel targets, new therapeutic strategies and future perspectives**  
N. Van Zandwijk, Concord, NSW/AU

11:00 - 11:10 **Q&A**

**09:40 - 11:10 Optimal management of brain metastases in NSCLC** **Room C**  
Moderation: N. Leigh<sup>1</sup>, M. Weller<sup>2</sup>; <sup>1</sup>Toronto, CA, <sup>2</sup>Zurich, CH

09:40 - 09:40 **Session DOI**

09:40 - 10:00 **Is there still a role for surgery?**  
M. Weller, Zurich, CH

10:00 - 10:20 **The role of brain irradiation**  
C. Faivre-Finn, Manchester, GB

10:20 - 10:40 **Sequencing systemic therapy without driver mutations**  
N. Leigh, Toronto, CA

10:40 - 11:00 **Sequencing systemic therapy with driver mutations**  
E. Arriola Aperribay, Barcelona, ES

11:00 - 11:10 **Q&A**



<b>11:10 - 11:30</b>	<b>Coffee break</b>	<b>Foyer</b>
<b>11:30 - 12:00</b>	<b>Overcoming resistance to immune checkpoint inhibitors</b> Moderation: G. Scagliotti, Orbassano, TO/IT	<b>Room A</b>
11:30 - 11:30	<b>Session DOI</b>	
11:30 - 12:00	<b>Overcoming resistance to immune checkpoint inhibitors</b> <u>W. Fridman</u> , Paris, FR	
<b>12:00 - 12:15</b>	<b>Closing remarks</b> Moderation: P. Garrido Lopez <sup>1</sup> , J. Wolf <sup>2</sup> ; <sup>1</sup> Madrid, ES, <sup>2</sup> Cologne, DE	<b>Room A</b>
12:00 - 12:00	<b>Session DOI</b>	